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Abstract 
 
 
The post infectious paralytic autoimmune disease, Guillain-Barré syndrome (GBS), 
has  been  associated  with  the  generation  of  cross-reactive  auto-antibodies  after 
Campylobacter  jejuni  infection.  These  auto-antibodies  interact  with  both  the 
ganglioside  mimicking  C.  jejuni  lipo-oligosaccharides  (LOS)  and  endogenous 
gangliosides.  This study sought to investigate novel interactions of the ganglioside 
mimicking  LOS  with  immune  system  ganglioside  specific  receptors.  In  addition, 
studies investigated if such receptor recognition affects antigen trafficking or the 
immunostimulatory potency of the LOS, which could participate in auto-antibody 
generation.  Results  presented  in  this  thesis  demonstrate  for  the  first  time  that 
certain members of the siglec receptor family are capable of recognising LOS from 
a GBS associated strain of C. jejuni. This interaction did not definitively result in 
enhanced, or altered, potency of ganglioside mimicking LOS in stimulating immune 
cells.  Interestingly, ganglioside mimicry was shown to enhance phagocytosis of C. 
jejuni, however, in vivo differences in bacterial trafficking were not observed. 
   3 
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1  Introduction 
 
1.1  Guillain-Barré syndrome (GBS) 
 
Guillain-Barré  syndrome  is  an  autoimmune  inflammatory  disease  of  the  peripheral 
nervous system characterised by  an acute progressive flaccid paralysis  followed by a 
variable recovery
1.  GBS represents a spectrum of clinical and pathological entities with a 
number of subtypes being recognised.  These include Acute Inflammatory Demyelinating 
Polyradiculopathy (AIDP)
2, Acute Motor Axonal Neuropathy (AMAN)
3-5, Acute Motor 
and Sensory Axonal Neuropathy (AMSAN)
6 and Miller Fisher syndrome (MFS)
7.  Since 
the widespread eradication of polio, GBS has become the foremost cause of acute flaccid 
paralysis in the world with an incidence of between 0.6 and 4 cases per 100,000 per 
year
8. 
 
The  disease  subtype  is  determined  by  the  clinical  manifestations  supplemented  by 
laboratory investigations
1.  AIDP typically presents with muscle weakness which spreads 
proximally  and  can  lead  to  respiratory  paralysis.    Numbness  and  paraesthesia  are 
frequently present.  AIDP is complicated by an autonomic neuropathy in 15% of cases, 
leading  to  life  threatening  dysfunction  of  the  cardiovascular,  alimentary  and  urinary 
systems.  The disease reaches its nadir at two weeks and after a variable period of time 
recovery begins.  This can take weeks to months with up to 16% of patients suffering 
recurring episodes
7,9-11.  The axonal forms, AMAN and AMSAN, cause a pure motor 
impairment  or  motor  and  sensory  impairment  respectively.    These  axonal  subtypes 
progress more rapidly, are more severe and more often require ventilation.  Autonomic 
complications are mild and less common
6,9,10.  MFS is a triad of acute ophthalmoplegia, 
ataxia and areflexia
7.  The GBS subtypes show regional variations in incidence.  AIDP is 
the most common subtype worldwide and constitutes 90% of cases in Western countries.  
The axonal forms (AMAN, AMSAN and MFS) constitute 5% of cases in North America 
and Europe and 30-47% of cases in China, Japan and South/Central America
4,5,11,12.  17 
 
The most severe and life threatening complication of GBS is paralysis of the respiratory 
muscles which, in 25% of cases, leads to a requirement for artificial ventilation
13.  Ten to 
20% of patients suffer permanent disability, one third need to make substantial changes to 
their lifestyle
14 and 4 to 15% of cases result in mortality within 1 year
15,16. 
 
GBS patients represent a clinical challenge due to the multitude of systems affected by 
the disease.  Respiratory function must be closely monitored for early signs of failure.  
Autonomic  dysfunction  can  cause  arrhythmias  and  blood  pressure  crises  as  well  as 
gastrointestinal and bladder paralysis.  Deep vein thrombosis is a risk in non-ambulatory 
patients
1.  Other than supportive measures, the mainstay of treatment is immunotherapy, 
either plasmapheresis or intravenous immunoglobulin (IVIg).  Both are equally effective 
at reducing disability, reducing mortality and reducing the number of patients requiring 
artificial ventilation
17.  However, even with immunotherapy intervention, 14% of patients 
still require ventilation
8.  The current immunotherapy regimes are inadequate due their 
restricted  efficacy,  expense,  inherent  risks  and  lack  of  availability,  particularly  in 
developing  countries.    There  is  a  pressing  need  for  a  better  understanding  of  the 
pathogenesis  of  GBS  to  allow  development  of  novel  targeted  treatments  and  better 
prognostic  indicators  that  will  allow  clinicians  to  predict  who  will  require  intensive 
treatment and who will benefit most from which intervention. 
 
1.2  Pathophysiology of GBS 
 
The pathophysiology of GBS is incompletely understood. AIDP is frequently associated 
with multifocal lymphocytic infiltrations
2 in which both αβ and γδ T cells have been 
identified
18.  AIDP is also characterised by a macrophage infiltrate around peripheral 
nerves.  At this site the macrophages penetrate the Schwann cell basal lamina and ingest 
and digest the myelin, leading to demyelination of the axons
3,19,20.  The distribution of 
this  infiltrate  correlates  with  the  neurological  deficits.    T  cell  mediated  pathology  is  18 
considered  central  in  AIDP  and  the  disease  bares  similarities  to  the  animal  model, 
experimental autoimmune neuritis
2,21,22. 
 
AMAN and AMSAN show substantially different pathology from AIDP.  Macrophages 
are associated with the nodes of Ranvier and axons rather than Schwann cells, and the 
macrophages are often  observed beneath the intact myelin sheath in contact with the 
axons
3,6,23,24.    The  axonal  forms  of  GBS  produce  lesions  with  a  relative  lack  of 
lymphocyte  infiltrate  and,  in  contrast  to  AIDP,  are  believed  to  be  antibody  mediated 
diseases
20.  The primary pathological event is thought to be targeting of the nodes of 
Ranvier  and  nerve  terminals  by  auto-antibodies  leading  to  complement  activation.  
Activated complement components have been identified around the axons
25, resulting in 
damage between the axon and Schwann cell, leaving the myelin sheath initially intact.  
Antibody mediated cellular cytotoxicity may also play a role.  The molecular targets of 
these  auto-reactive  antibodies  have  been  identified  as  a  class  of  sialylated 
glycosphingolipids  called  gangliosides
2,24,26,27.    Gangliosides  comprise  a  membrane 
bound lipid tail (ceramide) and an external sialylated carbohydrate side chain.  While 
gangliosides  are  found  throughout  the  body,  they  are  concentrated  in  the  nervous 
system
28.  Ganglioside nomenclature describes the number of sialic acid residues and 
migration on thin layer chromatography e.g. GM1 describes Ganglioside, Mono sialic 
acid and 1 is the position of the migration band.  
 
Antibodies specific for a number of different gangliosides have been identified in the 
various axonal form of GBS
28-31 and are found in up to 50% of patients
20.  For example, 
anti-GM1 antibodies have been detected in 10 to 42% of AMAN patients
29,32-34 while 
Anti-GQ1b  IgG  antibodies  are  strongly  associated  with  MFS
35.    This  picture  is 
complicated  by  the  finding  that  some  GBS  patients  produce  autoantibodies  that  are 
reactive  with  ganglioside  complexes  (e.g.  GD1a  and  GD1b)  but  not  the  individual 
ganglioside  in  isolation
36.    This  reflects  the  capacity  of  gangliosides  to  form  hetero-
complexes with other gangliosides.  
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Approximately  two  thirds  of  all  subtypes  of  GBS  patients  experience  an  infectious 
episode in the six weeks prior to GBS onset
37.  The infection is often gastroenteritis or a 
flu-like  illness
2,8,38.    The  organisms  most  commonly  associated  with  GBS  are 
Campylobacter  jejuni  (4-66%),  cytomegalovirus  (5-15%),  Epstein-Barr  virus  (2-10%) 
and mycoplasma pneumonia (1-5%)
28.  
 
A  mechanistic  connection  between  an  antecedent  C.  jejuni  infection  and  GBS  was 
established when it was found that the lipo-oligosaccharide (LOS) synthesised by GBS 
associated  strains  of  C.  jejuni  often  have  inner  core  sugars  which  perfectly  mimic 
gangliosides in their structure
39.  Thus molecular mimicry between pathogen and self was 
proposed  as the underlying  aetiology.   In support of this hypothesis, anti-ganglioside 
antibodies from the sera of GBS and MFS patients cross react with LOS purified from 
ganglioside mimicking strains of C. jejuni
27,40.  It has since been shown that a number of 
strains of C. jejuni mimic a range of gangliosides, including mixtures of gangliosides, as 
part of their LOS molecule
41,42. 
 
1.3  Models of GBS 
 
The role of anti-ganglioside autoantibodies and the molecular mimicry hypothesis are 
supported by a number of animal and human studies which have revealed the importance 
of gangliosides, ganglioside mimics and genetic factors found in the pathogen and host.  
Immunisation  of  rabbits  with  gangliosides  GD1b  or  GM1  induces  acute  neuropathies 
which are histologically similar to acute ataxic neuropathy (GD1b) and AMAN (GM1)
43-
45.    In  addition,  humans  injected  with  animal  gangliosides  occasionally  develop  the 
AMAN subtype of GBS and this correlates with the production of anti-GM1 antibodies.  
These antibodies are not present in ganglioside recipients who do not develop GBS
46.  
The injection of anti-ganglioside antibodies alone into mice is insufficient to cause GBS.  
It is thought that this may be due to an intact blood nerve barrier protecting nerves, due to 
insufficient  ganglioside  expression  or  due  to  weak  murine  complement  activity.    In  20 
support of this, it has been shown that mouse monoclonal antibodies to GD1a, or serum 
from a patient with AMAN (in conjunction with a fresh source of human complement), 
can  cause  conduction  block  in  motor  axons  in  mice  genetically  engineered  to  over-
express GD1a
47.  
 
Important studies directly confirming the link between ganglioside mimicking C. jejuni 
LOS with anti-ganglioside antibodies have been conducted.  Rabbits immunised with 
ganglioside mimicking LOS have been shown to produce antibody responses which are 
cross reactive between gangliosides and their biochemically defined LOS mimics 
48-50.   
 
As gangliosides are a widely expressed self-antigen, it is expected that there is a high 
degree of immune system tolerance preventing self-reactivity.  The role of tolerance has 
been  investigated  using  GalNAc-Transferase  knockout  mice  in  which  the  ganglioside 
synthesising  biochemical  pathway  has  been  disrupted.    These  mice  lack  all  complex 
gangliosides  synthesised  beyond  the  GalNacT  step,  and  instead  over-accumulate  the 
simple gangliosides such as GM3 and GD3
51.  When normal mice are immunised with 
gangliosides or ganglioside mimicking LOS, they produce a weak antibody response.  
However,  when  complex  ganglioside-naïve  mice  are  immunised  with  complex 
gangliosides, or ganglioside mimicking LOS, they produce a robust antibody response 
with  isotype  class  switching  to  T  cell  dependent  IgG  isotypes  and  immunological 
memory
52.    This  confirms  that  failure  of  tolerance  is  an  important  factor  in  GBS 
pathogenesis. 
 
1.4  Immunobiology of GBS 
 
Analysis  of  GBS  patient  sera  reveals  intriguing  insights  into  the  induction  of 
autoimmunity and the requirements for tissue damage.  There are several reasons for 
believing  antibody  isotype  class  switching  to  IgG  is  an  important  factor  in  GBS 
pathogenesis.  IgG1 and IgG3 are associated with AMAN and IgG1, IgG3 and IgG2 are  21 
associated with MFS
53,54.  The predominant isotype appears to be related to the triggering 
infection, for example, IgG1 responses are associated with C. jejuni
55.  Antibody isotype 
is  also  a  prognostic  indicator  as  IgG1  is  associated  with  an  increased  duration  of 
disease
56. 
 
Class switch recombination to IgG1 and IgG3 is thought to be a T cell dependent process 
characteristic of a Th1 dominated response, although the requirements for class switch 
recombination are poorly defined in humans
57.  Interestingly, these isotypes are more 
often  associated  with  responses  against  protein  antigens,  whereas  IgG2  is  normally 
associated with responses to glycolipids such as gangliosides or LOS
58,59.  In C. jejuni 
enteritis not associated with GBS, IgG2 is the antibody isotype seen in response to the 
glycolipid  LOS
60.    This  suggests  that  ganglioside  mimicking  strains  may  sometimes 
induce  idiosyncratic  immune  responses  in  GBS.    In  contrast  to  IgG  anti-ganglioside 
antibodies, poly-reactive IgM anti-ganglioside antibodies of low affinity are present in 
normal  human  serum  as  part  of  the  “natural”  antibody  repertoire  associated  with 
responses to bacteria
61 and these are not pathogenic.   
 
A rabbit model of GBS shows that affinity maturation and the appearance of high affinity 
antibodies coincides with disease onset
62.  Affinity maturation of high affinity antibodies 
is  generally  thought  to  be  a  T  dependent  phenomenon.    The  importance  of  affinity 
maturation is highlighted by occasional case reports of humans with low affinity IgG 
anti-ganglioside antibodies who remain disease free
63. 
 
These studies suggest that isotype class switching and affinity maturation are important in 
most  instances  of  GBS.    Different  subclasses  of  IgG  possess  substantially  different 
effector functions with the GBS associated isotypes, IgG1 and IgG3, being more effective 
at  fixing  complement  and  binding  Fcγ  receptors
64.    Class switching  to  IgG  has  been  
associated  with  onset  of  autoimmunity  in  mouse  models  of  various  autoimmune 
diseases
65.  Models studying anti-erythrocyte specific mouse IgG antibodies show that  22 
high affinity IgG is essential for pathogenic complement activity although binding to Fcγ 
receptor bearing effector cells could compensate for low affinity binding to the target
66,67 
(mouse IgG2a is the most effective isotype at complement activation and Fcγ receptor 
binding).  These studies demonstrate that both class switching and affinity maturation can 
contribute to pathogenicity. 
 
GBS is an uncommon outcome following C. jejuni enteritis and occurs in approximately 
one in every thousand cases
68.  This may be due to factors associated with the host or 
pathogen.  There is very limited, and inconclusive, evidence to support genetic influences 
leading to an increased susceptibility to GBS.  A small study showed a 2.6 fold increased 
risk in siblings developing GBS and repeated episodes of GBS occasionally occur in the 
same patient (although this may represent immunological memory)
69.  A TNFα2 allele 
has  been  linked  to  increased  risk  of  GBS  in  Japanese  patients
69,70.    Other  studies  of 
immune receptor polymorphisms (FcγRIIIb and mannose binding lectin) show links to 
disease severity rather than occurrence
71-73.  In contrast to the majority of autoimmune 
diseases, there is a lack of conclusive evidence linking GBS to particular MHC class I or 
II  alleles
72,74.    In  addition,  there  is  no  evidence  of  an  association  of  GBS  with 
polymorphisms in the glycolipid antigen presenting molecules CD1A or CD1E
75 and a 
study of 242 GBS patients found no association of GBS with polymorphisms in the LPS 
receptor molecules CD14 and TLR4 (Toll Like Receptor 4)
71. 
 
1.5  C. jejuni pathogenesis 
 
C. jejuni is a genetically variable, gram negative, spiral shaped, motile bacterium with 
unipolar or bipolar flagellum
20,76.  It is a leading cause of food poisoning world-wide
77.  
While  it  is  often  a  common  commensal  of  birds  and  mammals,  in  humans  it  causes 
gastroenteritis with bloody or watery diarrhoea
76.  A large number of strains of C. jejuni 
are recognised and these are typed either by the heat-stable antigenic system of Penner 
(over 70 serotypes), the heat-labile antigen of Loir (over 100 serotypes) or by direct DNA  23 
comparisons
78.  The Penner serotype O:19 and GD1a mimicking strains appear to be 
over-represented in GBS cases
79,80,81.   C. jejuni strains express ganglioside mimics either 
alone or in differing ratios (for example GM1 and GD1a at a 1:1 ratio, GM1 and GD1a at 
a 9:1 ratio, GM2 alone etc).  Although C. jejuni is a gut mucosal pathogen, it occasionally 
causes systemic infections with systemic immune responses
82,83.  IgA antibodies against 
GM1 are found in 17% of C. jejuni associated GBS cases and these antibodies belong to 
the IgA1 subclass which is more commonly found in systemic responses (rather than the 
secretory subclass seen in mucosal responses)
84. 
 
Following colonisation of the small bowel, C. jejuni transits to the colon which is the 
main target organ of disease
85.  C. jejuni adheres to epithelial cells using a number of 
adhesins
86,87 and can disrupt tight junctions
88-90.  C. jejuni is able to invade
91 epithelial 
cells and macrophages where it replicates intracellularly
92,93.  These interactions trigger a 
number of inflammatory signalling pathways, such as NF-κB (Nuclear Factor κB)
94,95.  
The sensing of C. jejuni by innate pattern recognition receptors is poorly understood 
although it appears that C. jejuni has evolved to limit immune activation in humans.  For 
example, C. jejuni flagellin lacks the sites necessary to activate the flagellin receptor 
TLR5
96,97, while the low CpG (Cytosine-phosphate-Guanine) content of C. jejuni DNA 
results  in  reduced  ability  to  stimulate  the  unmethylated-CpG-dinucleotide-receptor 
TLR9
98.  However, C. jejuni derived LOS triggers cytokine release from dendritic cells
99 
suggesting LOS is the principal immunostimulatory element of C. jejuni. 
 
The role of C. jejuni LOS genes in GBS has been studied.  Biosynthesis of ganglioside 
mimicking  LOS  requires  specific  enzymes;  sialyltransferase  (CSTII);  N-
acetylgalactosaminyl-transferase  (CgtA)  and  galactosyltransferase  (CgtB)
100.    Genes 
responsible  for  LOS  biosynthesis  cluster  into  specific  LOS  biosynthesis  gene  loci.  
Specific loci are associated with GBS and with the presence of ganglioside mimicking 
LOS
101.    Mutant  strains  of  GBS  associated  C.  jejuni  which  are  incapable  of  LOS 
sialylation (CSTII knock out) have been generated and studied.  These knock out strains 
produce non-sialylated LOS structures such as asialo-GM3 (lactosyl ceramide), asialo- 24 
GM2 (GA2) and asialo-GM1 (GA1).  Unlike the wild type variant, the LOS molecules in 
the CSTII knock out strains do not cross react with GBS patient sera nor do they generate 
anti-ganglioside antibodies when injected into susceptible mouse strains
101.  This study 
demonstrates the importance of C. jejuni LOS biosynthesis genes in GBS. 
 
1.6  C. jejuni LOS signalling in the immune system 
 
Lipopolysaccharide (LPS) is a glycolipid molecule which is a vital component of the 
outer membrane of gram negative bacteria and also functions as one of the main targets 
of  the  mammalian  innate  immune  system
102.    LPS  is  generally  divided  into  three 
covalently  linked  parts;  the  Lipid  A,  the  carbohydrate  O-side  chain  and  the  core 
sugars
103,104.  While LPS has an extended O-side chain, LOS has a truncated structure 
consisting of the core sugars alone (see figure 1 for a diagrammatic representation of 
Escherichia coli smooth mutant LPS and C. jejuni rough mutant LOS).  Immune sensing 
of LPS results in activation of a wide range of cells such as macrophages, dendritic cells 
and specific classes of B and T lymphocytes
105-110.  The immunostimulatory properties of 
LPS reside in the Lipid A tail
111.  The structure of Lipid A varies between, and within, 
strains of gram negative bacteria and this imparts species specific properties and potency 
on LPS molecules
102.  E. coli LPS is considered the most potent LPS.  The C. jejuni Lipid 
A backbone has a unique structure amongst gram negative bacteria.  Despite this, C. 
jejuni retains its endotoxic activity although it is somewhat less potent than other forms 
of LPS
102,112. 
 
Toll Like Receptors (TLRs) are sensing receptors of the innate immune system capable 
of recognising conserved Pathogen Associated Molecular Patterns (PAMPs) expressed by 
bacteria,  viruses  and  fungi
113,114.    These  receptors  form  the  first  line  of  pathogen 
recognition and trigger a broad range of activation events including secretion of cytokines 
and  functional  maturation  of  immune  cells
114,115.    TLR4  was  demonstrated  to  be  the 
principal receptor mediating recognition of bacterial LPS when it was shown that the LPS  25 
hyporesponsive mouse strains, C3H/HeJ and C57BL/10ScCr, have mutations affecting 
the Tlr4 gene
116.  TLR4 recognition of LPS involves a number of associated molecules 
and  is  partly  dependent  on  the  specific  structure  of  the  LPS  being  recognised.    LPS 
Binding  Protein  (LBP)  is  a  serum  protein  which  binds  to,  and  delivers,  LPS  to 
CD14
117,118.  CD14 is expressed by myeloid cells and is found in serum in a soluble form.  
CD14  transfers  LPS  to  a  complex  consisting  of  TLR4  and  MD-2
119  and  this  in  turn 
causes TLR4 oligomerisation which brings TLR4 intracellular Toll-interleukin-1 receptor 
(TIR) domains  together and facilitates signal transduction
120.   
 
There  are  five  adaptor  proteins  involved  in  TLR4  signalling:    MyD88  (myeloid 
differentiation  primary  response  gene  88),  Mal  (MyD88  adapter  like),  TRIF  (TIR 
domain-containing  adaptor inducing  IFN-β), TRAM (TRIF related adaptor molecule), 
and  SARM    (sterile  α  and  HEAT-Armadillo  motifs-containing  protein)
121.    TLR4  is 
unique amongst TLRs in its use of all of these adaptor molecules while other TLRs 
employ  only  some.    Signalling  via  TLR4  is  divided  into  two  pathways;  the  MyD88 
dependent pathway and the MyD88 independent (TRIF dependent) pathway.  While both 
pathways cross over at the level of NF-κB, the MyD88 dependent pathway is generally 
considered to trigger pro-inflammatory cytokine production, while the TRIF dependent 
pathway induces Type I interferons and interferon inducible genes
122.  Studies of CD14 
mutated mouse strains have shown that “rough mutant” LPS, such as the truncated LOS 
found in C. jejuni, are capable of signalling via the TLR4-MyD88 pathway in the absence 
of CD14, whereas “smooth mutants”, such as E. coli LPS, cannot
123. 
 
Negative regulators of TLR4 signalling are numerous and act at multiple levels in the 
signalling  cascade
122.    For  example,  the  plasma  membrane  expressed  receptor  RP105 
(radioprotective 105) is believed to function on myeloid cells to inhibit LPS association 
with TLR4.  Consistent with this, RP105 deficient mice show higher levels of serum 
TNF-α  following  LPS  challenge
124.    TRIAD3A  (triad-domain  containing  protein  3 
variant  A)  and  SOCS-1  (suppressor  of  cytokine  signalling  1)  are  both  intracellular 
proteins which inhibit the TLR4 signalling cascade at multiple points.  TRIAD3A over- 26 
expression promotes degradation of TLR4 and TRIF, as well as downregulation of NF-
κB activation
125.  SOCS-1 promotes degradation of TIRAP and there is increased pro-
inflammatory cytokine secretion in LPS stimulated SOCS-1deficient macrophages
126. 
 
LPS stimulation of B cells causes polyclonal proliferation and differentiation. LPS is not 
considered a good initiator of class switching or memory
109.  B cells are distinct from 
macrophages and dendritic cells in their requirements for LPS stimulation.  Firstly, B 
cells are considered less sensitive than myelomonocytes to LPS stimulation.  Secondly, a 
novel  set  of  receptor  molecules,  RP105/MD1,  which  are  structurally  similar  to 
TLR4/MD2 but lacking TIR domains, are important for LPS responses.  B cells lacking 
RP105 are hyporesponsive to LPS in terms of proliferation and antibody production
127.  
However,  co-stimulator  up-regulation  is  not  impaired  in  the  absence  of  RP105
128.  
Although TLR4 and MD2 are expressed at extremely low levels on naïve B cells, in their 
absence, B cells do not respond to LPS at all.  RP105/MD1 is expressed elsewhere by the 
immune system and in contrast to the apparent stimulatory function on B cells, they serve 
to inhibit TLR4 signalling
129.  It is clear from these studies that the molecular pathways 
of B cell activation by LPS are complex and there is potential for unique or aberrant 
signals by unusual Lipid A structures (such as C. jejuni) or rough versus smooth mutants. 
 
LPS causes polyclonal activation of B cells in an antigen independent manner through 
TLR4 signalling.  However, by linking the hapten 4-hydroxy-3, 5-dinitrophenyl (NNP) to 
LPS  and  measuring  anti-NNP  antibody  production  following  in  vitro  stimulation  of 
splenocytes with LPS-NNP, it was shown that antigen specific activation of B cells by 
LPS  occurs  at  substantially  lower  concentrations  than  polyclonal  activation
130.    It  is 
thought that in these circumstances the B cell receptor (BCR) can concentrate the LPS 
near the B cell surface which potentially allows cross-linking of the BCR and TLR4.  The 
BCR essentially substitutes for CD14, which is not expressed by B cells, in the function 
of concentrating LPS to the TLR4 complex. 
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LPS is frequently used as an in vitro B cell mitogen at concentrations of between 10 and 
30µg/ml.  Polyclonal activation begins at about 0.1µg/ml.  However, concentrations as 
low as 2ng/ml LPS-NNP are sufficient to stimulate NNP antigen specific B cells
130.  The 
Marginal Zone (MZ) B cell subset is more sensitive to LPS than Follicular Origin (FO) B 
cells and responds at lower concentrations with more rapid kinetics
131.  A serum LPS 
concentration of 10ng/ml is associated with an extremely high mortality in humans
132.  It 
is clear that in vivo polyclonal activation of B cells by LPS is an uncommon event except 
in severe sepsis.  B cell sensitivity to LPS serves to select out antigen specific clones 
useful  in  the  immune  response  against  the  LPS  bearing  pathogen.    This  concept  can 
explain  the  selection  and  emergence  of  ganglioside  specific  B  cells  in  GBS  without 
polyclonal activation (which is not a feature of GBS).  In addition, if unique or aberrant 
signalling  occurs  via  C.  jejuni  LOS  then  it  may  be  restricted  to,  or  amplified  on, 
ganglioside  specific  B  cells  due  to  the  concentrating  effect  of  the  BCR.    Cross-talk 
between the B cell receptor and TLR4 has been shown to occur during LPS stimulation
133 
indicating that both signalling pathways can be modulated by each other, or perhaps any 
additional signal, for example, if the ganglioside mimic is able to deliver a signal. 
 
1.7  Gangliosides in the immune system 
 
GBS-associated  C.  jejuni  LOS  mimics  gangliosides  which  are  glycolipid  molecules 
expressed widely in the body including on immune cells.  Although their exact function 
remains enigmatic, they are associated with various immune-modulating functions
134.  
 
Gangliosides exhibit immunomodulatory activity towards a number of different immune 
cell populations and, generally speaking, their effects tend to be inhibitory
135-138.  The 
mechanisms by which exogenous, or tumour derived, gangliosides mediate receptor non-
specific  effects  are  poorly  understood.    Gangliosides  have  been  shown  to  negatively 
regulate  the  transcription  factor  NF-κB  by  inhibiting  its  activation  and  nuclear 
translocation in macrophages
138,139 and T cells
140.  Certain gangliosides, including GM1  28 
and GD1a, have been shown to reversibly inhibit activation of monocytes which were 
stimulated  through  a  number  of  TLR  receptors,  including  TLR4,  and  this  inhibition 
coincided  with  upregulation  of  the  inhibitory  molecule  IRAK-M  (IL-1  receptor 
associated kinase-M)
141.  In a separate study, it was shown that the carbohydrate moiety 
is necessary for the immunosuppressive activity of GD2 ganglioside.  However, it was 
the  length  of  the  acyl  chains  in  the  ceramide  moiety  that  appeared  to  determine  the 
strength of the effect
142.  This is an important consideration as C. jejuni LOS only mimics 
the carbohydrate portion and not the ceramide portion of gangliosides.  It is thought that 
non-receptor specific ganglioside effects rely on insertion of gangliosides into lipid rafts. 
 
An  alternative  mechanism  of  ganglioside  immune-modulation  is  via  receptor  specific 
interactions such as the sialic acid binding immunoglobulin like lectins (siglecs).  Siglecs 
are  a  family  of  receptors  which  bind  sialylated  glycoconjugates  and  are  expressed 
differentially on various immune system cells
143 (see Appendix 2 for siglec structure and 
cellular  expression;  see  Appendix  3  for  known  siglec  binding  profiles).    Siglecs  are 
divided into two categories on the basis of sequence similarity.  Sialoadhesin (Siglec 1), 
CD22 (Siglec 2), Myelin Associated Glycoprotein (Siglec 4) and Siglec 15 form one 
group while CD33 (Siglec 3), Siglec 5 to 11 and Siglec 14 make up the second group 
(termed the CD33 related siglecs)
144.  The murine CD33 related siglecs comprise CD33, 
Siglec E, Siglec F, Siglec G and Siglec H while the non-CD33 related siglecs are named 
the  same  as  for  humans
144.    Most  of  the  CD33  related  siglecs  have  two  conserved 
cytoplasmic  Immunoreceptor  Tyrosine-Based  Inhibitory  Motifs  (ITIMs)  or  ITIM-like 
motifs
144.    Classically  ITIMs  function  to  inhibit  signalling  through  Immunoreceptor 
Tyrosine-Based Activation Motifs (ITAMs) which form the signalling motifs of several 
types of activating receptors
145.  There are significant variations in siglec receptors in 
their expression on haemopoietic cells, their sialic acid binding specificity and in their 
signalling motifs.  Some siglecs, for example Siglec 13, Siglec 14, Siglec 15, and Siglec 
H,  associate with adaptor proteins such as DAP12 which itself has an activating ITAM 
motif
146, while other siglecs such as Sialoadhesin have no signaling motif, although the 
receptor  appears  to  enhance  phagocytosis  while  inhibiting  dendritic  cell  antigen 
presentation
147.  Numerous studies have demonstrated the immunomodulatory function of  29 
siglecs  and  these  effects  include  inhibiting  proliferation  and  activation,  promoting 
apoptosis and promoting pro-inflammatory cytokine secretion
144.  Certain members of the 
siglec  family  are  capable  of  binding  gangliosides  and  in  one  instance  binding  to 
ganglioside mimicking LOS has been shown.  Siglec 7 (expressed on human NK cells 
and  monocytes)  mediates  sialic  acid  dependent  binding  to  LOS  extracted  from 
GM1/GT1a or GM3 mimicking strains of C. jejuni
148.  The functional consequence of 
this remains to be investigated.   
 
The ganglioside GM1 is one of the few endogenous ligands known to be presented by the 
CD1  class  of  MHC  I-like  antigen  presenting  molecules.    CD1  presents  glycolipid 
antigens to specific classes of T cells which are potent sources of immune polarising 
cytokines
149.    However,  there  is  no  conclusive  evidence  to  suggest  that  ganglioside 
mimicking LOS can substitute for gangliosides in the binding pocket of CD1 molecules. 
 
Rough  and  smooth  O-antigen  side  chains  alter  the  interaction  of  LPS  with  the 
TLR4/MD2 receptor complex
123.  Few studies have addressed whether the side chain is 
capable  of  signalling  independently,  or  co-operatively,  with  the  Lipid  A  through 
interactions with non-TLR4 receptors.  However, it has been shown that  LPS O-side 
chains bearing mannose are capable of mediating enhanced adjuvant activity through co-
operative signalling via the mannose receptor on myeloid cells
150-152.  A possible direct 
link  between  gangliosides  and  TLR4  signalling  has  been  revealed  using  Neu1 
(neuraminidase 1) deficient mice and neuraminidase inhibitors such as Tamiflu.  For full 
TLR4 signalling to occur, endogenous α2-3 linked sialic acid residues associated with the 
TLR4  must  be  cleaved,  otherwise  there  is  a  deficiency  in  inflammatory  cytokine 
production
153,154.  LOS which mimics gangliosides GM1 and GD1a expresses α2-3 linked 
sialic  acid  residues.    It  is  theoretically  possible  that  these  can  substitute  for  the 
endogenous sialic acid and affect TLR4 signalling. 
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There are clearly a number of ways in which gangliosides can alter immune function and 
it is possible that ganglioside mimicking LOS can substitute for gangliosides in these 
properties.  For example, they could deliver a second signal in addition to Lipid A/TLR4 
and also alter how the bacteria are taken up and processed by immune cells.  Either of 
these  events  might  have  a  substantial  effect  on  the  immune  response  to  ganglioside 
mimicking C. jejuni or the maintenance of self-tolerance by the responding cells. 
 
1.8  Immune responses to carbohydrate antigens 
 
Thymus independent (TI) antigens are molecules capable of directly stimulating B cell 
antibody responses without the requirement of conventional, MHCII restricted, T cell 
help
155.  Although not an exclusive rule, generally speaking, carbohydrate and glycolipid 
molecules, such as LOS and gangliosides, tend to be TI antigens, while proteins and 
peptides tend to be thymus dependent (TD) antigens.  TI antigens are sub-classified into 
TI-1,  which  stimulate  all  sensitive  B  cells  through  innate  receptor  signalling  such  as 
TLR4, and are capable of causing polyclonal activation, and TI-2, which have repeating 
epitopes which cross link B cell receptors delivering an antigen specific signal which 
drives activation
156.  LPS, and presumably C. jejuni LOS, signals through the innate LPS 
receptor TLR4 and are therefore TI-1 antigens.  Although gangliosides do not express 
multiple epitopes on the same molecule, they behave as TI-2 antigens
157 presumably due 
to aggregates of molecules providing repeating epitopes, for example in micelles or cell 
membranes.  Ganglioside mimicking LOS might also be considered a TI-2 antigen, as 
well  as  a  TI-1  antigen,  for  this  same  reason.    Immune  responses  to  TI  antigens  are 
substantially different than responses to conventional TD antigens and involve specific 
sub-populations of B and T cells.  TI responses provide prompt and specific humoral 
responses to common bacterial products such as capsular polysaccharides and LPS
156. 
 
There is no conclusive evidence that GBS represents a pure TI immune response or that 
C. jejuni LOS alone is sufficient to induce GBS.  Natural infection with C. jejuni results  31 
in exposure to a range of antigens including proteins and bacterial DNA/RNA.  Models 
of  GBS  use  adjuvants  such  as  Freund’s  and  Keyhole  Limpet  Haemocyanin  which 
introduce  protein  antigens  and  thus  engage  T  cell  help.    In  addition,  the  pathogenic 
antibody isotypes often seen in GBS are considered to be “T dependent”.  However, the 
ganglioside target in GBS, like LOS, is a non-protein molecule and is not presented for T 
cell help by conventional means.  The immune response associated with GBS is often 
transient and no clear evidence of a lasting B cell memory has been shown.  These are 
features  more  in  keeping  with  TI  responses.    The  lack  of  an  MHC  association  with 
GBS
72,  which  is  virtually  unique  amongst  auto-immune  diseases,  raises  important 
questions about the exact role of T cells, or more specifically, protein antigens. 
 
The naïve murine B cell compartment consists of two broad subsets, B1 (comprising B1a 
and  B1b)  and  B2  (comprising  MZ  and  FO  B  cells).    Each  subset  shows  distinct 
anatomical localisation.  B1 B cells are found primarily in the peritoneal and pleural 
cavities
158 while the B2 subsets are located in secondary lymphoid organs such as the 
spleen and lymph nodes.  Within the secondary lymphoid organs, MZ B cells are located 
near  the  marginal  sinus  where  they  are  able  to  interact  with  particulate  blood  borne 
antigens such as encapsulated bacteria
131.  The traditional view is that B1 B cells and MZ 
B  cells  contribute  to  TI  immune  responses  to  glycolipid  antigens  and  have  a  limited 
capacity  for  affinity  maturation  and  class  switch  recombination
131,158.    FO  B  cells 
participate  in  TD  immune  responses  to  protein  antigens  and  produce  highly  specific 
affinity matured antibodies, with class switch recombination.  They are classically not 
thought to play a major role in TI responses.  However, the roles of B cell subsets are not 
as clearly delineated as this model suggests. 
 
B1 B cells are thought to bridge the gap between innate and adaptive immunity.  They are 
long  lived  cells  with  a  BCR  repertoire  which  is  skewed  towards  polyreactivity  with 
common  bacterial  and  self  antigens,  particularly  carbohydrate  antigens.    Being 
exquisitely sensitive to LPS, they are believed to be important in TI-1 immune responses.  
B1 B cells, alongside MZ B cells, are considered to be the source of natural IgM.  B1 B  32 
cells undergo class switch recombination to IgG3 and IgA although they do not usually 
undergo affinity maturation to any great extent
158,159.  Animal and human studies of GBS 
indicate that isotype class switching and possibly affinity maturation are key events in 
pathogenesis.    Although  B1  B  cells  are  probably  responsible  for  the  natural  anti-
ganglioside IgM (not usually associated with GBS), their restricted capacity for affinity 
maturation  and  class  switch  recombination  makes  them  an  unlikely  candidate  as  the 
source of the high affinity IgG autoantibodies seen in GBS. 
 
MZ  B cells are essential for TI-2 responses
155.  MZ  B cells (reviewed
160) are highly 
enriched in the marginal zone of the spleen.  This region contains a number of specialised 
immune  cells  such  as  marginal  dendritic  cells  and  marginal  zone  metallophilic 
macrophages.  The latter population expresses siglec receptors and are postulated to play 
a role in capturing  carbohydrate antigens to present to B cells
161.  MZ B cells share 
properties with B1 B cells that make them important in TI responses
162; they are highly 
sensitive to LPS (expressing higher levels of RP105/MD1 than FO B cells) and they 
respond rapidly following activation and produce large quantities of antibody
158,163.  The 
preferred isotypes of murine MZ B cells are IgM and IgG3
158 although they are capable 
of class switching to all IgG isotypes including those associated with GBS
160,164.   
 
Marginal  zone  B  cells  participate  in  both  TI  and  TD  immune  responses
165.    When 
stimulated with TD antigens, MZ B cells are able to form early antibody secreting cells as 
well  as  later  germinal  centres  with  associated  affinity  maturation  and  class  switch 
recombination
166.    MZ  B  cells  also  selectively  participate  in  extrafollicular  immune 
responses to TI-2 antigens which do not involve germinal centres.  Although an initial 
interaction  with  T  cells  is  seen,  the  plasmablasts  depend  on  accessory  help  from  a 
specialised  population  of  CD11c
+  dendritic  cells  which  provide  survival  signals  and 
promote  isotype  class  switching  in  a  T-independent  manner.    Both  class  switch 
recombination  and  affinity  maturation  occur  to  a  lesser  degree  than  that  found  in 
germinal centres
165,167.  MZ B cells, unlike FO B cells, are potent activators of naïve CD4 
T cells early in the immune response.  They express higher levels of MHCII, higher  33 
levels of co-stimulatory molecules and are capable of polarising T cells towards a Th1 
phenotype
168.  In addition, MZ B cells express the antigen presenting molecule CD1c 
which  allows  presentation  of  glycolipid  antigens  to  specific  subsets  of  T  cells
160,169.  
However,  the  transient  nature  of  GBS  and  the  lack  of  any  evidence  supporting  the 
existence of B cell memory following GBS would suggest that T cells are not involved in 
the conventional sense. 
 
Models of GBS and other autoimmune diseases suggest that isotype class switching and 
affinity  maturation  are  important  events  leading  to  pathogenesis.    The  factors  which 
control these during B cell responses to TI antigens are less well understood than to TD 
antigens.  This is made more complicated by the fact that substantial differences exist 
between human and mice in the generation of the MZ B cell pool.  For example, genetic 
studies  of  MZ  B  cells  in  humans  before  and  after  immunisation  with  polysaccharide 
antigens  have  shown  that  MZ  B  cells  which  participate  in  the  response  had  already 
undergone  somatic  mutation  prior  to  vaccination  suggesting  humans  have  a  pre-
diversified repertoire.  Isotype switching however takes place during the evolution of the 
response
160,170,171.    Whatever  factors  govern  this  pre-diversification  may  have  a 
substantial bearing on GBS.  The factors that govern isotype class switching are also 
poorly understood.  The antigen itself appears to have some bearing on the nature of the 
response  and  the  resulting  IgG  isotype.    For  example,  an  antigen  engineered  to  be 
expressed internally in E. coli triggered a TD response, while the same antigen expressed 
on the surface triggered a TI response
172.  In addition, a polysaccharide antigen and a 
protein  antigen  which  mimics  the  polysaccharide  antigen  (an  idiotype  antibody)  both 
triggered  TI  type  responses  (IgM  and  IgG3)
173-175,  indicating  the  shape  and  not  the 
chemistry  of  the  antigen  was  important.    Other  factors  common  to  both  TD  and  TI 
responses appear important in class switching to the highly pathogenic IgG2a isotype, for 
example co-operative signalling through complement receptors and IFN-γ.  IFN-γ may be 
derived from conventional T cells, innate lymphocytes (such as Natural Killer (NK) cells) 
or other accessory cells
155. 
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T cells are able to recognise glycolipid molecules when they are presented on a novel 
family  of  MHC  I  like  antigen  presentation  molecules  termed  CD1  (reviewed
176).  
Humans express five CD1 molecules (CD1a to CD1e) on antigen presenting cells.  These 
are sub-classified into families.  CD1a to CD1c comprises one family and CD1d and 
CD1e comprises two additional families. Mice only express CD1d.  There is a degree of 
lipid  binding  specificity  between  CD1  molecules  although  some  molecules,  such  as 
sulphatide, show promiscuity in being able to bind to several CD1 types.  
 
T cells capable of engaging CD1 fall into two broad categories: those that engage CD1a 
to CD1d, which behave in a similar manner to conventional peptide specific T cells, and 
those that engage CD1d alone.  The majority of this latter group (termed iNKT cells) 
have semi-invariant T cell receptors and behave in an innate manner in that they are 
capable of rapidly producing large quantities of cytokines including IL-4 and IFN-γ.   
 
There has been considerable progress made in the identification of ligands for CD1, and 
these include both pathogen and self molecules(reviewed
176).  The majority of bacterial 
antigens  are  cell  wall  components,  particularly  those  derived  from  Mycobacterium 
tuberculosis.  Bacterial lipopeptides have also been found to bind to CD1.  Intriguingly, 
gangliosides  are  prominent  amongst  the  known  self-ligands,  particularly  of  CD1b.  
Ganglioside specific T cells have been isolated from multiple sclerosis patients.  In order 
to bind to CD1, the fatty tail of the ligand must conform to the hydrophobic binding 
pockets of the CD1 molecule while the carbohydrate portion must sit in, or extend from, 
the binding groove.  There is no evidence that LPS lipid A, and presumably LOS lipid A, 
is capable of binding to CD1. Binding would not be predicted by the nature of the acyl 
chains  on  the  Lipid  A  tail.    Therefore  it  is  unlikely  that  C.  jejuni  LOS,  with  its 
ganglioside  mimic,  can  be  presented  directly  to  T  cells  (unless  there  is  some,  as  yet 
unknown, processing pathway that substantially alters its Lipid A tail). 
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There are alternative routes by which LPS molecules might activate the T cell arm of the 
immune system.  Studies using Salmonella typhimurium LPS (rough mutant) have shown 
that dendritic cells activated by LPS secrete IL-12 which in turn activates iNKT cells.  
Surprisingly this was in a CD1d dependent manner, indicating that some sort of self 
antigen,  or  alteration  of  self  antigen,  was  being  sensed  alongside  the  IL-12  (as  LPS 
cannot itself be presented on CD1d).  In addition, there is evidence that iNKT cells can be 
activated directly by TLR ligands
110. 
 
The role of T cells in GBS is largely unexplored although studies show no association 
with CD1
75 or MHC haplotypes.  In addition, a mouse model generating anti-ganglioside 
antibodies  showed  no  role  for  the  murine  glycolipid  antigen  presenting  molecule 
CD1d
177.  However, this does not rule out non-antigen specific T cell help, as discussed 
above, in providing the cytokines necessary for pathogenic class switching. 
 
1.9  Tolerance to carbohydrate antigens 
 
Humoral  tolerance  to  carbohydrate  antigens  probably  follows  similar  mechanisms  to 
tolerance to protein antigens.  A number of complex factors determine tolerance  and 
some  of  the  principal  mechanisms  are  receptor  editing  or  deletion  during  ontogeny, 
antigen ignorance, anergy and suppression. 
 
These processes may have specific differences when they relate to carbohydrate antigens 
and GBS.  For example, MZ B cells and B1 B cells which take part in anti-carbohydrate 
responses also contribute to the natural immune antibody repertoire which contains anti-
ganglioside specificities even in healthy people
61,63.  Rather than negative selection of 
auto-reactive clones, the B cells which contribute to the natural repertoire are positively 
selected against self-antigen and possibly commensal flora in the gut
178-181.  It appears 
that the affinity of the self-reactive BCR determines the fate of the B cell.  For example, 
mice have been genetically engineered to express an anti-αGal (carbohydrate) antibody.   36 
In an αGal negative background, these B cells escape into the periphery and produce IgM 
antibodies of a sufficient affinity to reject αGal expressing grafts.  However, in an αGal 
expressing background, the anti-αGal (auto-reactive) B cells are located in the marginal 
zone  (presumably  becoming  MZ  B  cells),  but  have  edited  their  receptors  to  produce 
lower affinity, non-pathogenic, anti-αGal IgM antibodies
182.  In genetically engineered 
anti-red blood cell autoantibody transgenic mice, the conventional B cells get clonally 
deleted  but  auto-reactive  B1  B  cells  persist  in  the  peritoneal  cavity  usually  without 
causing  disease.    Anaemia  develops  when  the  B1  B  cells  are  activated  by  oral 
administration of LPS
183 or injections of cytokines IL-10 or IL-5
184.  
 
It is clear that the presence of anti-ganglioside antibodies is not in fact the mystery of 
GBS, but rather what activation events take place that allow them to become pathogenic.  
Animal  models  and  human  studies  suggest  isotype  switching  and  affinity  maturation 
(either one or both) are important events.  As low affinity anti-ganglioside specificities 
are  already  in  place  there  are  additional  mechanisms  of  tolerance  in  these  B  cell 
populations which must be bypassed if they are to be responsible for the autoimmunity 
seen in GBS.  For example, cross linking of the BCR in B1 B cells does not lead to 
activation, as it does in conventional B cells, but instead induces apoptosis
185.  Additional 
stimulation in the form of LPS or cytokines is also required
183,186.  In addition, despite 
repeated  immunisation,  B1  cell  anti-carbohydrate  responses  will  only  show  limited 
isotypes (IgM, IgA and IgG3 in mice), no typical memory responses and limited or no 
affinity maturation
187-190.  These combined factors will serve to protect the host from 
autoimmunity even when LPS type stimulation is present alongside ganglioside mimicry, 
such as with ganglioside mimicking LOS.  MZ B cells present a different problem as they 
are more like conventional FO B cells in their capabilities to class switch and affinity 
mature.  Previously described studies have demonstrated that MZ B cell receptors are 
edited to remove those with high affinity for self-antigens.  In addition, extensive cross 
linking of the BCR renders both immature and mature B cells anergic
156 and therefore 
epitope  density  and  presumably  whether  the  antigen is  soluble  or  particulate  may  be 
important in determining tolerance to TI-2 antigens.  Those MZ B cells that enter the 
germinal centre to participate in responses might be subject to the same T cell help and  37 
regulatory mechanisms as FO B cells responding to conventional peptide antigens, while 
those  MZ  B  cells  that  participate  in  extra-follicular  responses  show  less  affinity 
maturation and isotype switching
167, presumably due to a lack of T cell help. 
 
Antigen ignorance may play an important role in GBS.  While gangliosides are expressed 
throughout  the  body,  specific  gangliosides  are  concentrated  in  certain  regions.    For 
example,  GM1  is  concentrated  in  peripheral  motor  nerve  myelin
191  and  GQ1b  is 
concentrated in the occulomotor nerve
192.  Antibodies to GM1 are associated with motor 
deficits and antibodies to GQ1b are associated with opthalmoplegia
27.  Complexes of 
mixed gangliosides provide unique epitopes from single gangliosides
36 and the nerves are 
partially protected from the immune system by a blood nerve barrier.  Therefore, due to 
localised expression levels, the unique configurations of complexes and the blood nerve 
barrier,  it  is  possible  that  B  cell  receptors  are  not  exposed  to  all  of  the  possible 
arrangements  of  gangliosides  during  their  development  and  so  are  not  adequately 
tolerised.    In  addition,  it  is  possible  that  low  levels  of  low  affinity  anti-ganglioside 
antibodies can safely exist due the protection afforded by the blood nerve barrier. 
 
Substantial differences exist between the human and murine immune systems.  Some of 
these may impact on responses to TI-1 and TI-2 antigens, such as LOS and gangliosides, 
in GBS.  Murine B1 B cells have been recognised for some time and their function and 
phenotype have been studied extensively
188,193-195.  However, human B1 B cells remain a 
controversial entity whose existence is disputed, although B cells with an appropriate 
phenotype (CD5 positive) have been identified  in human peritoneal washings
196.  An 
additional  important  difference  is  that  the  LPS/LOS  receptor  TLR4  is  expressed  by 
murine, but not human, B cells
107,108,127,197.  This difference in TLR4 expression is no 
doubt responsible for a major difference in function between human and murine MZ B 
cells, that is, murine MZ B cells respond to TI-1 antigens whilst human MZ B cells do 
not
198.  However, there are more similarities than differences as both murine and human 
MZ B cells express high levels of CD21 and IgM.  In addition, both human and murine 
MZ B cells respond vigorously to TI-2 antigens, respond to TD antigens and are efficient  38 
antigen presenting cells
198.  No such comparison can be made between human and murine 
B1 B cells as the principal murine B1 marker, CD5, is expressed on a wider range of B 
cell populations in humans.  While such differences can be related directly to GBS, there 
are many more general differences between human and murine immunity
170.  This means 
that findings in murine models of GBS must always be taken in context and interpreted 
appropriately.  
 
1.10 Hypothesis  
 
The over-arching hypothesis is that ganglioside mimicking C. jejuni interact with the 
immune  system  in  a  unique  way  by  virtue  of  their  ganglioside  mimicry,  and  this 
contributes to the events that lead to a break in tolerance.  More specifically, the aim of 
this study is to address the following hypotheses: 
 
1.  LOS derived from a GBS associated strain of C. jejuni is able to bind to cellular 
or humoral ganglioside specific receptors through the ganglioside mimicking core 
sugars. 
2.  Binding  of  LOS  to  these  ganglioside  specific  receptors  alters  the  potency  or 
polarising properties of ganglioside mimicking LOS compared to non-mimicking 
LOS. 
3.  Binding of ganglioside mimics to these ganglioside receptors alters trafficking of 
the C. jejuni within the immune system. 
 
In essence, it is possible that ganglioside mimicking LOS can deliver three signals.  First, 
the Lipid A can be sensed by TLR4; second, the ganglioside mimic can interact with 
ganglioside specific BCR; and third, putatively, the ganglioside mimic can interact with 
endogenous  ganglioside  specific  receptors  or  can  mediate  cis  interactions  with 
endogenous gangliosides.  The importance of gangliosides goes beyond receptor specific  39 
interactions as they also play an important role in humoral immunity through interactions 
with natural antibody and complement components such as Factor H (fH)
199-201.  GBS is a 
heterogeneous  condition  and  it  is  clear  that  there  is  no  single  underlying  aetiology.  
Therefore it is unlikely there is a single pathway that leads to breaking of tolerance and 
autoimmunity.   
 
If all, or some, of these hypotheses are proven correct it will alter our understanding of 
how GBS associated strains of C. jejuni interact with the immune system and might shed 
light  on  the  events  leading  to  pathogenesis.    In  addition,  if  it  can  be  established  in 
principle that the ganglioside mimic is not simply a passive target of the BCR, but instead 
actively manipulates the immune system, this would provide an interesting new paradigm 
for any autoimmune disease in which molecular mimicry of a self signalling molecule 
can be shown to be a preceding event.  40 
2  Materials  and  Methods  (see  Appendix  1  for  buffers  and 
media) 
 
2.1  Analysis software  
 
2.1.1  Statistical analysis 
 
Data  were  analysed  using  GraphPad  Prism  4  (GraphPad  Software  Inc).    Figure 
illustrations follow the standard format (* = p<0.05, ** = p<0.01 and *** = p<0.001).  
Data were analysed using 1way ANOVA, 2way ANOVA with Bonferroni’s posttest or 
students T test where appropriate (detailed in text).  Graphs all show mean and standard 
error of the mean (SEM). 
 
2.1.2  Acquisition and analysis of FACS data 
 
FACS acquisition was done on a FACSCalibur machine (BD Biosciences) and analysis 
was done using FlowJo software (Treestar Inc)  
 
2.1.3  Analysis of immunohistology and immunocytology 
 
Immunohistology  and  immunocytology  were  visualised  using  an  Apotome/Zeiss 
microscope  or  Laser  Scanning  Confocal  microscope  and  the  images  analysed  using 
AxioVision Rel 4.7 software with co-localisation module. 
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2.2  Preparation of Lipo-oligosaccharide (LOS) 
 
2.2.1  C. jejuni strains 
 
The strains of C. jejuni used were Penner serotype O:19 (HS O:19) in which the LOS 
structure mimics gangliosides GM1 and GD1a at 50:50 ratio 
202; Penner serotype O:3 
(HS O:3) in which the LOS does not mimic gangliosides 
203; C. jejuni strains GB2 and 
GB11 in which the LOS structure mimics gangliosides GM1 and GD1a at 50:50 ratio; 
and the isogenic sialyltransferase gene (CSTII) knock-out strains, GB2 CSTII knock out 
and GB11 CSTII knock out, in which the LOS does not mimic gangliosides due to the 
failure of addition of sialic acid to the carbohydrate side chain
101.  GB19 LOS (GD1c 
mimic)  and  its  CSTII  knock  out  isogenic  counterpart
101  were  also  provided  as  pre-
purified LOS. The GB2, GB11 and GB19 strains and their CSTII knock out counterparts 
were kind gifts from B. Jacobs and M. Kuijf, Erasmus University, Netherlands. 
 
2.2.2  Growth and heat inactivation of C. jejuni 
 
For  LOS  purification  C.  jejuni  were  grown  for  48  hours  at  37
oC  in  a  microaerobic 
environment on Columbia Agar and Horse Blood plates (E & O Laboratories, Scotland. 
Container P090).  The bacteria were harvested into PBS (phosphate buffered saline) and 
heat  inactivated  at  60
oC  for  1  hour.    For  siglec  binding  experiments  bacteria  were 
harvested into 8% formalin/PBS and left for 1 hour to inactivate. 
 
2.2.3  Crude hot phenol extraction of LOS 
 
Heat  inactivated  bacteria  were  centrifuged  at  6000rpm  for  10  minutes  (Sorval 
ultracentrifuge, Rotor SS34) and the supernatant discarded.  The pellet was resuspended 
at 10g/ml in dH2O (distilled water) and blended to a paste, on ice, using an Ultra Turrax  42 
homogeniser.  An equal volume of 85% liquid phenol (Sigma, UK) was added and the 
cells were blended on ice for 5 minutes.  The mix was placed in a water bath at 65
oC and 
blended for 1 minute at 2 minute intervals for 10 minutes.  The mix was centrifuged at 
2500rpm for 20 minutes at < 10
oC.  The aqueous (top) layer was removed and stored. An 
equal volume of dH2O was added to the remaining sample and blended for five minutes 
on ice repeating the procedure.  The combined aqueous layers were dialysed for 3 days at 
4
oC against 5 litres of dH2O (whole volume changed twice daily) using 3.5 kDa MWCO 
(molecular weight cut-off) Snakeskin pleated dialysis tubing (Pierce Laboratories, UK).  
The crude LOS extract was lyophilised (Christ Alpha 1-2 LD lyophiliser). 
 
2.2.4   Quantification of LOS by dry weight 
 
LPS and LOS were lyophilised in pre-weighed conical flasks and the dry weight was 
determined using accurate scales (Ohous Explorer Pro). 
 
2.2.5  Purification of LOS 
 
The LOS was resuspended to 10mg/ml in dH2O.  200 µg/ml DNase I (Merck, UK) and 
50 µg/ml RNase A (Merck, UK) were added and incubated at 37
oC for 2 hours. 1mg/ml 
of Proteinase K (Merck, UK) was added and the LOS was incubated for a further 3 hours 
at 65
oC to allow auto-digestion of the Proteinase K.  The LOS was dialysed against 5 
litres dH2O for 48 hours (whole volume changed twice daily) at 4
oC then lyophilised and 
resuspended to 2mg/ml in sterile dH2O. 
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2.2.6  Purification of commercially bought LPS 
 
Smooth mutant E. coli 0111:B4 LPS (Sigma, UK), rough mutant S. typhimurium LPS 
SL1181 (RE mutant) (Sigma, UK) and smooth mutant S. typhimurium LPS (RA mutant) 
(Sigma, UK) were subjected to the DNase, RNase and Proteinase K purification protocol 
to remove contaminants.  
 
2.2.7  Determination of LOS purity by silver stain 
 
SDS (sodium dodecyl sulphate) PAGE (Polyacrylamide Gel Electrophoresis) of LOS was 
carried  out  using  a  Novex  10-20%  Tricine  gel  according  to  the  manufacturer’s 
instructions.  Briefly, 5µg of LOS was added to 5µl Tricine SDS sample buffer and 1µl 
Nupage reducing  agent  (All  Invitrogen, UK).   The sample was heated to 85
oC for 2 
minutes  and  10µl  was  then  loaded  into  the  wells.    The  gel  was  run  in  Tricine  SDS 
running buffer (Invitrogen, UK) at 125 V constant for 90 minutes.  A silver stain of the 
gel was performed using a SilverXpress silver stain kit (Invitrogen, UK) following the 
manufacturer’s instructions. 
 
2.2.8  Determination of LOS purity by spectrophotometry 
 
2mg/ml LOS was titrated with 4µM EDTA (ethylenediaminetetraacetic acid) /dH2O and 
1% triton X to disperse micelles and clarify the solution for spectrophotometry. DNA, 
RNA  and  protein  content  was  determined  by  spectrophotometry  (Eppendorf 
biophotometer AG 22337) (Fisherbrand semi-micro cuvettes). 
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2.2.9  Determination of LOS epitopes by Western blot 
 
LOS  was  subjected  to  SDS-PAGE  and  transferred  onto  an  Invitralon  PVDF 
(Polyvinylidene Fluoride) membrane (0.45µm pore size, Invitrogen, UK) following the 
manufacturer’s  instructions.  The  PVDF  membrane  was  either  stained  immediately  or 
dried and stored overnight at 4
oC then reactivated with methanol.  The membrane was 
blocked using 3% w/v Marvel (powdered milk)/PBS for 1 hour then washed three times 
for 5 minutes in PBS with 0.5% Tween 20.  The GM1 epitope was detected using cholera 
toxin  conjugated  to  HRP  (horse  radish  peroxidase)  (Sigma,  UK)  diluted  in  a  1:7000 
solution in 0.2% Marvel/PBS while the GD1a epitope was detected using the MOG-35 
monoclonal  antibody
204  (159µl  diluted  in  10ml  PBS  with  0.5%  Tween  20)  used  in 
conjunction with an anti-mouse IgG HRP conjugated antibody (Southern Biotech, USA) 
diluted 1:2000 in PBS with 0.5% Tween 20.  All incubation steps lasted 1 hour and the 
membrane was washed between steps three times in 0.5% PBS/Tween for 5 minutes.  
The membrane was developed using Super Signal West Pico (Pierce, USA) following the 
manufacturer’s instructions. 
 
2.2.10 Generation of GM1 mimicking LOS from GM1/GD1a mimicking 
LOS 
 
LOS was resuspended to 1mg/ml in dH2O and 0.3 units/mg of cholera neuraminidase 
(Calbiochem, UK) was added. Samples were incubated at 37
oC for 2 hours.  Proteinase K 
was then added for 3 hours at 65
oC to remove the neuraminidase and allow for auto-
digestion of the Proteinase K.  The LOS was dialysed, lyophilised and resuspended as 
before. 
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2.2.11 Determination of LOS purity by alcian blue stain 
 
A positive control for capsular polysaccharide was generated by lysing 200µl of heat 
inactivated  C.  jejuni  (OD600  of  3.5)  using  200µl  of  200mg/ml  Cell  Lytic  Express 
(Sigma, UK) according to the manufacturer’s instructions.  The sample was incubated for 
20  minutes  then  centrifuged  at  16,000g  for  15  minutes  and  the  supernatant  kept  for 
analysis.  SDS-PAGE of LOS and the lysed bacteria supernatant was carried out. The gel 
was transferred to a PVDF membrane (Invitralon, 0.45µm, Invitrogen, UK) following the 
manufacturer’s instructions.  The PVDF membrane was dyed with 0.5% alcian blue in 
7% acetic acid for 2 minutes then washed in PBS until clean. 
 
2.2.12 Quantification of LOS by thiobarbituric acid assay 
 
A 3 deoxy-D-manno-oct-2-ulosonic acid (KDO) standard curve was generated from 0, 
0.5, 2.5, 5 and 7.5µl of 0.5mM KDO (Sigma, UK) dried overnight in eppendorf tubes.  
10µg of each LOS was also dried overnight.  250µl of pH4.4, 0.1M, sodium acetate 
(Sigma, UK) was added to each tube and the solution heated at 100
oC for 1 hour.  125µl 
of 40mM periodic acid in 0.125M sulphuric acid (H2SO4) was added and the solution was 
vortexed briefly then left to stand for 30 minutes at room temperature.  250µl of 0.2M 
sodium  arsenite  (Sigma,  UK)  in  0.5M  hydrochloric  acid  was  added  and  mixed 
thoroughly.  250µl of fresh 2-thiobarbituric acid (Sigma, UK) (60mg/10ml dH20) was 
added and the tubes heated to 100
oC for 15 minutes.  500µl of DMSO was added into the 
hot tubes and mixed.  The optical density (OD) of the solution was determined at 549nm.  
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2.3  Binding of cellular receptors and humoral factors to C. jejuni and 
LOS 
 
2.3.1  Binding  of  Sialoadhesin,  Siglec  E  and  Siglec  F  to  LOS  and 
gangliosides 
 
Purified  GB11  wild  type,  GB11  CSTII  knock  out,  HS  O:19  and  HS  O:3  LOS  were 
adsorbed onto 96 well half area ELISA plates by dissolving in methanol at 5µg/ml and 
adding 50µl per well before allowing the methanol to evaporate in a fume hood.  The 
plates were washed twice with PBS then blocked with 100µl per well of 3% BSA (bovine 
serum albumin)/PBS for 1 hour.  The plates were washed once with PBS then specific 
siglecs  were  added  to  each  well.    The  siglec  reagents  were  murine  Siglec-human-Fc 
fusion proteins kindly supplied by Prof P. Crocker, University of Dundee (see Appendix 
4 for siglec-human-Fc fusion protein structures).  Sialoadhesin and Siglec F were made 
up at 1µg/ml in blocking buffer while Siglec E was used at 0.5µg/ml.  The siglecs were 
combined with 3 times the volume of anti-human IgG-HRP (Southern Biotech, USA) and 
left  for  1  hour  at  room  temperature  to  form  complexes.    50µl  of  siglec,  diluted  in 
blocking buffer, was added per well and incubated for 1 hour.  The plates were washed 5 
times then developed using Sure Blue TMB solution (Insight Biotechnology, UK) and 
read at 450nm using a Labsystems Multiscan Ascent plate reader.  When siglec binding 
to gangliosides GM1 and GD1a (Sigma, UK) and O-side chain sugar molecules, asialo-
GM1, asialo-GM2 (both Sigma, UK) and lactosyl ceramide (Merck, UK) was assessed, 
the gangliosides were adsorbed onto the plate at 2µg/ml.  For complex ganglioside/O-side 
chain ELISAs (mixed ganglioside and sugar targets), the sugar molecules were dissolved 
together in methanol and sonicated for 5 minutes to generate micelles containing the 
different epitopes.  
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2.3.2  Binding of Sialoadhesin, Siglec E and Siglec F to C. jejuni 
 
C. jejuni were grown and harvested into 8% formalin/PBS and left for 1 hour at room 
temperature  to  inactivate.    The  bacteria  were  washed  3  times  in  20ml  PBS  by 
centrifugation at 12,000 g for 10 minutes (Beckman Coulter Allegra 64R, rotor F0630).  
They were then diluted in PBS to an OD600 of 1 and frozen at -80
oC following the 
addition of glycerol to a final concentration of 10%. C. jejuni strains GB11 wild type, 
GB11 CSTII knock out, HS O:19 and HS O:3 were defrosted, centrifuged at 13,000g for 
1 minute and resuspended to an OD600 of 0.1 in PBS.  50µl of bacteria were put in each 
well of a 96 well half area ELISA plate (Costar, UK) and allowed to adsorb onto the 
surface overnight at 4
oC.  The plate was washed twice with PBS and then blocked using 
100µl per well of 3% BSA/PBS for 1 hour.  The plate was washed  once before the 
desired siglec was added at a diluting concentration (siglecs were made up as detailed 
earlier) and incubated for 1 hour. 50µl was added per well.  The plate was washed 5 times 
with PBS before being developed using 50µl of Sure Blue TMB substrate solution per 
well and stopped using 25µl 4N H2SO4.   
 
2.3.3  Visualisation of siglec binding to C. jejuni 
 
70µl  of  formalin  fixed  HS  O:19  and  HS  O:3  C.  jejuni  with  an  OD600  of  0.5  were 
centrifuged onto a microscope slide (VWR Superfrost Plus) using a cytospin (600g, 5 
minutes).  The bacteria were labelled using Sialoadhesin, Siglec E and Siglec F adapting 
the  above  ELISA  protocol  except  using  a  FITC  labelled  anti-human  IgG  (BD 
Biosciences, UK) instead of the HRP labelled antibody.  The slides were mounted using 
Vectashield DAPI containing mounting media (Vector, USA) and visualised using an 
Apotome/Zeiss microscope. 
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2.3.4  Binding of Sialoadhesin to C. jejuni following neuraminidase 
treatment 
 
Formalin fixed HS O:19 and HS O:3 were defrosted, centrifuged at 13,000g for 1 minute 
and resuspended to an OD600 of 0.1 in PBS.  50µl of bacteria were put in each well of a 
96 well half area ELISA plate (Costar, UK) and allowed to adsorb overnight at 4
oC. The 
plate was washed twice with PBS. Selected wells were treated with 50µl of 0.004 U/ml of 
neuraminidase from vibrio cholerae (Merck) in HBSS (Hanks buffered salt solution) for 
1 hour at 37
oC while control wells were incubated with HBSS alone.  The plate was 
washed twice with PBS and then blocked using 100µl per well of 3% BSA/PBS for 1 
hour.  The ELISA was carried out as before.  Increased GM1 expression was confirmed 
using the anti-GM1 mouse mAb DG2.  50µl of Ab (0.5mg/ml) diluted 1:200 in blocking 
buffer  was added per well and incubated for 1  hour at room temperature.  This was 
washed three times and an anti-mouse IgG HRP secondary (southern biotech) was added 
(1mg/ml diluted 1 in 500) and incubated for 1 hour.  Following five washes the plate was 
developed with Sure Blue. 
 
2.3.5  Binding of purified human Factor H to C. jejuni by ELISA 
 
Formalin  fixed  C.  jejuni  were  adsorbed  onto  ELISA  plates,  washed  and  blocked  as 
before.  The wells were incubated with 60µg/ml of purified human Factor H (fH) (Sigma, 
UK) for 1 hour at 37
oC.  The plate was washed twice with PBS and then incubated with a 
mouse monoclonal anti-human fH antibody (OX-23 clone, 1mg/ml, Serotec, UK) used at 
a 1:250 dilution.  Following two washes the plate was incubated with an anti-mouse IgG 
HRP secondary antibody (1:500 dilution)(Southern Biotech) to detect fH binding to the 
bacteria.  The plate was developed using Sure Blue substrate. 
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2.3.6  Binding of purified human Factor H to C. jejuni by FACS 
 
Heat inactivated C. jejuni were washed and resuspended to an OD600 of 3.6 in sterile 
filtered HBSS.  90µl of bacteria were incubated with 5µg of purified human fH in 10µl of 
PBS  for  30  minutes  at  37
oC  then  washed  with  400µl  HBSS.    The  bacteria  were 
resuspended  then  incubated  with  50µl  of  the  anti-fH  monoclonal  antibody  (1:100 
dilution) for 30 minutes.  After another wash they were incubated with 50µl of anti-
mouse IgG FITC (1:100 dilution) (Southern Biotech) for 30 minutes.  Following two 
final washes they were resuspended to 250µl in HBSS and acquired using a FACSCalibur 
FACS machine. 
 
2.3.7  Visualisation of Factor H binding to C. jejuni 
 
70µl of formalin fixed C. jejuni (OD600 of 0.5) were adsorbed onto a microscope slide 
by centrifugation (600g, 5 minutes), allowed to dry and marked using a pap pen.  The 
bacteria were incubated with 5µg of purified human fH in 30µl of HBSS for 30 minutes 
at 37
oC.  Following a single wash the bacteria were incubated with the anti-fH mAb 
(30µl, 1:100 dilution) for 30 minutes.  The slides were washed and the bacteria incubated 
with anti-mouse IgG FITC (1:100 dilution) for 30 minutes.  The slides were washed and 
mounted with DAPI containing mounting media.  The slides were visualised using an 
Apotome/Zeiss microscope. 
 
2.3.8  Deposition of C3c and C9 on C. jejuni using ELISA 
 
Formalin inactivated C. jejuni were adsorbed onto ELISA plates as before.  The plates 
were blocked using 100µl of 3% BSA/PBS.  Human serum (donated by individuals self-
reporting no previous infection or exposure to C. jejuni) was diluted in PBS (dilutions 
detailed in results).  Following two washes, 50µl of the diluted sera was added per well  50 
and the plates incubated at 37
oC for 20 minutes.  The plates were washed 3 times after 
which  50µl  of  detection  antibody  was  added:  sheep  anti-C3c  or  sheep  anti-C9  (both 
Dako,  Denmark)  all  diluted  1:500  in  blocking  buffer,  and  incubated  for  1  hour.  
Following three washes anti-sheep IgG HRP (Santa Cruz Biotechnology, USA), diluted 
1:500 in blocking buffer, was added.  The plates were washed 5 times and developed 
using Sure Blue TMB solution. 
 
2.3.9  Binding of natural IgM and IgG to C. jejuni or LOS 
 
Formalin  inactivated  C.  jejuni  or  LOS  was  adsorbed  onto  ELISA  plates  as  before.  
Human  sera  was  prepared  as  before  and  incubated  for  1  hour  at  room  temperature.  
Following 3 washes, IgM and IgG was detected using anti-human IgM HRP and anti-
human IgG HRP (Southern Biotech, USA) diluted 1:1000 in blocking buffer.  Following 
1 hour incubation and five washes, the plates were developed using Sure Blue TMB 
solution. 
 
2.4  Harvesting and labelling of cells for in vitro experiments 
 
2.4.1  Mouse strains 
 
Unless otherwise stated, the mice used were C57BL/6 wild type strains aged between 6 
and 14 weeks old taken from the in-house colony of Dr C Goodyear or Prof H Willison.  
C3H/HeJ  and  C3H/HeN  mice  were  female,  aged  8  to  12 weeks  and  purchased  from 
Harlan (UK).  TLR2
-/- mice were female, aged 14 weeks and kindly supplied by Dr C 
Michels, University of Glasgow, UK. 
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2.4.2  Harvesting of splenocytes 
 
Mice were sacrificed by suffocation with CO2 and the spleens removed and placed in 3ml 
sterile cRPMI (complete RPMI).  A cell strainer (Falcon, 70µm) was used to produce a 
single  cell  suspension  of  splenocytes  which  was  washed  in  10ml  cRPMI  by 
centrifugation at 500g for 5 minutes (Eppendorf Centrifuge 5408) with the supernatant 
being discarded. The pellet was resuspended in 2ml of ACK lysis buffer (BioWhittaker, 
UK) per spleen and gently mixed for 2 minutes before being washed with 10ml cRPMI 
and resuspended to 10ml in cRPMI.  Any cell debris was removed using a sterile pipette 
and  the  cell  concentration  was  determined  using  a  haemocytometer.  The  splenocytes 
were then resuspended to 1x10
7/ml in cRPMI and kept on ice.  For experiments involving 
overnight culture the cRPMI was supplemented with 500µl 2-mercaptoethanol and 5ml 
non-essential amino acids per 500ml of media.  
 
2.4.3  Purification of splenic B cells 
 
Spleens were harvested as above and B cells were purified by negative selection using the 
EasySep magnetic B cell negative selection kit (Stemcell Technologies, USA) according 
to  the  manufacturer’s  instructions.    Purity  was  assessed  by  flow  cytometry  (BD, 
FACSCalibur).  Briefly, Fc receptors were blocked by incubating cells with Fc block 
(anti-mouse CD16/32, BD, UK), diluted 1:200 per million cells in 50µl FACS buffer for 
10 minutes at 4
oC.  Cells were then stained with fluorophore labelled antibody (diluted 
1:200 per million cells) in 50µl FACS buffer and incubated for 15 minutes at 4
oC.  The 
cells were washed in 500µl FACS buffer then resuspended in 250µl FACS buffer.  Purity 
was  assessed  by  comparing  the  percentage  of  B220
+  cells  (anti-mouse  B220  APC, 
Southern Biotech, USA) before and after purification and typically showed >90% B220
+ 
cells (example FACS plot in results). 
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2.4.4  Carboxyfluorescein diacetate succinimidyl ester (CFSE) labelling of 
splenocytes and B cells 
 
Splenocytes, including erythrocytes, were harvested and resuspended to 1x10
7 nucleated 
cells/ml in RPMI (without added serum) at 37
oC.  5mM stock CFSE (Invitrogen, UK) 
was diluted in RPMI so that 1µM CFSE was added to the cells.  This was incubated at 
37
oC for 10 minutes with shaking.  The cells were washed four times with 10ml of ice 
cold cRPMI (with added serum to mop up free CFSE) by centrifuging at 500g for 5 
minutes.    The  cells  were  then  resuspended  to  the  desired  concentration.    For  CFSE 
labelling of purified B cells the above protocol was followed with the exception of no 
erythrocytes being present. 
 
2.4.5  Generation of M-CSF containing supernatant 
 
L-929  cells  are  a  murine  fibrosarcoma  cell  line  which  secretes  M-CSF  (macrophage 
colony  stimulating  factor).    The  conditioned  supernatant  can  be  used  to  induce 
macrophage differentiation in bone marrow derived cells
205,206.  L-929 cells were grown 
to 90% confluence in cRPMI in T75 flasks before being split into T150 flasks and grown 
to confluence.  The cells were left for 3-4 days before the supernatant was collected by 
centrifugation  (500g  for  5  minutes).    Aliquots were  frozen  at  -20
oC  and  were  sterile 
filtered (0.2µm Minisart filter, Sartorius) before use.   
 
2.4.6  Generation of GM-CSF containing supernatant 
 
X-63 cells are a fibroblast cell line transfected with the murine granulocyte-macrophage 
colony stimulating factor (GM-CSF) gene.  The conditioned supernatant can be used to 
generate bone marrow derived dendritic cells from bone marrow cells
207.  X-63 cells were 
grown in 18ml ISCOVES Modified Medium (IMDM with 2mM L-glutamine, 10% foetal  53 
bovine serum, 100 units/ml Penicillin and 100 units/ml Streptomycin) until confluent.  
The cells were then washed in IMDM and recultured in 18ml Iscoves Modified Medium 
with 1mg/ml G418 (Geneticin antibiotic, Promega, USA) for 4 days.  The cells were 
washed in RPMI 1640 and seeded into 25cm
2 flasks and grown in complete IMDM.  
When the cells reached log growth they were transferred to 75cm
2 flasks and grown until 
confluent.  The cells were harvested by centrifugation (500g for 5 minutes) and seeded 
into  150cm
2  flasks  in  complete  IMDM.    Once  confluent  and  after  4-7  days  the 
supernatant was collected and stored at -20
oC. 
 
2.4.7  Harvesting of bone marrow 
 
Mice were sacrificed by CO2 suffocation and the hind limbs taken and stripped of flesh.  
The femurs and tibia were flushed with sterile PBS by inserting a 23 gauge needle into 
the marrow space and washing with PBS loaded into a 20ml syringe.  The cells were 
vortexed thoroughly to break up clumps and broken up by aspirating gently through a 21 
gauge needle if necessary.  The cells were centrifuged and resuspended in 10ml cRPMI. 
The cells were passed through a cell strainer to remove clumps and then counted using a 
haemocytometer and resuspended at 1x10
7/ml in cRPMI. 
 
2.4.8  Generation of bone marrow derived macrophages 
 
Bone marrow cells were plated out in 90mm Petri dishes (Sterlin, UK) at 5x10
6 cells in 
10ml cRPMI with 20% M-CSF (supernatant from the L-929 cell line) and incubated at 
37
oC in 5% CO2.  After 4 days the cells were supplemented with 7ml of cRPMI with 20% 
M-CSF and then used on day 7.  Non-adherent cells were removed by aspirating the 
supernatant and gently washing with 5ml PBS.  Adherent cells were harvested by adding 
5ml  ice  cold  PBS  and  scraping  off  with  cell  scrapers.    Purity  was  assessed  by  flow 
cytometry.  Fc receptors were blocked by incubating cells with Fc block (diluted 1:200 
per million cells) in 50µl FACS buffer for 10 minutes at 4
oC.  Cells were then stained  54 
with anti-mouse F4/80 biotin (Biolegend clone BM8, UK) diluted 1:200 per million cells 
in 50µl FACS buffer or the appropriate isotype control (Rat IgG2aκ biotin, Biolegend, 
UK) and incubated for 15 minutes at 4
oC.  The cells were washed in 400µl FACS buffer.  
The cells were resuspended by flicking the tube and incubated in 50µl FACS buffer with 
streptavidin APC (Southern Biotech, USA) diluted 1:200 for 15 minutes at 4
oC.  The 
cells were then washed twice in 400µl FACS buffer then resuspended in 250µl FACS 
buffer.  Purity was assessed by comparing the percentage of F4/80
+ cells to the isotype 
control and was typically >90% F4/80
+ (example FACS plots in results). 
 
2.4.9  Generation of bone marrow derived dendritic cells 
 
Bone marrow cells were plated out in 90mm petri dishes at 5x10
6 cells in 10ml cRPMI 
with 10% GM-CSF (supernatant from the X-63 cell line) and cultured at 37
oC in 5% 
CO2.  The cells were supplemented after 4 days with 10ml cRPMI and 10% GM-CSF.  
The cells were used after 8 days with only the non-adherent cells being taken by gently 
swirling the plate and taking the supernatant. Purity was assessed using the same protocol 
as for macrophages (antibodies used were anti-mouse CD11c biotin (BD biosciences, 
UK), hamster IgG1 isotype control (BD Biosciences, UK) and streptavidin APC, all at a 
1:200  dilution  per  million  cells  in  50µl  FACS  buffer).    Purity  was  typically  >70% 
CD11c
+ as assessed by flow cytometry (example FACS plot in results). 
 
2.5  In vitro stimulation of splenocytes, B cells, dendritic cells and 
macrophages 
 
2.5.1  Stimulation of splenocytes and purified B cells 
 
CFSE labelled cells were prepared as above and resuspended to 1x10
7 cells/ml in cRPMI 
supplemented with 2-mercaptoethanol and non-essential amino acids.  The cells were 
divided into eppendorfs at 7x10
5 cells in 700µl of supplemented cRPMI and LOS was  55 
added at the desired concentration before mixing. The cells were plated out in a 96 well 
round bottom plate (Corning, UK) at 2x10
5 cells per well at 1x10
6 cells per ml.  The cells 
were cultured at 37
oC with 5% CO2 for 48 and 72 hours.  Following culture, the plates 
were  centrifuged  at  400g  for  5  minutes  and  the  supernatant  collected  and  stored  for 
further analysis.  The cells were resuspended in-situ in ice cold FACS buffer containing 
Fc block diluted 1 in 100 per million cells and incubated on ice for 10 minutes.  The cells 
were then transferred to FACS tubes for further labelling. 
 
2.5.2  Stimulation of bone marrow derived dendritic cells with LOS 
 
Bone marrow derived dendritic cells were generated from C57BL/6 mice.  Cells were 
resuspended to 1x10
7/ml in cRPMI then transferred to eppendorfs at 1x10
6/ml in cRPMI. 
LOS was added to the cells at the appropriate concentration, vortexed then plated out in a 
96 well flat bottomed plate (Corning, UK) with 3x10
5 cells in each well.  Cells were 
cultured  for  12  hours  at  37
oC  with  5%  CO2.    The  supernatant  was  harvested  by 
centrifuging the plate at 300g for 5 minutes then carefully aspirating 200µl with a multi-
channel pipette.  The supernatant was either analysed immediately by ELISA or frozen at 
-20
oC for later analysis.  FACS analysis of the cells was carried out by using gentle 
agitation (pumping the pipette up and down, followed by scraping the well with the tip) 
to resuspend the cells before transferring them to FACS tubes.  Fc receptors were blocked 
by incubating cells with Fc block (diluted 1:200 per million cells) in 50µl FACS buffer 
for 10 minutes at 4
oC.  Cells were then stained with anti-mouse CD11c biotin and anti-
mouse CD40-PE (BD Biosciences, UK) diluted 1:200 per million cells in 50µl FACS 
buffer with the appropriate isotype controls (For CD40, Rat IgG2aκ Pe BD Biosciences, 
UK)  and incubated for 15 minutes at 4
oC.  The cells were washed in 400µl FACS buffer.  
The cells were resuspended by flicking the tube and incubated in 50µl FACS buffer with 
streptavidin APC (Southern Biotech, USA) diluted 1:200 for 15 minutes at 4
oC.  The 
cells were then washed in 400µl FACS buffer then resuspended in 250µl FACS buffer. 
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2.5.3  Quantification of bacteria 
 
C. jejuni were grown and harvested into PBS then heat inactivated.  The bacteria were 
dialysed against dH2O using 12-14kDa MWCO dialysis tubing.  The bacteria were then 
lyophilised and the dry weight recorded.  The lyophilised bacteria were resuspended to 
5mg/ml in PBS and a double dilution standard curve was generated comparing the dry 
weight to the OD600 to generate an equation linking dry weight and optical density at 
600nm.  For the purposes of estimating the number of bacteria it was assumed the mass 
of a single bacterium is approximately 1x10
-12g (the estimated mass of an E. coli cell
208) 
and this value was applied to all the strains being compared. 
 
2.5.4  Stimulation of bone marrow derived dendritic cells with whole C. 
jejuni 
 
Bone marrow derived dendritic cells were generated and prepared as before.  3x10
5 cells 
were pipetted in 100µl of cRPMI into sterile eppendorfs.  Heat inactivated C. jejuni were 
defrosted and washed as before.  Both strains were diluted to an OD600 of 0.6 in sterile 
PBS and the quantity of bacteria was estimated using the OD to dry weight formula 
established above.  The bacteria were diluted into cRPMI.  The desired ratios of bacteria 
to dendritic cell was 12:1, 6:1, 3:1 and 1.5:1 and the bacteria were diluted such that the 
desired number of bacteria for 3x10
5 dendritic cells was present in 200µl of cRPMI.  The 
C. jejuni were  added to the dendritic  cells at the diluting titration (200µl of bacteria 
containing cRPMI added to 100µl of dendritic cell containing cRPMI making the final 
concentration of dendritic cells 1x10
6/ml).  The cells were vortexed, then plated out for 
overnight culture in 96 well flat bottomed tissue culture plates.  The supernatant was 
harvested and stored as before. 
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2.5.5  Blocking of siglec receptors on bone marrow derived dendritic cells 
 
Bone  marrow  derived  dendritic  cells  were  generated  as  above.    3x10
5  cells  were 
transferred into eppendorfs at 1x10
7cells/ml and siglec blocking antibodies (sheep anti-
mouse Siglec E, sheep anti-mouse Siglec F and rat anti-mouse Sialoadhesin clones 3D6 
and  SER-4
209)  were  added  at  1µg  per  million  cells.  The  cells  were  incubated  for  15 
minutes on ice then diluted to 1x10
6cells/ml whereupon LOS was added at 10µg/ml.  The 
cells were incubated for 12 hours at 37
oC with 5% CO2 and the supernatant collected for 
analysis.  All  blocking  antibodies  were  kind  gifts  from  Prof  P  Crocker,  University  of 
Dundee.   
 
2.5.6  Stimulation of bone marrow derived macrophages with LOS 
 
Bone marrow derived  macrophages were  generated from C57BL/6 mice as described 
previously.  Cells were resuspended to 1x10
7/ml in cRPMI then transferred to eppendorfs 
at 1x10
6/ml in cRPMI. LOS was added to the cells at the appropriate concentration.  The 
cells were vortexed then plated out in a 96 well flat bottomed plate with 3x10
5 cells in 
each well.  Cells were cultured for 12 hours at 37
oC with 5% CO2 and the supernatant 
harvested as described for dendritic cells. 
 
2.5.7  Stimulation of bone  marrow derived macrophages with whole C. 
jejuni 
 
Bone marrow derived macrophages were generated and prepared as before.  The same 
protocol was used for macrophages as for dendritic cell stimulation by whole bacteria 
only the bacteria to cell ratios for the diluting titration were 100:1, 50:1, 10:1 and 1:1.  
The supernatant was harvested and stored as before.  For analysis of CD40 upregulation, 
the macrophages were pulse stimulated with C. jejuni at 50:1 bacteria to cell ratio for 15  58 
minutes in eppendorfs while incubated at 37
oC with 5% CO2.  The cells were washed 
with 1.5ml cRPMI by twice centrifuging the tubes at 400g for 5 minutes.  The cells were 
then resuspended to 1x10
6 per ml and 3x10
5 were aliquoted into each well in a 96 well 
round bottom culture plate for overnight culture.  The cells were harvested and stained 
for CD40 upregulation using the same protocol detailed for dendritic cells above only 
anti-F4/80 antibody was used instead of anti-CD11c. 
 
2.5.8  Stimulation  of  bone  marrow  derived  dendritic  cells  and 
macrophages with exogenous gangliosides and LOS 
 
Bone marrow derived dendritic cells and macrophages were generated from C57BL/6 
mice  as  described  previously.    Cells  were  resuspended  to  1x10
7/ml  in  cRPMI  then 
transferred to eppendorfs at 1x10
6/ml in cRPMI.  The cells were stimulated with PBS, 
5µg/ml each of bovine brain derived gangliosides GM1 and GD1a (both from Sigma, 
UK), 10µg/ml of GB11 wild type LOS, 10µg/ml of GB11 knock out LOS or 10µg/ml of 
GB11 knock out LOS sonicated with 5µg/ml each of GM1 and GD1a for 5 minutes prior 
to addition to cells.  The gangliosides were prepared by taking 100µl each of GM1 and 
GD1a (stock was 1mg/ml in 50:50 methanol chloroform) and transferring this to a 15ml 
falcon tube.  The gangliosides were dried by blowing with nitrogen from a compressed 
gas cylinder (BOC, UK).  The gangliosides were then resuspended in 200µl sterile PBS 
(i.e. still at 1mg/ml) and sonicated and centrifuged repeatedly for 15 minutes.  They were 
then  stored  in  a  glass  vial  until  the  desired  quantity  was  added  to  LOS  or  cells  as 
described above.  The cells were vortexed then plated out in a 96 well flat bottomed plate 
with 3x10
5 cells in each well.  Cells were cultured for 12 hours at 37
oC with 5% CO2 and 
the supernatant harvested as described for dendritic cells. 
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2.5.9  Quantification of dead cells by trypan blue exclusion assay 
 
Dendritic cells or macrophages were stimulated overnight with 10µg/ml LOS or PBS as 
described above.  After 200µl of supernatant had been aspirated (leaving 100µl), the plate 
was placed on ice at 4
oC for 15 minutes following which the wells were scraped with a 
pipette tip to loosen off any adherent cells.  20µl was aspirated from the cells and added 
to 50µl cRPMI and stored on ice.  Shortly before counting, 10µl of trypan blue was added 
to the cells and a sample transferred to a haemocytometer where the live and dead cells 
were counted and the percentage of trypan blue positive cells (dead cells) was calculated. 
 
2.6  Analysis of stimulated cells 
 
2.6.1  Preparation  and  staining  of  B  cells  and  splenocytes  for  FACS 
analysis 
 
Fc receptors were blocked by incubating cells with Fc block (diluted 1:200 per million 
cells) in 50µl FACS buffer for 10 minutes at 4
oC.  Cells were then stained with primary 
fluorophore labelled or biotinylated antibody (diluted 1:200 per million cells) in 50µl 
FACS buffer and incubated for 15 minutes at 4
oC. The cells were washed in 300µl FACS 
buffer  (500g  for  5  minutes)  and  resuspended  in  50µl  FACS  buffer  streptavidin 
conjugated fluorophore (diluted 1:200 per million cells) then incubated for 15 minutes at 
4
oC.  The cells were washed a final time in 500µl FACS buffer then resuspended in 
250µl  FACS  buffer.    Immediately  before  acquisition,  counting  beads  (Caltag 
laboratories) were added to the tubes according to the manufacturer’s instructions. The 
cells were  acquired using a  BD FACSCalibur. The data were analysed using FlowJo 
software (Treestar, USA).   
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2.6.2  IgG immunoglobulin ELISA 
 
Half  area  ELISA  plates  were  coated  overnight  with  50µl  of  5µg/ml  anti-mouse  IgG 
(Southern Biotech, USA) in sodium carbonate buffer (see appendix 1).  The plates were 
washed three times with 0.3% PBS/Tween then blocked for 1 hour with 100µl of 2% 
BSA/PBS  at  room  temperature.    The  plate  was  washed  three  times  and  mouse  IgG 
standard (Bethyl laboratories, USA) was added at 50µl per well starting with 200ng/ml in 
0.1%  BSA/PBS  with  doubling  dilutions.    Supernatant  from  the  splenocyte  or  B  cell 
cultures was diluted 1:5, 1:10 and 1:20 in 0.1% BSA/PBS and 50µl added to each well.  
Samples were incubated for 1 hour at room temperature then the plates were washed 3 
times.    Detection  antibody,  anti-mouse  IgG-HRP,  was  added  (50µl  per  well,  1:4000 
dilution) and incubated for 1 hour.  The plate was washed 5 times and 50µl of developing 
solution was added per well.  (1 OPD tablet was added to 14ml Citric acid with 16ml of 
0.2M Na2HPO4 and 30ml of dH2O.  20µl of H2O2 was added immediately before use).  
The  reaction  was  stopped  using  25µl  of  3N  H2SO4  and  the  plate  was  read  using  a 
Labsystems Multiscan Ascent plate reader at 490nm within 15 minutes. 
 
2.6.3  IgM Immunoglobulin ELISA 
 
Half  area  ELISA  plates  were  coated  overnight  with  50µl  of  5µg/ml  anti-mouse  IgM 
(Southern Biotech, USA) in sodium carbonate buffer.  The plates were washed three 
times  with  0.3%  PBS/Tween  then  blocked  for  1  hour  with  2%  BSA/PBS  at  room 
temperature.    The  plate  was  washed  three  times  and  mouse  IgM  standard  (Bethyl 
laboratories, USA) was added at 50µl per well starting with 100ng/ml in 0.1% BSA/PBS 
with 1:3 dilutions.  Supernatant from the splenocyte or B cell cultures was diluted 1:250, 
1:500  and  1:750  in  0.1%  BSA/PBS  and  50µl  added  to  each  well.    Samples  were 
incubated for 1 hour at room temperature then the plates were washed 3 times.  Detection 
antibody,  anti-mouse  IgM-HRP,  was  added  (50µl  per  well,  1:4000  dilution)  and 
incubated for 1 hour.  The plate was washed 5 times and 50µl of developing solution was  61 
added  per  well.    (1  OPD  tablet  was  added  to  14ml  Citric  acid  with  16ml  of  0.2M 
Na2HPO4 and 30ml of dH2O.  20µl of H2O2 was added immediately before use.) 
 
2.6.4  Interleukin-10 ELISA 
 
Supernatant from stimulation cultures was assayed using an OptEIA IL-10 ELISA kit 
(BD Biosciences, UK) as per the manufacturer’s instructions except the top standard was 
extended to 4000pg/ml.  The supernatant was either used neat or occasionally had to be 
diluted 1:2.  The plate was developed using Sure Blue TMB solution and read at 450nm 
in an Ascent Multiscan plate reader. 
 
2.6.5  Interferon Gamma (IFN-γ) ELISA 
 
Supernatant from stimulation cultures was assayed using an OptEIA IFN-γ ELISA kit 
(BD Biosciences) as per the manufacturer’s instructions.  Supernatants were used neat 
and developed as for the IL-10 ELISA. 
 
2.6.6  Interleukin-12 ELISA 
 
Supernatant from stimulation cultures was assayed using an OptEIA IL-12 p70 ELISA kit 
(BD Biosciences) as per the manufacturer’s instructions.  Supernatants were used neat 
and developed as for the IL-10 ELISA. 
 
2.6.7  Tumour Necrosis Factor Alpha (TNF-α) ELISA 
Supernatant from stimulation cultures was assayed using an OptEIA TNF-α mono/mono 
ELISA kit (BD Biosciences) as per the manufacturer’s instructions.  Supernatants were 
used neat, 1:10 or 1:20 dilutions, and developed as for the IL-10 ELISA.  62 
 
2.7  Immunisation of mice with LOS 
 
2.7.1  Injection of mice with LOS 
 
Male C57BL/6 mice aged between 6 and 8 weeks were injected intra-peritoneally with 
50µg of GB2 wild type or GB2 CSTII knock out C. jejuni LOS in 200µl sterile PBS.  
Controls  included  PBS  alone,  smooth  mutant  S.  typhimurium  and  rough  mutant  S. 
typhimurium LPS at the same concentration.  The mice were sacrificed 18 hours later.  
The spleens were taken and placed in a 5ml bijou where they were immersed in Cryo-M-
bed (Bright, UK) and transferred to a -80
oC freezer. 
 
2.7.2  Immunohistochemical staining of spleen following LOS injection 
 
Spleens from the above mice were cut into 8µm frozen sections using a Bright cryostat 
(model  OTF).    The  sections  were  allowed  to  air  dry  for  two  hours  and  were  then 
permeabilised in ice cold acetone for 10 minutes.  After drying, the sections were blocked 
with 100µl of 5% foetal bovine serum in PBS for 1 hour.  The sections were then washed 
3 times for 5 minutes in 0.3% PBS/Tween.  The sections were stained overnight with 
antibodies  diluted  1:100,  100µl  per  section.    Antibodies  used  were  anti-mouse  B220 
AlexaFluor 647 (Biolegend, USA) and anti-mouse MOMA-1 FITC.  The sections were 
washed 5 times then mounted using CitiFluor (CitiFluor, UK).  Slides were analysed 
using a Laser Scanning Cytometer (Compucyte) microscope. 
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2.8  Harvesting and fluorophore labelling of C. jejuni  
 
2.8.1  CFSE labelling of bacteria 
 
C.  jejuni  were  grown  as  before  and  harvested  into  sterile  PBS.    The  bacteria  were 
centrifuged at 4500g for 15 minutes, the supernatant discarded and the pellet suspended 
in PBS.  The bacteria were diluted to an OD600 of 1.0 and divided into 10ml aliquots.  
Stock 5mM CFSE was diluted to 5µM in PBS.  An equal volume of the 5µM CFSE was 
added  to  the  bacteria  and  incubated  for  30  minutes at  37
oC  in  the  dark  with  regular 
mixing.  The labelled bacteria were transferred to a 65
oC water bath and heat inactivated 
for 1 hour. They were then washed three times with 20ml of sterile PBS by centrifuging 
at  12,000g  for  10  minutes.    The  concentration  of  bacteria  was  standardised  between 
strains using OD600 and then aliquoted to store at -80
oC in 10% glycerol.  Before use, 
the aliquots were centrifuged at 13,000g for 5 minutes and the supernatant discarded.  
The pellet was resuspended and the concentration standardised by OD600. 
 
2.8.2  Quantification of the fluorescence of labelled bacteria 
 
20x10
6 labelled bacteria were added to 250µl FACS buffer and acquired using a BD 
FACSCalibur flow cytometer.  The data were analysed using FlowJo software and the 
MFI (mean fluorescence intensity) of the fluorophore labelled bacteria was determined.  
Only  those  batches  where  the  ganglioside  mimicking  strain  and  the  control  strain 
exhibited an equal fluorescence were used in phagocytosis experiments.   In  addition, 
20x10
6  bacteria  were  centrifuged  onto  a  coated  microscope  slide  using  a  cytospin 
(600rpm for 5 minutes) and the bacteria were visualised using a Carl Zeiss Apotome 
microscope to examine morphology and confirm the fluorescence. 
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2.8.3  Confirmation CFSE remains bound to bacteria 
 
20x10
6  CFSE  labelled  or  unlabelled  control  bacteria  were  added  to  1ml  RPMI  and 
incubated for 1 hour at 37
oC.  The bacteria were  removed by twice centrifuging the 
sample at 12,000g for 10 minutes and aspirating the supernatant.  1x10
6 mixed mouse 
splenocytes were then incubated with the supernatant for 30 minutes at 37
oC.  The cells 
were centrifuged at 500g for 5 minutes and resuspended in 4% formalin for 10 minutes 
before being washed and resuspended in FACS buffer.  The splenocytes were acquired 
and the CFSE MFI determined to establish if CFSE had leaked from the labelled bacteria 
and been taken up by the splenocytes. 
 
2.9  Phagocytosis and cell association of intact bacteria 
 
2.9.1  Association  of  C.  jejuni  with  splenic  B  cells  in  the  presence  or 
absence of fresh serum 
 
C57BL/6 mice were sacrificed by CO2 suffocation and a terminal bleed was carried out.  
The blood was centrifuged at 4000rpm and the serum collected and stored on ice.  The 
spleen was taken and digested using 1ml of cRPMI containing 100µl of DNase and 100µl 
collagenase  (both  10mg/ml)  and  incubating  for  10  minutes  at  37
oC.    A  single  cell 
suspension  was  made  and  the  red  cells  lysed.    The  splenocytes  were  washed  and 
resuspended to 1x10
7cells/ml and kept on ice.  CFSE labelled GB11 strain C. jejuni were 
defrosted, centrifuged (13,000g for 1 minute) and resuspended in PBS with the OD600 of 
wild type and CSTII knock out strains matched.  The bacteria were then opsonised by 
adding the bacteria to cRPMI supplemented with 20% fresh homologous mouse serum 
(taken  earlier)  at  a  concentration  of  40,000  bacteria  per  µl.    2x10
6  splenocytes  were 
transferred into FACS tubes at 1x10
6/ml in cRPMI supplemented with 5mM NaAzide 
and 5mM EDTA, and opsonised or non-opsonised wild type or CSTII knock out bacteria 
were added to the cells at a ratio of 3:1.  The cells were vortexed then split into triplicate  65 
tubes before being incubated for 15 minutes at 4
oC.  The cells were then washed with 3ml 
of ice cold PBS and, following blocking of Fc receptors, stained for B cells using anti-
mouse  CD19  APC  (Southern  Biotech,  USA).    The  cells  were  analysed  using  flow 
cytometry and the percentage of B cells with associated CFSE labelled C. jejuni was 
determined. 
 
Various controls were included to establish the role of complement.  The homologous 
mouse serum was heat inactivated (56
oC for 30 minutes) and used for opsonisation and 
purified exogenous mouse complement (Sigma, UK) was reintroduced (20%) to the heat 
inactivated serum before opsonisation. 
 
2.9.2  Identification  of  Sialoadhesin  receptor  on  bone  marrow  derived 
macrophages 
 
Bone marrow derived macrophages were grown and harvested as before.  The cells were 
fixed with 4% formalin/PBS then a cytospin was carried out (450g for 5 minutes).  Cells 
were blocked for 1 hour with 100µl 5% BSA/PBS and 1:100 Fc Block.  The slides were 
then washed once in 0.3% PBS/Tween followed by overnight staining at 1:100 dilution 
with anti-mouse F4/80 biotin (Biolegend) and anti-mouse MOMA-1 FITC (Serotec, UK).  
Slides  were  then  washed  3  times  before  incubating  the  anti-F4/80  samples  with 
streptavidin Alexa 647 (1:100 dilution) for 1 hour then washed a further 5 times.  The 
slides  were  mounted  using  DAPI  containing  Vectashield  and  analysed  using  a  laser 
scanning confocal microscope. 
 
2.9.3  Bone marrow derived macrophage phagocytosis of C. jejuni 
 
Bone  marrow  derived  macrophages  were  grown  and  harvested  as  before.    Complete 
RPMI supplemented with Ultra-low IgG foetal bovine serum (Invitrogen, UK) was used 
at all steps to exclude the possibility of natural Ig affecting phagocytosis.  FACS tubes  66 
were labelled for each time point (0, 15, 30 and 60 minutes) and for cells cultured at 37
oC 
and  control  tubes  cultured  at  4
oC.    The  cells  were  resuspended  to  1x10
7  per  ml  and 
300,000 cells were transferred into the FACS tubes and kept on ice.  CFSE labelled 
GB11  wild  type  and  CSTII  knock  out  C.  jejuni  were  defrosted,  centrifuged  and 
resuspended to remove bacterial debris.  The OD600 of both strains were matched.  C. 
jejuni were diluted in cRPMI then added to the macrophages at a 20:1 ratio so that the 
final  concentration  of  macrophages  was  1x10
6cells/ml.    The  cRPMI  used  in  the  4
oC 
control  tubes  was  supplemented  with  5mM  NaAzide.    All  tubes  were  vortexed 
thoroughly. The 37
oC tubes were transferred to an incubator and cultured at 37
oC with 
5% CO2, with mixing every ten minutes, for the desired time before being washed with 
3ml ice cold PBS with 5mM NaAzide.  The cells were stained as for previous FACS 
analysis using anti-mouse F/480 biotin and streptavidin APC.  For analysis, F4/80
+ cells 
were  gated  and  the  MFI  of  these  cells  (representing  phagocytosed  CFSE  labelled 
bacteria) was determined. The MFI of the 4
oC, NaAzide cultured controls was subtracted 
from the 37
oC cultured cells for each time point. The residual sample following FACS 
analysis was deposited on slides (Superfrost plus, VWR) using a cytospin (450g for 5 
minutes)  and  visualised  using  an  Apotome  microscope  to  confirm  the  intracellular 
location of the bacteria. 
 
2.9.4  Inhibition of bone marrow derived macrophage phagocytosis 
 
Bone marrow derived macrophage phagocytosis of C. jejuni was carried out as above and 
cells were analysed at a single 40 minute time point.  Prior to addition of the bacteria, the 
macrophages were incubated with 0.3µg each of Sialoadhesin blocking antibodies SER-4 
and 3D6 per million cells for 15 minutes at 4
oC.  CFSE labelled GB11 wild type and 
GB11 CSTII knock out C. jejuni were added to the cells at a 10:1 ratio and the amount of 
phagocytosis with and without Sialoadhesin blocking antibody was determined as before.  
In order to confirm that Sialoadhesin was the only receptor mediating enhanced uptake of 
the ganglioside mimicking C. jejuni strain, a titration of Sialoadhesin blocking antibodies 
was  used  ranging  from  0  to  0.5µg  of  SER-4  and  3D6  per  million  macrophages.    In  67 
addition, some cells were incubated with an isotype control antibody for the blocking 
antibodies at 1µg/million cells before the bacteria were added.   
 
2.9.5  Injection and tracking of labelled C. jejuni 
 
Age and sex matched C57BL/6 mice were injected i.v. with 200µl of heat inactivated, 
CFSE labelled, GB2 wild type and knock out C. jejuni diluted to an OD600 of 0.6 in 
PBS.  200µl of PBS i.v was used as a control.  The mice were sacrificed after 1 or 3 hours 
by  CO2  anaesthesia  and  harvested  for  spleen,  blood,  lymph  nodes  and  liver.    For 
Immunohistology studies, the tissues were transferred to filter paper and deposited on a 
drop of Cryo-M-bed media then placed in small metal containers and rapidly frozen using 
liquid nitrogen.  They were then stored at -80
oC.  For FACS studies, the spleens were 
homogenised to a single cell suspension.  Briefly, cell strainers were first wet with 1ml 
PBS  then  the  spleen  tissue  was  mashed  through  using  a  syringe  plunger  before  the 
strainer was washed with 4ml PBS.  The tissue was immediately lightly fixed using 1% 
paraformaldahyde for 15 minutes before labelling.  
 
2.9.6  Immunohistology of splenic sections 
 
Sections were cut to 8µm thickness using a cryostat and allowed to dry before being 
stored at -80
oC.  Following defrosting, the sections were permeabilised with acetone for 
10 minutes, air dried and washed with PBS/tween for 10 minutes.  Sections were blocked 
with 10% normal goat serum in PBS/1%BSA for 1 hour.  For metallophilic macrophage 
staining  supernatant  from  a  clone  producing  MOMA1  antibody  directed  against  the 
Sialoadhesin antigen was used. The MOMA1 clone is Rat IgG2a and the supernatant was 
kindly gifted by Dr P Leenen, Dept of Immunology, Erasmus MC, the Netherlands.  The 
supernatant was diluted 1:4 in PBS with 1% BSA and 300µl/slide was used for 1 hour at 
room  temperature  (control  sections  were  incubated  with  1%BSA/PBS  alone).    Slides 
were washed for 1 minute then 10 minutes in PBS/tween.  The secondary antibody was  68 
goat anti-rat IgG TRITC (Southern Biotech, USA) and was diluted 1:200 as before.  Each 
slide was incubated with 300µl for 1 hour at room temperature.  The slides were washed 
as before.  The sections were blocked with 1% normal rat serum before the anti-B220 
AlexaFluor  647  antibody  was  added  diluted  1:75  in  1%  normal  mouse  serum 
(250µl/slide).   Slides  were  washed  as  before  then  mounted  using  CitiFluor  mounting 
medium.   
 
For marginal zone macrophage staining, supernatant from a hybridoma producing an ER 
TR-9 antibody was used.  The ER TR-9 antibody is rat IgM and is directed against the 
marginal zone macrophage marker SIGN R1.  The supernatant was a kind gift from Dr P 
Leenen, Dept of Immunology, Erasmus MC, the Netherlands.  The protocol was the same 
as above only the supernatant was used at a 1:2 dilution and the secondary antibody was 
goat anti-rat IgM TRITC (Southern Biotech), used at 1:200 dilution. 
 
Sections  were  analysed  using  an  Apotome/Zeiss  microscope  and  Axiovision  software 
with the co-localisation module.  For co-localisation studies, two sections were cut from 
each spleen and three follicles in each section were analysed. 
 
2.9.7  FACS analysis of spleen following bacterial injections 
 
Age  and  sex  matched  C57BL/6  mice  were  separated  into  three  groups  of  three  and 
injected  with  bacteria  as  before.    After  1  hour  the  mice  were  sacrificed  by  CO2 
suffocation and the spleens were harvested.  A single cell suspension was made and the 
cells  were  briefly  fixed  in  1%  paraformaldahyde  for  15  minutes  then  kept  at  4
oC.  
Collagenase was not used and cells were fixed in paraformaldahyde because pilot studies 
had shown that the cells have to be analysed very rapidly following harvesting in order to 
detect  the  bacteria.    The  cells  were  counted  and  resuspended  to  10x10
6/ml  in  FACS 
buffer.  1 million cells were transferred to each FACS tube and the cells were blocked 
with 50µl of Fc block diluted 1:200.  To facilitate better compensation of fluorophores,  69 
each cell population was studied in two colour flow cytometry, that is, C. jejuni in FL1 
and the cell identifying antibody in FL4.  F4/80 biotin, CD11c biotin, GR1 APC and their 
respective isotype controls were used at 50µl of 1:100 dilution.  CD19 APC (Southern 
Biotech, USA) was used at 1:200 dilution.  MOMA1 supernatant was used at 1:4 dilution 
(secondary antibody alone served as the isotype control for MOMA1).  Following a 45 
minute incubation the cells were washed and, where appropriate, 50µl of streptavidin 
APC was added at 1:200 dilution.  For the cells labelled with MOMA1, an anti-rat IgG2a 
biotin was added at 1:200 dilution.  After a half hour incubation, the cells were washed 
and  resuspended  to  250µl  for  analysis  (a  final  staining  step  was  carried  out  on  the 
MOMA1 cells using streptavidin APC as before).  70 
Figure 1: Structure of E. coli LPS and C. jejuni LOS. 
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Figure 1. Diagrammatic representation of A) E. coli LPS and B) C. jejuni LOS (mimicking ganglioside 
GM1).   KDO – 3-deoxy-D-manno-octulosonic acid; HGlcN3N - 2,3-diamino-2,3-dideoxy-D-glucose; Hep 
- L-glycero-D-manno heptose; Glc – glucose; PEA – phosphorylethanolamine; Gal – galactose; GalNac - 
N-acetylgalactosamine and  P – phosphate.  Numbers represent length of acyl chain.  71 
3  Isolation and purification of C. jejuni LOS 
 
3.1  Introduction 
 
The aims of the experiments presented in this chapter are to purify LOS from C. jejuni, 
eliminate contamination, confirm ganglioside mimicry and accurately quantify the LOS.  
This  will  allows  us  to  address  one  of  the  central  hypotheses  of  the  thesis;  that  the 
ganglioside mimicking epitopes found on the LOS molecules of GBS associated strains 
of C. jejuni alter the immunostimulatory properties of the LOS. 
 
Bacterial LPS is found in the outer membrane of gram negative bacteria
102.  LPS is a 
glycolipid  molecule  that  is  classically  considered  as  three  covalently  linked  sections 
103,104: the hydrophobic Lipid A, the core oligosaccharide and the hydrophilic antigenic 
O-side chain.  The Lipid A usually consists of a diglucosamine backbone with attached 
fatty  acyl  chains  which  show  inter-  and  intra-species  variability  in  length  and 
substitution.    Lipid  A  determines  endotoxicity
102,111,210,211.    The  inner  core 
oligosaccharide contains bacterial specific sugars such as 3-deoxy-D-mano-octulosonic 
acid (KDO), while the outer core contains hexoses and hexosamines.  The O-side chain 
consists of repeating saccharide units
102.  GBS associated C. jejuni synthesise a truncated 
O-side chain. The resultant molecule, which is essentially Lipid A with attached core 
sugars, is termed lipo-oligosaccharide (LOS).  Figure 1(A) illustrates the structure of a 
“smooth” mutant E. coli LPS with an extended O-side chain and figure 1(B) shows a 
“rough” mutant C. jejuni LOS with a truncated O-side chain.   72 
Figure 2: Structures of HS O:19 and HS O:3 C. jejuni LOS. 
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Figure 2.  Diagrammatic representation of the LOS structures of the ganglioside mimicking C. jejuni strain 
HS  O:19  and  non-mimicking  strain  HS  O:3.    HS  O:19  produces  GM1  and  GD1a  mimicking  LOS  in 
equimolar amounts. KDO – 3-deoxy-D-manno-octulosonic acid; HGlcN3N - 2,3-diamino-2,3-dideoxy-D-
glucose;  Hep  -  L-glycero-D-manno  heptose;  Glc  –  glucose;  PEA  –  phosphorylethanolamine;  Gal  – 
galactose;  GalNac  -  N-acetylgalactosamine,    P  –  phosphate,  Cer  –  ceramide,  GlcNAc  –  N-
acetylglucosamine and DdGlc – dideoxyglucose.  73 
The initial experiments described in this chapter use two strains of C. jejuni from the 
clinical  bacteriology  departmental  collection  of  C.  jejuni  at  the  Southern  General 
Hospital, Glasgow.  HS O:19 is a GBS associated strain in which the LOS molecules 
mimic gangliosides GM1 and GD1a at a 50:50 ratio
202 while HS O:3 is not associated 
with GBS and does not mimic gangliosides
203.  Both LOS structures are illustrated in 
figure 2. 
 
For  later  experiments,  through  collaboration  with  Erasmus  University,  Rotterdam, 
additional useful strains of C. jejuni were used and were supplied as both the parent 
organism (GB11 and GB2 wild type and CSTII knock out) and as purified LOS (GB11, 
GB2  and  GB19  wild  type  and  CSTII  knock  out)
101.    GB11  and  GB2  both  mimic 
gangliosides GM1 and GD1a in equimolar amounts.  Isogenic knock-out mutants were 
created lacking the sialyltransferase gene (CSTII) which attaches sialic acid to the core 
sugars.  These strains produce three asialo-sugars as part of their internal core sugar 
(structures illustrated in figures 3 (A) and 3 (B)) and do not mimic gangliosides. At least 
two of their core sugars mimic other self glycolipids.  Importantly, within the isogenic 
strains, all other structures in the bacteria and LOS (including Lipid A) are predicted to 
be  identical.    GB19  (as  distinct  from  HS  O:19)  mimics  ganglioside  GD1c  and  no 
information is available about the structure of the CSTII knock out mutant.  74 
Figure 3(A): Structures of GB2 and GB11 wild type C. jejuni LOS. 
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Figure 3 (A).  Diagrammatic representation of the structures of the LOS molecules purified from the GB2 
and GB11 wild type strains of C. jejuni as well as the gangliosides that they mimic.  Each LOS molecule is 
produced by the bacteria in equimolar amounts (i.e. 50:50 ratio). KDO – 3-deoxy-D-manno-octulosonic 
acid; HGlcN3N - 2,3-diamino-2,3-dideoxy-D-glucose; Hep - L-glycero-D-manno heptose; Glc – glucose; 
PEA – phosphorylethanolamine; Gal – galactose; GalNac - N-acetylgalactosamine,  P – phosphate, Cer – 
ceramide.   75 
Figure 3(B): Structures of GB2 and GB11 CSTII knock out C. jejuni LOS. 
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Figure 3 (B).  Diagrammatic representation of the structures of the LOS molecules purified from the GB2 
and GB11 CSTII knock out strains of C. jejuni as well as the asialo-sugars that they mimic.   Percentages 
indicate  the  proportion  of  each  LOS  molecule  produced  by  the  bacteria.  KDO  –  3-deoxy-D-manno-
octulosonic acid; HGlcN3N - 2,3-diamino-2,3-dideoxy-D-glucose; Hep - L-glycero-D-manno heptose; Glc 
–  glucose;  PEA  –  phosphorylethanolamine;  Gal  –  galactose;  GalNac  -  N-acetylgalactosamine,    P  – 
phosphate, Cer – ceramide.  76 
Figure 4: Silver stain analysis of hot phenol extracted LOS. 
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Figure 4.  SDS-PAGE and silver stain of hot phenol extracted LOS. (A) C. jejuni LOS. (B)  Smooth mutant 
E. coli LPS.  Each lane contained 5µg of LOS (the blank spacer lane contained dH2O).  77 
3.2  Results 
 
3.2.1  Hot phenol extraction of C. Jejuni LOS and assessment of purity 
 
C. jejuni were grown for 48 hours at 37
oC in a microaerobic environment on Columbia 
Agar and Horse Blood plates, harvested into PBS and heat inactivated at 60
oC for 1 hour.  
These bacteria were used as a source for LOS which was extracted using the hot-phenol-
water technique.  The resultant product was analysed by SDS-PAGE and silver stain to 
assess purity and mass. 
 
Figure 4 (A) shows that there are distinct high molecular weight bands in the silver stain 
of the LOS which indicates contamination (the spacer lane with dH2O shows no such 
contamination).  This contamination is likely to be protein or nucleic acids
212-214.  There 
is a distinct band at 4kDa which is the expected mass of LOS.  Figure 4 (B) shows a 
silver stain of smooth mutant E. coli LPS demonstrating the ladder pattern produced by 
LPS molecules with differing lengths of O-side chain which contrasts with the single 
mass of rough mutant LOS.   78 
Figure 5: Photograph of LOS solution following enzyme treatment. 
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Figure 5.  Photographs of LOS purified in enzyme buffer using DNase, RNase, lysozyme and Proteinase K.    
(A) Photograph of the settled precipitate. (B) Photograph the opaque colloid solution after agitation.   79 
3.2.2  Purification of hot phenol extracted LOS 
 
To  obtain  a  purified  sample  of  LOS  it  was  necessary  to  remove  the  contaminating 
DNA/RNA, glycolipids and protein.  To do this hot phenol extracted LOS was treated 
with DNase, RNase, lysozyme and Proteinase K. 
 
LOS was resuspended in enzyme buffer (0.1M TrisHCL, 5mM CaCl2 and 5mM MgCl2. 
pH 7.5) and the enzymes added sequentially.  The enzyme buffer was derived from LPS 
purification protocols
215 using suggested cation concentrations from the enzyme product 
data sheets.  Although the LOS solution was initially clear, the addition of lysozyme 
caused a precipitate to form which came out of suspension and settled in the universal.  
Figure 5 (A) and 5 (B) show photographs of the LOS solution containing the settled 
precipitate and the precipitate in a colloid suspension following vortexing.  80 
Figure 6: Silver stain analysis of LOS precipitate. 
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Figure 6.  SDS-PAGE and silver stain of HS O:3 LOS precipitate and supernatant. The precipitate shows a 
continuous smear with no distinct bands.  The clear supernatant resolves into two distinct bands, one of 
which is double the mass of the other.  81 
3.2.3  Assessment  of  purity  and  determination  of  the  nature  of  the 
precipitate 
 
SDS-PAGE and silver staining was used to analyse the precipitate and the supernatant 
(5µg of each).  Figure 6 shows that the precipitate consists of a continuous smear of 
material with the staining characteristics of LOS and that there are no distinct bands of 
contamination  like  those  seen  in  figure  4  (A).    The  supernatant  also  contains  LOS 
although it resolves into two bands, one at 8kDa and one at 4kDa. 
 
The two bands produced by the supernatant in lane 3 were interpreted to represent single 
LOS molecules (4kDa) and LOS “dimers” (8kDa).  These dimers probably consist of two 
LOS molecules held together, tail to tail, by hydrophobic interactions (illustrated in figure 
16 (B)).  
 
In order to test this hypothesis, HS O:19 LOS was subjected to SDS-PAGE and Western 
blotting.  HS O:19 produces two LOS molecules in equimolar amounts, one mimicking 
ganglioside GM1 and the other mimicking ganglioside GD1a.   The Western blot was 
labelled  using  cholera  toxin  (to  identify  GM1)  and MOG35  monoclonal  antibody  (to 
identify GD1a).  82 
Figure 7: Western blot analysis of ganglioside mimicking LOS epitopes. 
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Figure  7.    SDS-PAGE,  Western  blot  and  silver  stain  of  HS  O:19  and  HS  O:3  LOS  demonstrating 
ganglioside  epitopes.  (A)  Labelled  with  cholera  toxin  (binding  GM1  epitope)  and  (B)  Labelled  with 
MOG35 mAb (binding GD1a epitope). (C) Loading control showing a silver stain of a gel run in parallel to 
(A) and (B).  83 
The Western blot in Figure 7 shows that both epitopes (GM1 and GD1a) are present in 
both the 4kDa and 8kDa bands.  This is consistent with LOS dimers being responsible for 
the 8kDa band. In addition, the HS O:3 strain only produces a single LOS species and yet 
silver staining resolves into two bands (figure 6) consistent with an LOS homodimer. 
 
The  continuous  smear  produced  by  the  precipitate  was  interpreted  to  represent 
incompletely fragmented lamellar LOS macro-structures. Such structures form in solution 
as a consequence of the amphipathic nature of LOS. They are held together by lateral 
electrostatic  interactions  and  bilayer  hydrophobic interactions  (illustrated  in  figure  16 
(A)).  The smear indicates that they were incompletely separated by the electrophoresis 
process.    84 
Figure 8: Silver stain analysis of LOS following micelle dispersal. 
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Figure 8.  SDS-PAGE and silver stain of HS O:3 LOS or HS O:3 LOS treated with EDTA and Triton X 
detergent. (A) LOS prior to treatment.  (B) The same LOS sample after treatment.   85 
3.2.4  Control of macro-molecular structures 
 
Macro-molecular  structures,  such  as  micelles  and  lamellar  sheets,  can  potentially 
influence LPS activity and so it was decided to regulate their formation. 
 
Eliminating  lysozyme  from  the  protocol  prevented  the  formation  of  the  settled 
precipitate.    However,  the  LOS  continued  to  from  a stable  opaque  colloidal  solution 
which resolved into double bands following SDS-PAGE and silver stain (figure 8 (A)).  
The opaque appearance of the solution and the dual band on silver stain were interpreted 
to represent continued aggregation into macro-molecular structures.   
 
LOS was subjected to treatment to disperse the macromolecular structures.  This was 
done by altering the pH (titration of NaOH), removing cations (addition of EDTA) or 
adding detergents.  A combination of treatments (EDTA with Triton X detergent) caused 
a visual dispersal of the colloid solution.  SDS-PAGE and silver stain of the treated LOS 
(figure 8, (B)) shows that it resolves into a single band of approximately 4kDa.  The LOS 
solution in figure 8 (A) was an opaque colloid solution while the solution in figure 8 (B) 
was clear. This confirms that double bands seen by silver stain correspond with macro-
molecular structures in the LOS and that these are visible as an opaque colloid solution.  
The clarification of the solution allowed spectrophotometry to be carried out on the LOS 
and no DNA, RNA or protein was detected.    86 
Figure 9: Western blot analysis of LOS epitopes following neuraminidase treatment. 
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Figure 9.  SDS-PAGE, Western blot and silver stain of HS O19, HS O:3 and neuraminidase treated HS 
O:19 LOS demonstrating  ganglioside  mimicking epitopes.  (A) Shows all three strains incubated  with 
cholera toxin (binds GM1 epitope). (B) Shows all three strains incubated with MOG35 mAb (binds GD1a 
epitope).  Cholera toxin labels HS O:19 and neuraminidase treated HS O:19 while MOG35 only labels HS 
O:19. (C)  Loading control showing a silver stain of a gel run in parallel to the gels used in (A) and (B). 
(These samples had not been pre-treated with detergent/EDTA).  87 
3.2.5  Generation  of  a  control  strain  of  LOS  and  confirmation  of 
ganglioside mimicking epitopes  
 
Intra-species differences in the structure of LOS Lipid A may alter LOS potency.  HS 
O:19 LOS was treated with cholera neuraminidase to remove sialic acid and provide a 
control strain with an identical Lipid A but without ganglioside mimicry.  
 
A Western blot was carried out, using cholera toxin and MOG35, in order to confirm the 
ganglioside mimicry of HS O:19, the non-mimicry of the neuraminidase treated HS O:19 
and the non-mimicry of HS O:3.  Figure 9 (A) and (B) confirms that HS O:19 LOS 
mimics ganglioside GM1 and GD1a respectively.  HS O:3 LOS does not mimic either of 
these gangliosides.  However, neuraminidase treated HS O:19 LOS continues to mimic 
GM1 (figure 9(A)) but no longer mimics GD1a (figure 9(B)).    88 
Figure 10: Silver stain analysis of enzyme purified LOS. 
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Figure 10.  SDS-PAGE and silver stain of new strains of LOS, purified in Milli-Q. 5µg of LOS loaded per 
well.   89 
3.2.6  Isolation and purification of GB11 wild type, GB11 CSTII knock 
out, GB2 wild type and GB2 CSTII knock out LOS 
 
New strains of C. jejuni were provided by collaborators as both the parent organism and 
as pre-purified LOS.  Isolation and purification was done using an identical protocol with 
the  exception  that  Milli-Q  distilled  and  deionised  H2O  was  used  at  all  steps  of  the 
procedure in place of enzyme buffer.  Silver stain was carried out on the LOS to establish 
if the new protocol successfully removed impurities.  Figure 10 shows that there is no 
evidence  of  impurities  using  silver  stain,  indicating  that  the  purification  enzymes 
remained active in the absence of calcium and magnesium.  In addition, the LOS formed 
a clear solution and resolved primarily into a single band.  All subsequent purifications 
used this protocol.  90 
Figure 11: Alcian blue and silver stain analysis of purified LOS and whole cell lysate. 
45 kDa Capsular
polysaccharide
A B
4 kDa LOS
65 kDa
Flagellum
M
u
l
t
i
m
a
r
k
s
t
a
n
d
a
r
d
W
i
l
d
 
T
y
p
e
C
S
T
I
I
 
K
n
o
c
k
 
o
u
t
Whole
Cell
lysate
W
i
l
d
 
T
y
p
e
C
S
T
I
I
 
K
n
o
c
k
 
o
u
t
LOS
M
u
l
t
i
m
a
r
k
s
t
a
n
d
a
r
d
W
i
l
d
 
T
y
p
e
C
S
T
I
I
 
K
n
o
c
k
 
o
u
t
Whole
Cell
lysate
W
i
l
d
 
T
y
p
e
C
S
T
I
I
 
K
n
o
c
k
 
o
u
t
LOS
 
Figure 11.  SDS-PAGE with alcian blue and silver stain of a whole cell lysate of GB2 C. jejuni and purified 
GB2 LOS (5µg of each). (A) Shows alcian blue stain and (B) shows silver stain.    91 
3.2.7  Detection of capsular polysaccharide contamination 
 
Capsular polysaccharide (CPS) is a glycolipid molecule with similar chemical properties 
to  LOS  and  LPS.    Although  steps  were  taken  to  eliminate  nucleic  acid  and  protein 
contamination, no precautions had been taken to eliminate CPS.  CPS can potentially 
signal through TLR2
216 which would result in inaccurate measurements of LOS potency.  
LOS was tested for CPS contamination using an alcian blue stain.  A positive control was 
generated using whole cell C. jejuni lysate.  Figure 11(A) shows the alcian blue stain of 
the LOS and whole cell lysate and figure 11(B) shows the silver stain.  In the lanes 
containing cell lysate, there is a faint band of alcian blue staining at 45kDa which is the 
reported mass of C. jejuni CPS
217.  There are additional bands at 65kDa (consistent with 
flagellum) and 4kDa (consistent with LOS).  In the lanes containing purified LOS there is 
a single LOS band at 4kDa.  No contaminating CPS is detected in the purified LOS.  92 
Figure 12: Western blot analysis of gangliosides mimicry by GB11 and GB2 LOS. 
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Figure 12.  SDS-PAGE and Western blot of GB11 and GB2 strains of LOS demonstrating ganglioside 
mimicry. 5µg of LOS was used in each well. (A) shows membrane incubated with cholera toxin (specific 
for GM1 epitope) and (B) membrane incubated with MOG35 mAb (specific for GD1a epitope).    93 
3.2.8  Confirmation of GM1 and GD1a epitopes on GB11 and GB2 wild 
type LOS. 
 
GB11 and GB2 wild type LOS are reported to mimic gangliosides GM1 and GD1a at a 
50:50 ratio.  SDS-PAGE and Western blot was carried out to confirm the ganglioside 
mimicry.  Figure 12 shows that GB11 and GB2 wild type LOS mimic gangliosides GM1 
and GD1a and that the CSTII knock out LOS strains do not mimic these gangliosides.  
GB19 LOS is reported to mimic GD1c and as expected does not label with cholera toxin 
or MOG35.  The Western blot also confirms that the LOS resolves primarily into a single 
4kDa band although very weak labelling was present at 8kDa.  94 
Figure 13: LOS concentration determined by thiobarbituric acid assay. 
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Figure 13.  Concentration of LOS determined using the thiobarbituric acid assay.  There is a significant 
difference in LOS concentration (p<0.001) between GB11 wild type and knock out, and GB19 wild type 
and knock out.  Mean and SEM calculated from triplicate tubes with Students two tailed t test.  Experiment 
repeated twice.  95 
3.2.9  Determination of LOS concentration by thiobarbituric acid assay 
 
In  all  experiments  described  above,  LOS  was  quantified  by  dry  weight  following 
lyophilisation.  The thiobarbituric acid assay was used to confirm the concentration and 
ensure that wild type and CSTII knock out strains were equimolar.  The thiobarbituric 
acid assay measures the concentration of KDO, a core sugar unique to bacteria.  Figure 
13 shows the concentration of GB11, GB2 and GB19 wild type and CSTII knock out 
LOS.   There is a statistically  significant difference  (p<0.001) in the concentration of 
GB11 wild type and GB11 CSTII knock out strains as well as the GB19 wild type and 
GB19 CSTII knock out strains.  In both cases the sialylated strains are more concentrated.  
The GB2 wild type and CSTII knock out strains are equimolar.  96 
Figure 14: Thiobarbituric acid assay of GM1 and sialic acid. 
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Figure 14.  Thiobarbituric acid assay of native GM1 and native sialic acid.  There is an increase in OD549 
for both molecules. Mean and SEM calculated from triplicate tubes.  Single experiment.   97 
3.2.10 Assessment of the validity of the thiobarbituric acid assay 
 
A potential cause for the difference in molarity is interference in the assay.  Sialic acids 
are 2-keto-3-deoxy sugars which are similar in structure to KDO.  To test whether sialic 
acid in the ganglioside mimicking LOS is interfering with the thiobarbituric acid assay, 
native GM1 ganglioside and native sialic acid molecules were used as substrates in the 
assay.  Figure 14 shows that both GM1 and sialic acid cause an increase in absorbance at 
OD549 in the thiobarbituric acid assay.   
 
A  second  experiment  was  carried  out  to  determine  if  sialic  acid  makes  a  significant 
contribution to the colour change when compared to KDO.  Native KDO molecules and 
native sialic acid molecules were used in the thiobarbituric acid assay.  Figure 15 (note 
that the graph x and y axes have been reversed) indicates that an approximately four 
times greater concentration, by molarity, of sialic acid is required to produce the same 
absorbance at OD549 as KDO.  Sialic acid and KDO exist in LOS at a 1.5:1 ratio in 
GB11 and GB2 LOS strains.  98 
Figure 15: Thiobarbituric acid assay of KDO and sialic acid. 
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Figure 15.  Thiobarbituric acid assay of native KDO and native sialic acid comparing potency in inducing 
colour change at OD 549.  (Note that the graph x and y axes have been reversed).  Single experiment. 
  99 
3.3  Discussion 
 
The  principal  concerns  when  isolating  LOS  were  purity,  ganglioside  mimicry  and 
accurate  quantification.    The  additional  issue  of  secondary  structures  (how  the  LOS 
molecules associate with each other in solution) became apparent during the purification 
process. 
 
The technique of isolating LPS or LOS using hot phenol and water has been described 
previously
218.  This involves disrupting bacterial cells in a hot water phenol mix and 
allowing the LOS to partition into the aqueous phase while cooling the mixture.  This 
method is not entirely specific as it relies solely on the relative solubility of the LOS for 
separation from other constituents.  Bacteria contain a number of immunostimulatory 
molecules such as proteins, glycolipids and DNA/RNA, all of which can be sources of 
contamination.  There are a number of variations of this technique optimised for different 
types of LPS.  My particular technique was chosen because the major studies on the 
structure on C. jejuni LOS have used the basic hot phenol technique to extract LOS
202,203.  
 
My initial studies show that hot phenol extraction of LOS does not yield a pure product.  
The use of DNase, RNase and Proteinase K in an appropriate enzyme buffer to remove 
contamination is an established technique
219 and this was employed to improve purity.  
SilverXpress
tm  staining  is  exquisitely  sensitive  for  proteins  (detecting  sub-nanogram 
quantities) and DNA (detecting nanogram quantities).  SilverXpress
tm staining detected 
no evidence of contamination in LOS purified using the final protocol.  In support of this, 
after  LOS  solutions  had  been  clarified  using  detergent  and  EDTA,  biophotometry 
detected no evidence of DNA, RNA or protein.   
 
Lysozyme was initially used to remove CPS.  However, lysozyme caused a precipitate to 
form which was interpreted as the formation of LOS lamellar macro-structures.  Studies 
have shown that lysozyme interacts electrostatically with phosphate groups on the Lipid   100 
A in Re (rough mutant) LOS causing increased rigidity of the acyl chains which affects 
the  LOS aggregate structures
220.  This is a likely explanation for my observations of 
precipitate formation, although changes in the pH or ionic concentration of the solution 
might also account for this.  For this reason it was decided to eliminate lysozyme from 
the protocol.  Capsular polysaccharide produced by C. jejuni is detectable using alcian 
blue staining
217.  LOS purified without lysozyme was tested by this method. No evidence 
of CPS is seen in the LOS while a band at the expected molecular mass was visible in the 
whole cell lysate positive control.  Based on these findings it was concluded that CPS is 
either absent or present at levels below the limits of the alcian blue assay sensitivity. 
 
The structures of LOS molecules produced by HS O:19, HS O:3, GB11 wild type, GB2 
wild  type,  GB11  CSTII  knock  out  and  GB2  CSTII  knock  out  have  been 
established
101,202,203.  Western blot analysis using reagents directed against gangliosides 
GM1 and GD1a confirms the expected ganglioside mimicry and shows no evidence of 
such mimicry  in the  control strains.  An  attempt was made to produce an  additional 
control strain for HS O:19 by treating the LOS with cholera neuraminidase.  However, 
this resulted in the GD1a epitopes being converted to GM1 which can be explained by 
the  fact  that  cholera  neuraminidase  is  only  active  against  external  sialic  acids
221,222.  
Additional  neuraminidase  enzymes  capable  of  cleaving  internal  sialic  acids,  such  as 
Arthrobacter  ureafaciens  sialidase
223,  could  have  been  used  alongside  cholera 
neuraminidase to completely remove all sialic acid residues.   101 
Figure 16: Diagram of LOS macromolecular structures. 
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Figure  16.    Diagrammatic  representation  illustrating  potential  macro-molecular  LOS  structures.    (A) 
represents a lamellar bilayer.  (B) shows a “dimer” structure comprising GM1 and GD1a mimicking LOS 
molecules linked by hydrophobic bonds. (C) shows a monolayer micelle.   102 
LPS is an amphipathic molecule consisting of a hydrophobic tail and hydrophilic head.  
In aqueous solutions LPS spontaneously forms a variety of macro-molecular structures
224-
226. These include lamellar bilayers, micelle bilayers, single layer micelles and dimer 
structures
102  (illustrated  in  figure  16).    The  precise  nature  of  these  macro-molecular 
structures  depends  on  a  variety  of  factors  including  LPS  concentration,  ionic 
concentration, pH and temperature.  LOS is more hydrophobic than LPS and has a greater 
tendency to form these structures.  Divalent cations, required for activity of the DNase
227, 
RNase
228  and  Proteinase  K
229,  increase  the  tendency  for  such  structures  to  form.    A 
number  of  different  purification  protocols  were  tested  to  try  and  prevent  colloid 
formation and these included varying the pH and cation concentrations. 
 
Macromolecular structures are a concern because several studies report aggregated LPS 
to be more potent than monodisperse LPS
230-232 and aggregate dependent differences in 
mAb binding to LPS have been demonstrated
232.  This means that important epitopes 
might  be  hidden  by  secondary  structures,  for  example  ganglioside  availability  for 
antibody  binding  can  be  influenced  by  neighbouring  gangliosides
233.    To  allow  a 
comparison  of  potency  of  the  ganglioside  mimicking  versus  non-mimicking  strains 
without the confounding influence of aggregate effects, it was decided to regulate the 
micelle structures.  Micelles could be dispersed by treating the colloidal LOS with EDTA 
and detergent and dispersal was confirmed by changes in the silver staining properties.  
However, EDTA and detergent proved difficult to remove by dialysis. 
 
New strains of C. jejuni and LOS were provided by a collaborating group.  In addition to 
eliminating potential differences in the Lipid A, the GB2, GB11 and GB19 strains of 
LOS were purified using a procedure that omitted divalent cations and minimised micelle 
formation.  Tests of LOS purity under these alternative conditions confirmed that the 
DNase,  RNase  and  proteinase  remained  effective  in  removing  contamination.  
Presumably residual cations chelated by the LOS were available to activate the enzymes.  
The visual appearance of the LOS and the resolution of the LOS into a mainly single   103 
band by SDS-PAGE and silver stain indicate that the omission of divalent cations at all 
stages of purification provides a simple solution to colloidal aggregate formation. 
 
It  was  noted  that  the  bands  formed  by  silver  staining  of  these  LOS  strains  showed 
variations in size and intensity.  It is thought that silver staining binds to the carbohydrate 
rather than the lipid portion of LPS/LOS
234,235.  Therefore differences in staining intensity 
are probably due to differences in the carbohydrate structure of wild type and knock out 
LOS rather than differences in concentration. 
 
The LOS was quantified using a combination of dry weight and the thiobarbituric acid 
assay.  This chemical  assay relies on the cleavage of a diol  grouping  in 3 deoxy-D-
manno-oct-2-ulosonic acid (KDO) which is a unique sugar found in the LOS/LPS core 
region.  This releases a derivative which reacts with thiobarbituric acid to produce a 
chromophore
236.    LOS  concentration  is  determined  by  comparing  to  a  known 
concentration of KDO.  The initial assay shows that wild type and knock out strains of 
LOS  are  not  equimolar.    There  are  a  number  of  potential  explanations  including 
inaccuracy in the dry weight, differences in molecular mass and inaccuracy of the KDO 
assay. 
 
Variants  of  the  thiobarbituric  acid  assay  are  used  to  measure  sialic  acid.    Due  to 
differences in the chemical structure of these molecules, sialic acid requires harsher acid 
treatment in order to contribute to colour change in this assay
236.  Several variations of 
this assay were tested and the least harsh protocol was employed to measure the LOS.  
However,  both  free  sialic  acid  and  GM1  causes  a  colour  change  using  my  protocol, 
confirming inaccuracy in the KDO assay.   104 
A  further  attempt  at  quantification  was  done  using  the  Limulus  Ameobocyte  Assay 
although due to its exquisite sensitivity it was found to be impractical.  Quantification 
was therefore done using dry weight alone as this was considered the most convenient 
and reliable method of quantification.  It is recognised that this does not take into account 
differences in molecular mass. 
 
In  conclusion,  I  have  purified  LOS  to  such  a  degree  that  no  contamination  can  be 
demonstrated using standard detection techniques.  I have verified that my LOS strains 
either mimic or do not mimic gangliosides as predicted.  In addition, I have shown that 
the thiobarbituric acid assay is unreliable for quantifying sialylated LOS and concluded 
that dry weight is the most suitable alternative.  There is no evidence of differences in 
macromolecular structures between the wild type and knock out strains although I have 
not  shown  this  definitively.    Overall,  I  judge  the  LOS  to  be  suitable  for  testing  my 
hypotheses. 
    105 
4  Interaction  of  ganglioside  mimicking  LOS  and  whole  C. 
jejuni  with  ganglioside  specific  cellular  receptors  and 
complement components 
 
4.1  Introduction 
 
The aim of the experiments presented in this chapter is to establish if the ganglioside 
mimicking side chain of LOS can act as a ligand for cellular receptors and complement 
proteins which are believed to bind to endogenous gangliosides. 
 
The  pathophysiology  of  GBS  is  thought  to  involve  the  generation  of  LOS  specific 
antibodies  that  cross  react  with  gangliosides  on  self-cells  resulting  in  autoimmune 
damage
40,237.    This  model  of  pathogenesis  relies  on  gangliosides  substituting  for 
ganglioside mimicking LOS as a target for antibodies and this cross-reactivity has been 
confirmed
238,239.  I wish to establish if ganglioside mimicking LOS can substitute for 
gangliosides as a ligand for immune system receptors. 
 
A number of ganglioside binding cellular receptors are known. The best characterised 
family of receptors are siglecs (sialic acid binding immunoglobulin like lectins)
144,146,240. 
The  precise  specificities  and  physiological  roles  of  these  receptors  are  still  being 
investigated.  It has been shown that Siglec 7 binds to GT1a/GM1 mimicking C. jejuni 
and its purified LOS
148.  The myeloid expressed mouse siglecs, Sialoadhesin, Siglec E 
and  Siglec  F,  are  predicted  to  bind  to  GD1a/GM1  mimicking  C.  jejuni  and  its  LOS 
although this has not yet been confirmed experimentally.  (See Appendix 3 and 4 for 
siglec structure, cellular expression and binding profiles). 
   106 
The complement regulatory protein Factor H has a sialic acid binding site
241,242.  Factor H 
inhibits the alternative complement pathway and this protects self-cells from aberrant 
complement activation
241.  Non-campylobacter pathogens are thought to use sialylation 
and fH binding to enhance complement resistance
243-245.  It has not been established if 
ganglioside mimicry by C. jejuni facilitates  fH binding or if this affects complement 
activation on GBS associated strains.   107 
Figure 17: Sialoadhesin binding to whole C. jejuni. 
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Figure  17.  Sialoadhesin-Fc fusion protein binding to whole C. jejuni.  (A) whole GB11 wild type and 
GB11 knock out C. jejuni and (B) whole HS O:19 and HS O:3 C. jejuni. There is statistically significant 
binding of Sialoadhesin to ganglioside mimicking strains of C. jejuni (GB11 wild type and HS O:19) 
compared to their control strains (GB11 knock out and HS O:3) at each concentration of Sialoadhesin 
tested (A and B).  Mean and SEM calculated from triplicate wells.  Significance compares binding to 
ganglioside mimicking and control strain at each Sialoadhesin concentration using 2way ANOVA with 
Bonferroni’s post tests (*=p <0.05, ***p= <0.001). Graphs representative of 3 experiments.     108 
4.2  Results 
 
4.2.1  Sialoadhesin binding to C. jejuni.  
 
Murine Sialoadhesin-human-Fc fusion protein binding to whole, formalin fixed, C. jejuni, 
pre-adsorbed  onto  ELISA  plates,  was  measured.    Figures  17  (A)  and  (B)  show  that 
Sialoadhesin binds to both of the ganglioside mimicking strains (GB11 wild type (A) and 
HS O:19 (B)).  Sialoadhesin does not bind to the non-mimicking control strains (GB11 
knock  out  (A)  and  HS  O:3  (B)).    The  difference  in  binding  between  ganglioside 
mimicking strains and control strains is statistically significant (GB11 wild type v knock 
out: p<0.001 at 1µg/ml and 0.5µg/ml, p<0.05 at 0.25µg/ml.  HS O:19 v HS O:3: p<0.001 
at 1, 0.5 and 0.25µg/ml).  
 
Sialoadhesin is predicted to bind GD1a and GT1b.  Sialoadhesin binding to gangliosides 
and ganglioside mimicking LOS was assessed using ELISA.  The target gangliosides 
tested were GM1, GD1a and GT1b, and the asialo-glycolipids were asialo-GM1, asialo-
GM2 and lactosyl ceramide (the core components of GB11 knock out C. jejuni LOS).  
Sialoadhesin binding to GB11 wild type and knock out LOS, and HS O:19 and HS O:3 
LOS was also assessed.  No Sialoadhesin binding was detected to any of these targets 
(data not shown).   109 
Figure 18: Immunocytometry of Sialoadhesin binding to C. jejuni. 
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Figure 18.  Immunocytometry of Sialoadhesin binding to C. jejuni.  (A) DAPI labelled HS O:19.  (B) HS 
O:19 labelled with Sialoadhesin-Fc fusion protein and anti-human IgG FITC.  (C) Merge of (A) and (B).  
Inset is digital magnification of (C); arrow shows punctate staining of the bacteria.  (D)  Control 1 – 
merged image of DAPI labelled HS O:19 and anti-human IgG FITC (secondary Ab only). (E) Control 2 – 
merged image of DAPI labelled HS O:3 with Sialoadhesin-Fc fusion protein and anti-human IgG FITC.  
Single experiment.   110 
4.2.2  Visualisation of Sialoadhesin binding to C .jejuni 
 
Sialoadhesin was found to bind whole bacteria but not the LOS or native ganglioside.  It 
was decided to confirm the binding specificity by using Sialoadhesin to fluorescently 
label the bacteria.  Formalin fixed C. jejuni were adsorbed onto slides and labelled with 
Sialoadhesin-Fc  fusion  protein  pre-complexed  with  anti-human  IgG  FITC  labelled 
antibodies.  The DNA binding fluorophore DAPI was used to localise the bacteria.  Two 
test strains were chosen, HS O:19 and HS O:3, both of which are wild type strains of C. 
jejuni which mimic and do not mimic gangliosides respectively.  Figure 18 (A) shows 
DAPI labelled HS O:19 C. jejuni.  Figure 18 (B) shows Sialoadhesin labelled HS O:19 C. 
jejuni. Figure 18 (C) shows the merged and digitally magnified image which confirms 
that the Sialoadhesin binding is associated specifically with the bacteria.  Interestingly, 
the Sialoadhesin appears to show a punctuate pattern of staining (white arrow) which is 
often localised to one or both poles of the bacterium.  In addition, not all of the bacteria 
were labelled with Sialoadhesin.  Figures 18 (D) and (E) show the secondary antibody 
alone  and  Sialoadhesin  labelling  of  the  HS  O:3  strain  respectively.    These  show  no 
detectable binding.  These controls confirm the specificity of Sialoadhesin binding.   111 
Figure 19: Sialoadhesin binding to C. jejuni following neuraminidase treatment. 
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Figure 19.  Effect of removal of GD1a on Sialoadhesin binding.  (A) ELISA showing GM1 specific mAb 
DG2 binding to C. jejuni.  There is a statistically significant increase in binding to HS O:19 C. jejuni 
following neuraminidase treatment.  (B) ELISA showing Sialoadhesin binding to neuraminidase treated C. 
jejuni.  Sialoadhesin binding to HS O:19 is completely obliterated by neuraminidase treatment.  Mean and 
SEM calculated from triplicate wells and analysed using students 2 tailed t test (***=p<0.001).  Single 
experiment.   112 
4.2.3  Confirmation of Sialoadhesin binding to the GD1a epitope 
 
In order to confirm that Sialoadhesin was binding to the GD1a epitope, HS O:19 and HS 
O:3 whole C. jejuni were treated with cholera neuraminidase.  The experiment in chapter 
3.2.5 (figure 9) demonstrates that cholera neuraminidase cleaves the external sialic acid 
on LOS and converts GD1a to GM1.  The prediction is that neuraminidase treatment will 
result in an increase in GM1 epitopes on the surface of HS O:19 bacteria and a decrease 
in  GD1a  with  a  subsequent  decrease  in  Sialoadhesin  binding.    Figure  19  (A)  shows 
binding  of  the  GM1  specific  mAb  DG2  to  HS  O:19  and  HS  O:3  before  and  after 
neuraminidase treatment.  As expected, there is a significant (p<0.001) increase in DG2 
binding  following  neuraminidase  treatment  of  HS  O:19,  which  is  consistent  with  an 
increase in GM1 epitopes.  There is no DG2 binding to HS O:3.  Figure 19 (B) shows 
Sialoadhesin binding to HS O:19 and HS O:3 before and after neuraminidase treatment.  
Neuraminidase  treatment  completely  abrogates  Sialoadhesin  binding  to  HS  O:19 
(p<0.001)  consistent with a loss of the GD1a epitope.  There is no binding to the HS O:3 
control  strain.    This  experiment  confirms  that  GD1a  mimicry  is  necessary  for 
Sialoadhesin binding.    113 
Figure 20: Siglec F binding to gangliosides, LOS and C. jejuni. 
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Figure 20.  ELISAs measuring Siglec F-Fc fusion protein binding to (A) glycolipids (Siglec F used at 
1µg/ml); (B) LOS from GB11 wild type and knock out strains of C. jejuni; (C) LOS from HS O:19 and HS 
O:3 strains of C. jejuni; (D) whole GB11 wild type and GB11 knock out C. jejuni and (E) whole HS O:19 
and HS O:3 C. jejuni. Siglec F shows statistically greater binding to gangliosides GD1a and GT1b when 
compared to ganglioside GM1 and the asialo-sugars (A).  Siglec F shows significantly greater binding to 
ganglioside  mimicking  LOS  (GB11  wild  type  and  HS  O:19)  when  compared  to  the  non-mimicking 
counterparts (GB11 knock out and HS O:3) (B and C) . In addition, there is significantly greater binding of 
Siglec F to ganglioside mimicking strains of whole C. jejuni compared to their control strains at each 
concentration of Siglec F tested (D and E). Mean and SEM calculated from triplicate wells.  Significance 
compares Siglec F binding to GD1a and GT1b compared to each other glycolipid using 1way ANOVA and 
Bonferroni’s multiple comparison post test (A). Significance compares binding to ganglioside mimicking 
and control strain at each Siglec F concentration using 2way ANOVA with Bonferroni’s post tests (B to E) 
(*=p<0.05, ***=p<0.001).  Graphs representative of 3 experiments.   114 
4.2.4  Siglec F binding to gangliosides, LOS and C. jejuni  
 
Siglec F binding to glycolipids was assessed by ELISA.  In contrast to Sialoadhesin, 
figure 20 (A) demonstrates that Siglec F (used at 1µg/ml) can bind to native gangliosides.  
Comparing  GD1a  and  GT1b  to  the  other  glycolipids,  the  difference  in  binding  is 
statistically  significant  (p<0.001)  with  no  difference  between  GD1a  and  GT1b 
themselves.    Siglec  F  binding  to  GD1a  mimicking  LOS  was  tested  by  comparing 
ganglioside mimicking LOS to control strains.  Figures 20 (B) and (C) show significantly 
greater binding of Siglec F to the ganglioside mimicking strains GB11 wild type and HS 
O:19 respectively compared to the control strains GB11 knock out and HS O:3 (p<0.001 
at  1µg/ml  and  0.5µg/ml,  p<0.05  at  0.1µg/ml).    This  dose  dependent  effect  indicates 
specific  binding.    Finally,  Siglec  F  binding  to  whole,  formalin  fixed,  C.  jejuni  was 
assessed.    Figures  20  (D)  and  (E)  show  statistically  greater  binding  of  Siglec  F  to 
ganglioside mimicking strains (GB11 wild type and HS O:19 respectively) than to their 
relevant control strains (p<0.001 over the complete range of concentrations).   115 
Figure 21: Immunocytometry of Siglec F binding to C. jejuni. 
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Figure 21.  Immunocytometry of Siglec F binding to C. jejuni.  (A) DAPI labelled HS O:19.  (B) HS O:19 
labelled with Siglec F-Fc fusion protein and anti-human IgG FITC.  (C) Merge of (A) and (B).  Inset digital 
magnification of (C).  (D)  Control 1 – merged image of DAPI labelled HS O:19 and anti-human IgG FITC 
(secondary Ab only). (E) Control 2 – merged image of DAPI labelled HS O:3 with Siglec F-Fc fusion 
protein and anti-human IgG FITC.  Single experiment.   116 
4.2.5  Visualisation of Siglec F binding to C. jejuni 
 
Siglec F binding to formalin fixed HS O:19 and HS O:3 C. jejuni was visualised using 
the same method as for Sialoadhesin. 
 
Figures 21 (A) and (B) show DAPI labelled HS O:19 and Siglec F-Fc anti human IgG 
FITC labelled HS O:19.  Figure 21 (C) shows the merged and digitally magnified image.  
These  show  specific  Siglec  F  labelling  of  HS  O:19  and  they  also  reveal  a  punctate 
staining pattern similar to that of Sialoadhesin.  Figures 21 (D) and (E) show secondary 
antibody alone and Siglec F labelling of the HS O:3 strain respectively and confirm that 
Siglec F binds specifically to the ganglioside mimicking HS O:19 strain.   117 
Figure 22: Siglec E binding to gangliosides, LOS and C. jejuni. 
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Figure  22.  ELISAs measuring Siglec E-Fc fusion protein binding to (A) glycolipids (Siglec E used at 
0.5µg/ml); (B) LOS from GB11 wild type and knock out strains of C. jejuni; (C) LOS from HS O:19 and 
HS O:3 strains of C. jejuni; (D) whole GB11 wild type and GB11 knock out C. jejuni and (E) whole HS 
O:19 and HS O:3 C. jejuni. Siglec E shows significantly greater binding to gangliosides GD1a and GT1b 
when  compared  to  ganglioside  GM1  and  the  asialo-sugars  (A)  (analysis  by  1way  ANOVA  and 
Bonferroni’s multiple comparison posttest.). Siglec E shows statistically greater binding to non-ganglioside 
mimicking LOS (GB11 knock out and HS O:3) when compared to the mimicking counterparts (GB11 wild 
type and HS O:19) at higher concentrations of Siglec E (B and C).  Siglec E binding to whole C. jejuni 
showed  significantly  increased  binding  to  GB11  knock  out  compared  to  GB11  wild  type  at  a  single 
concentration and significantly increased binding to HS O:19 over HS O:3 at a single concentration.  Mean 
and  SEM  calculated  from  triplicate  wells.    Significance  was  calculated  using  2way  ANOVA  with 
Bonferroni’s  posttest  analysis.  (*=p<0.05,  **=p<0.01,  ***=p<0.001).    Graphs  representative  of  3 
experiments.    118 
4.2.6  Siglec E binding to gangliosides, LOS and C. jejuni 
 
Siglec E binding to selected gangliosides and asialo-glycolipids was assessed as before 
(Siglec E used at 0.5µg/ml).  Figure 22 (A) shows significantly greater binding of Siglec 
E to GD1a (p<0.001) than any other glycolipid and to GT1b compared to GM1 and the 
asialo-glycolipids (p<0.01).  Figures 22 (B) and (C), which show Siglec E binding to 
LOS, reveal unexpected findings.  Siglec E shows statistically greater binding at higher 
concentrations to the non-ganglioside mimicking strains, GB11 knock out (B) and HS 
O:3 (C), than the ganglioside mimicking strains (GB11 wild type v knock out: p<0.001 at 
0.5 and 0.1µg/ml.  HS O:19 v HS O:3: p<0.001 at 0.5µg/ml).  Figures 22 (D) and (E) 
show Siglec E binding to both ganglioside mimicking and non-mimicking strains of C. 
jejuni.  Siglec E does not show any clear trend as there is greater binding to GB11 knock 
out than wild type (p<0.05 at 0.25µg/ml) and greater binding to HS O:19 than HS O:3 
(p<0.05 at 0.5µg/ml) at a single concentration point in each titration.     119 
Figure 23: Immunocytometry of Siglec E binding to C. jejuni. 
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Figure 23. Immunocytometry of Siglec E binding to C. jejuni.  (A) DAPI labeled HS O:19.  (B) HS O:19 
labeled with Siglec E-Fc fusion protein and anti-human IgG FITC.  (C) Merge of (A) and (B).  Inset digital 
magnification of (C).  (D)  Control 1 – merged image of DAPI labelled HS O:19 and anti-human IgG FITC 
(secondary Ab only). (E) Control 2 – merged image of DAPI labelled HS O:3 with Siglec E-Fc fusion 
protein and anti-human IgG FITC.  Arrows in (C) show non-specific background binding of Siglec E-Fc 
fusion protein in the HS O:19 strains which is also present in HS O:3.   120 
4.2.7  Visualisation of Siglec E binding to C. jejuni 
 
In order to further understand this unexpected finding, Siglec E binding to formalin fixed 
C. jejuni was visualised as before.  Figures 23 (A) and (B) show DAPI labelled HS O:19 
and Siglec E-Fc anti-human IgG FITC labelled HS O:19 respectively.  Figure 23 (C) 
shows  the  merged  and  digitally  magnified  images.    Figure  23  (D)  shows  secondary 
antibody alone.  Figure 23 (E) shows merged DAPI and Siglec E-Fc anti-human IgG 
FITC labelled HS O:3 C. jejuni.  Figures 23 (C) and (E) show that some Siglec E is 
associated with both strains of bacteria.  However, intense non-specific staining (white 
arrows in (D)) and speckled background staining is also present.  These results show that 
Siglec E is binding non-specifically to the background material and not specifically to 
either strain of bacteria.   121 
Figure 24: Siglec E binding to LOS, gangliosides and complexed gangliosides. 
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Figure 24.  Siglec E binding to LOS, gangliosides and complexed gangliosides using ELISA. (A) Siglec E 
binding to LOS compared to gangliosides and complexed gangliosides.  The strongest binding observed 
was to GB11 knock out LOS which reached saturation (p<0.001 compared to all other targets). There was 
strong and equal binding to HS O:3 LOS, GD1a and GD1a/GM1 complexes (p<0.001 compared to other 
targets but not to each other).  There was no statistical difference between GB11 wild type LOS and HS 
O:19 LOS but both of these showed greater binding than GM1 and all the asialo-sugars (p<0.001). There 
was no difference between GM1 and all of the asialo-sugars.  (B) Siglec E binding to C. jejuni LOS was 
compared to binding to S. typhimurium LOS.  Similar to (A), GB11 knock out LOS shows greater binding 
than all the other targets (p<0.001) and HS O:3 shows greater binding than the two ganglioside mimicking 
strains (p<0.001).  There is no difference between GB11 wild type and HS O:19.  There is significantly less 
binding to S. typhimurium LOS (p<0.001) than any of the C. jejuni LOS strains. Only the key statistical 
differences have been marked for clarity.  Mean and SEM calculated from triplicate tubes.  Statistical 
analysis was by 1way ANOVA and Bonferroni’s posttests. (***=p<0.001).  Single experiment.   122 
4.2.8  Siglec E binding to LOS, gangliosides and ganglioside complexes 
 
In order to investigate the specificity of the binding of the Siglec E reagent it was decided 
to  directly  compare  LOS  to  ganglioside  binding,  and  to  include  complexes  of  mixed 
gangliosides and asialo-sugars.  Ganglioside complexes were included as LOS consists of 
mixed  GM1  and  GD1a  mimics  and  such  complexes  might  be  important  in  altering 
epitopes.  Figure 24 (A) shows Siglec E binding to gangliosides and to LOS.  Siglec E 
binding  to  GB11  knock  out  LOS  is  significantly  greater  than  any  other  LOS  or, 
surprisingly, the asialo-sugars (asialo-GM1, asialo-GM2 and lactosyl ceramide) which 
constitute the core sugars of the GB11 knock out LOS itself (p<0.001).  There is no 
statistical  difference  in  binding  to  HS  O:3  LOS,  native  GD1a  alone  and  GD1a/GM1 
complexes.  Binding to these three glycolipids is greater than to the other glycolipids 
tested (p<0.001) other than GB11 knock out LOS.  Interestingly, binding to GM1 and 
GD1a  targets  is  significantly  greater  (p<0.001)  than  binding  to  the  LOS  strains  that 
mimic these gangliosides.   
 
There is an inconsistency between Siglec E binding to LOS and the native sugars found 
in the LOS core.  This is seen in both the ganglioside mimicking strains and the non-
mimicking GB11 knock out strain.  This raises the question of whether the Siglec E target 
is the external core sugars or another part of the molecule such as Lipid A.  To address 
this,  a  rough  mutant  LOS  from  S.  typhimurium  was  used  as  a  target  to  provide  an 
independent Lipid A i.e. not from C. jejuni.  Figure 24 (B) shows binding of Siglec E to 
C.  jejuni  LOS  and  S.  typhimurium  LOS.    There  was  significantly  less  binding  to  S. 
typhimurium LOS than to any of the C. jejuni strains (p<0.001).    123 
Figure 25: Factor H binding to C. jejuni. 
GB11 Wild Type
GB11 Knock Out
HS O:19
HS O:3
0.0
0.5
1.0
Strain
O
D
 
4
5
0
 
Figure 25.  Purified human fH binding to whole C. jejuni using ELISA. Mean and SEM calculated from 
triplicate wells.  Graph representative of 3 experiments.   124 
4.2.9  Purified human complement Factor H binding to C. jejuni 
 
Purified human fH binding to formalin fixed C. jejuni was assessed using an ELISA 
technique.  Bacteria were adsorbed onto an ELISA plate and incubated with purified fH 
for 1 hour at 37
oC.  Binding was assessed using a monoclonal anti-human fH antibody.  
Figure 25 shows that no fH binding, above the limits of sensitivity, to either ganglioside 
mimicking or non-mimicking strains could be detected.  In order to confirm this finding, 
fH binding to heat killed bacteria was measured using FACS analysis (figure 26).  C. 
jejuni were incubated with 10µg purified fH for 30 minutes at 37
oC and a mouse anti-fH 
mAb with anti mouse Ig-FITC were used for detection.  There is no evidence of fH 
binding to  ganglioside  mimicking or non-mimicking strains of C. jejuni.  Binding to 
formalin fixed bacteria was assessed using immunocytometry (figure 27).  None of the 
methods employed showed evidence of purified fH binding to either sialylated or non-
sialylated  strains  whether  heat  inactivated  of  formalin  fixed.    Although  no  suitable 
positive control was available to test the purified fH reagent, subsequent experiments, 
detailed below, indicate that the anti-fH mAb works.  In addition, the FACS analysis 
protocol works as I have used this technique to demonstrate cholera toxin-FITC binding 
to ganglioside mimicking strains of C. jejuni in other projects
233 (data shown in figure 26 
(B)).   125 
Figure 26: FACS of Factor H binding to C. jejuni. 
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Figure 26 . Purified human fH binding to heat inactivated GB11 wild type or GB11 knock out C. jejuni 
using FACS analysis.  Dot plot (A)(i) shows bacteria gate. (A)(ii) Shows histograms of bacteria showing 
the FITC MFI as a measure of fH binding.  Anti-mouse Ig-FITC only (secondary) was used as a control.  
(B) Shows a separate experiment in which HS O:19 and HS O:3 bacteria were labelled with cholera toxin 
FITC which binds to GM1. (B)(ii) shows binding of cholera toxin to O:19 but not O:3 confirming that 
labelled bacteria can be detected by FACS analysis with this protocol.  Representative of triplicate tubes.   126 
Figure 27: Immunocytometry of Factor H binding to C. jejuni. 
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Figure 27.  Immunocytometry of purified human fH binding to HS O:19 and HS O:3 C. jejuni.  (A) and (C) 
show  mAb  anti-fH  and  anti-mouse  IgG  FITC  only  (negative  control).    (B)  and  (D)  shows  C.  jejuni 
incubated with 5µg purified human fH followed by anti-fH mAb and anti-mouse IgG FITC.  Experiment 
repeated twice.   127 
Figure 28: Factor H binding following incubation with serum. 
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Figure 28.  Serum fH binding to whole C .jejuni following incubation with active naïve human serum using 
ELISA.  (A) Shows fH binding to GB11 wild type and knock out C .jejuni.  (B) Shows binding to HS O:19 
and HS O:3 C. jejuni.   There are statistically significant differences in binding with increased fH binding 
to the non-sialylated strains.  Mean and SEM calculated from triplicate wells.  Statistical analysis was done 
using  a  2way  ANOVA  with  Bonferroni’s  posttests.  (*=p<0.05,  **=p<0.01,  ***=p<0.001).    Graphs 
representative of three donors.   128 
Factor H has a binding site for C3b and activated complement provides binding sites for 
fH by depositing C3b on target structures.  In order to test if activated serum provides 
binding sites for fH, and to confirm that the anti-fH mAb works, formalin fixed C. jejuni 
were  adsorbed  onto  an  ELISA  plate  and  incubated  with  naïve  human  serum  for  20 
minutes at 37
oC.  Serum fH binding was assayed as before using the monoclonal anti-fH 
antibody.  Figures 28 (A) and (B) show significantly greater binding of serum fH to non-
sialylated strains of C. jejuni compared to sialylated strains (GB11 wild type v knock out: 
p<0.001 at 20% and 10% serum, p<0.005 at 5% serum.  HS O:19 v HS O:3: p<0.001 at 
20%, p<0.005 at 10% and p<0.05 at 5% serum).    129 
Figure 29: Complement C3c and C9 deposition on C. jejuni. 
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Figure  29.  C3c and C9 deposition on whole C. jejuni after incubation with naïve human serum for 20 
minutes using ELISA.  (A) and (B)  show human C3c deposition on GB11 wild type v knock out and HS 
O:19 v HS O:3 respectively.  (C) and (D) show human C9 deposition on GB11 wild type v knock out and 
HS O:19 v HS O:3 respectively. Deposition was measured using rabbit anti-C3 or anti-C9 with an anti-
rabbit Ig-HRP detection antibody.  All graphs show greater C3 and C9 deposition on the non-ganglioside 
mimicking C. jejuni strains. Mean and SEM calculated from triplicate wells.  Significance measured using 
two way ANOVA with Bonferroni’s posttests (***=p<0.001). Graphs representative of 3 naïve donors.   130 
4.2.10 Human C3c and C9 complement deposition on C. jejuni 
 
Purified fH alone shows no binding to sialylated C. jejuni.  The previous results show 
enhanced  serum  fH  binding  to  non-sialylated  C.  jejuni  that  had  been  incubated  with 
active serum.  As complement activation provides fH binding sites, this suggests there is 
greater complement activation on the surface of non-ganglioside mimicking strains.  To 
test this hypothesis, deposition of C3c and C9 (the main component of membrane attack 
complex)  on  C.  jejuni  was  measured  following  incubation  with  naïve  human  serum.  
Figures 29 (A) and (B) show binding of complement C3c to whole formalin fixed C. 
jejuni following incubation with human serum for 20 minutes at 37
oC.  Although C3c is 
deposited on all the C. jejuni strains, there is significantly greater C3c deposited on the 
non-sialylated  strains,  GB11  knock  out  (B)  and  HS  O:3  (C),  than  the  corresponding 
sialylated strains (p<0.001 over the range of serum concentrations).  Figures 29 (C) and 
(D)  show  significantly  increased  Complement  C9  deposition  on  the  non-ganglioside 
mimicking C. jejuni strains when compared to the ganglioside mimicking strains under 
the same conditions (p<0.001 over the range of serum concentrations).  Serum from three 
naïve individuals showed the same pattern of C3c and C9 deposition.   131 
Figure 30: Anti-LOS natural IgM and IgG antibody. 
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Figure 30.  IgM and IgG binding to LOS following incubation with naïve human serum for 1 hour using 
ELISA.   (A) IgM binding to GB11 wild type and knock out LOS; (B) IgM binding to HS O:19 and HS O:3  
LOS; (C) IgG binding to GB11 wild type and knock out LOS and (D) IgG binding to HS O:19 and HS O:3 
LOS.  There is significantly greater IgM and IgG specific for non-ganglioside mimicking strains of LOS. 
Mean and SEM calculated from triplicate wells.  Significance was calculated using 2way ANOVA with 
Bonferroni’s posttest analysis (*=p<0.05, **=p<0.01, ***=p<0.001).  Graphs representative of 3 naïve 
donors.   132 
4.2.11 Natural IgM and IgG binding to C. jejuni LOS 
 
A potential explanation for increased complement deposition on non-sialylated strains is 
the  presence  of  pre-existing  “natural”  antibodies  which  can  activate  the  classical 
pathway.    Self-tolerance  predicts  that  there  will  be  less  natural  antibody  specific  for 
ganglioside mimicking strains of LOS.  To test this hypothesis, relative levels of IgM or 
IgG to ganglioside mimicking and non-mimicking LOS were compared using sera from 
three naïve human donors (each donor serum was tested individually).  Figures 30 (A) 
and (B) show significantly greater levels of IgM to the non-ganglioside mimicking LOS 
compared to the  relevant ganglioside mimicking  LOS (GB11  wild type v knock out: 
p<0.001 at 10%, 5% and 2.5% serum.  HS O:19 v HS O:3: p<0.001 at 10% serum and 
p<0.05 at 5 % serum).  Figures 30 (C) and (D) show significantly greater levels of IgG to 
the  non-ganglioside  mimicking  LOS  compared  to  the  relevant  ganglioside  mimicking 
LOS (GB11 wild type v knock out: p<0.01 at 10% and 2.5% serum, p<0.001 at 5% 
serum.  HS O:19 v HS O:3: p<0.01 at 10 and 5% serum).    133 
Figure 31: Anti-C. jejuni natural IgM and IgG. 
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Figure 31.  IgM and IgG to whole C. jejuni in naïve human serum using ELISA.  (A) IgM binding to GB11 
wild type and knock out C. jejuni; (B) IgM binding to HS O:19 and HS O:3 C. jejuni; (C) IgG binding to 
GB11 wild type and knock out C. jejuni (D) IgG binding to HS O:19 and HS O:3 C. jejuni.  There are 
significantly more natural antibodies (IgM and IgG) to non-sialylated strains of C. jejuni. Mean and SEM 
calculated from triplicate wells.  Significance was calculated using 2way ANOVA with Bonferroni’s post 
test analysis  (***=p<0.001).  Graphs representative of 3 naïve donors.   134 
4.2.12 Natural IgM and IgG binding to whole C. jejuni 
 
Having  demonstrated  that  there  are  fewer  natural  antibodies  specific  for  purified 
ganglioside mimicking LOS than non-mimicking LOS it was hypothesised that there will 
be less natural antibodies specific for whole C. jejuni in ganglioside mimicking strains.  
Whole formalin fixed bacteria were adsorbed onto an ELISA plate and incubated with 
naïve human serum following which the C. jejuni specific antibodies were measured.  
Figures 31 (A) and (B) show IgM binding to ganglioside mimicking and non-mimicking 
strains.   Figures 31 (C) and  (D) show  IgG binding.  There is statistically more  IgM 
(GB11 wild type v knock out: p<0.001 over the whole titration.  HS O:19 v HS O:3: 
p<0.001 over the whole titration) and IgG (GB11wild type v knock out: p<0.001 over the 
whole titration.  HS O:19 v HS O:3: p<0.001 at 5 and 2.5% serum) to the non-ganglioside 
mimicking strains of C. jejuni when compared to the relevant ganglioside mimicking 
strains.  Serum from three separate naïve individuals was tested and showed the same 
trend. 
   135 
4.3  Discussion 
 
Sialoadhesin (Siglec-1 or CD169) is a type 1 membrane protein with 17 extracellular 
immunoglobulin  like  domains
246.    Purified  sialoadhesin  is  approximately  40nm
247  in 
length  and  it  is  the  largest  member  of  the  siglec  family.  In  contrast  to  most  siglecs, 
Sialoadhesin  lacks  tyrosine  based  signalling  motifs.    Sialoadhesin  is  constitutively 
expressed  at  high  levels  on  specific  subpopulations  of  macrophage  including  the 
metallophilic macrophages of the spleen and subcapsular sinus macrophages in the lymph 
node. It is also expressed at lower levels by tissue resident macrophage populations of the 
bone marrow and liver
209,248.  Sialoadhesin expression can be modulated by a number of 
factors, for example IL4 inhibits Sialoadhesin expression
249 while type 1 interferons and 
specific  TLR  agonists  can  increase  expression
250.    Sialoadhesin  has  affinity  for  the 
terminal oligosaccharide sequence Neu5Acα2￿3Galβ1￿3GalNac and has been shown 
to bind the ganglioside GD1a.  It does not bind to GM1
247.  The function of Sialoadhesin 
is still being explored.  It has been postulated as a lymphocyte adhesion molecule
251 and 
is believed to inhibit the function of regulatory T cells
252.  Sialoadhesin knock out mice 
have  reduced  inflammation  in  experimental  autoimmune  uveoretinitis  suggesting  a 
possible pro-inflammatory role for Sialoadhesin
253.  In addition, knock out mice have 
subtle  changes  in  B  and  T  cell  populations  and  reduced  levels  of  IgM  suggesting 
Sialoadhesin may have a role in antibody or B cell population regulation
254.  Sialoadhesin 
has  also  been  shown  to  bind  sialylated  N.  meningitidis  resulting  in  enhanced 
phagocytosis
255.  
 
Due  to  its  affinity  for  Neu5Acα2￿3Galβ1￿3GalNac  it  was  predicted  that  the 
Sialoadhesin-Fc  fusion  proteins  would  bind  to  GD1a  and  GD1a  mimicking  LOS.  
However, in my assays I found no evidence of binding.  Contrary to this, I found that 
Sialoadhesin binds to GD1a mimicking whole C. jejuni.  GD1a mimicking LOS, in-situ, 
was confirmed as the target on the native bacterium.  The isogenic control strain, which 
differs only in its lack of ganglioside mimicry by the LOS, was unable to interact with 
Sialoadhesin.  Direct visualisation of the binding and the loss of binding after specific   136 
removal of the GD1a epitope further confirmed that Sialoadhesin is binding to GD1a on 
the bacteria. 
 
A number of possible explanations for the lack of binding to LOS and native gangliosides 
were addressed by varying the protocol.  Epitope density of the GD1a and LOS was 
increased  by  increasing  the  target  concentration.    The  effects  of  secondary  micelle 
structures were addressed by altering the buffer.  Low Sialoadhesin avidity was addressed 
by pre-complexing it with biotin labelled anti-Fc and streptavidin-HRP.  None of the 
changes to the protocol resulted in Sialoadhesin binding to gangliosides or ganglioside 
mimicking LOS.  The Sialoadhesin-Fc reagent is composed of a truncated Sialoadhesin 
molecule (comprising the four N-terminal Ig domains – see Appendix 4 for structure) and 
it  may  therefore  have  a  reduced  capacity  to  bind  its  ligand.    My  results  reflect  the 
complexity  of  carbohydrate  ligand  binding  in  which  repetitive  epitopes  and  three 
dimensional structures can be essential for increasing avidity and this might explain why 
the Sialoadhesin reagent binds whole bacteria but not the LOS.   
 
An additional unexpected finding is that Sialoadhesin does not bind to all of the GD1a 
mimicking C. jejuni and the binding tends to be localised to one or both poles of the 
bacterium.  Manual counting of three fields found that 34% (ranging from 26% to 39%) 
of  the  ganglioside  mimicking  bacteria  are  labelled  with  Sialoadhesin  and  that  16% 
(ranging from 11% to 21%) are labelled at both poles.  There are a number of possible 
explanations for this.  Phase variation within the population might alter LOS expression 
and the two types of ganglioside mimicking LOS (GM1 and GD1a) might not be evenly 
dispersed across the surface of the bacterium.  The C. jejuni polysaccharide capsule
217,256 
might be limiting access of the Siglec-Fc complexes to the poles of the organism where 
the  flagellum  penetrates  the  capsule.    In  addition,  it  is  known  in  standard 
immunohistochemistry that formalin fixation can alter epitope expression by allowing 
soluble epitopes to diffuse off the target. 
   137 
Siglec F has four extracellular immunoglobulin-like domains with an immunoreceptor 
tyrosine-based  inhibitory  motif  on  its  cytoplasmic  tail
257.    It  has  specificity  for  α2-3 
linked  sialic  acids  and  its  constitutive  expression  is  restricted  to  precursor  cells  of 
myeloid lineages
257 and mature eosinophils
258.  Siglec F is also expressed by a subset of 
CD4
+ T cells following induction of allergic lung inflammation
259.  As well as signalling, 
Siglec  F  has  endocytic  properties,  delivering  ligands  to  lysosomes
260.    The  human 
homologue, Siglec 8, is restricted to eosinophils and basophils.  Cross-linking Siglec F 
induces apoptosis in eosinophils and it has been postulated that upregulation of Siglec F 
ligands during allergic inflammation may contribute to a negative feedback loop, limiting 
disease
259. 
 
My assay shows Siglec F binding to GD1a and GT1b.  Consistent with this affinity for 
GD1a, for the first time, Siglec F binding to ganglioside mimicking LOS and whole C. 
jejuni  is  shown.    When  visualised,  the  binding  pattern  was  similar  to  Sialoadhesin 
although  it  appeared  that  more  of  the  ganglioside  mimicking  bacteria  were  labelled.  
Manual  counting  of  three  fields  found  that  87%  (ranging  from  86%  to  89%)  of 
ganglioside mimicking bacteria labelled for Siglec F.  In addition, 22% of these (ranging 
from 17% to 30%) had distinct labelling at both poles.  However, subjectively, the Siglec 
F  binding  was  more  diffuse  around  the  edge  of  the  bacteria  instead  of  the  distinct 
punctate staining seen with Sialoadhesin.  Siglec F binds native ganglioside, LOS and 
whole  bacteria,  therefore  the  different  binding  pattern  might  reflect  it  being  a  better 
reagent than Sialoadhesin.  Alternatively, it might bind to a more conserved part of GD1a 
or,  being  a  smaller  siglec  than  Sialoadhesin,  it  might  gain  easier  access  to  its  target 
epitopes.  Further studies could be carried out using FACS analysis to gain an objective 
measure of siglec binding and ideally heat inactivated or live bacteria should be used to 
exclude fixation artefact. 
 
Siglec  E  has  three  extracellular  immunoglobulin-like  domains  while  its  intracellular 
domain contains two immunoreceptor tyrosine based inhibitory motifs
261.  It appears to 
be a functional orthologue of human siglecs 7 and 9.  Siglec E shows differing affinity for   138 
a  number  of  sialic  acid  arrangements  in  the  order  α2,8  disialic  acid>α2,3 
sialylactose>α2,6  sialylactose
258.    Siglec  E  is  expressed  on  neutrophils,  peritoneal 
macrophages, splenic myeloid dendritic cells and subsets of NK cells
258.  Weak Siglec E 
expression is also found on peritoneal  B1a B  cells as well as splenic  T2 and MZ  B 
cells
258. 
 
Siglec E shows strongest binding to ganglioside GD1a with less binding to GT1b.  There 
was weak binding to the asialo-glycolipids, which are mimicked by the GB11 knock out 
strain.  However, in contrast to these findings, Siglec E shows very high affinity for the 
GB11 knock out LOS (significantly greater than the wild type strain) with greater binding 
to HS O:3 LOS compared to HS O:19 at high concentrations.  Binding to the whole C. 
jejuni shows a mixed profile. 
 
Binding  to  GB11  knock  out  LOS  and  its  respective  asialo-glycolipids  was  compared 
directly at matching concentrations.  Binding to LOS was significantly greater than to the 
respective asialo-sugars suggesting that the epitope is not the core sugars of the LOS.  
Using complexed asialo-glycolipid molecules (i.e. asialo-GM1, asialo-GM2 and lactosyl 
ceramide together) did not replicate the LOS binding.  Further, an additional species of 
LOS (salmonella) was compared to establish if the lipid A or internal core sugars might 
provide a conserved epitope unique to LOS but not found in asialo-glycolipids. There 
was no evidence that this is the case. 
 
Direct visualisation of Siglec E binding to whole C. jejuni reveals high levels of non-
specific background staining.  One possibility is that epitopes are shed from whole killed 
C. jejuni perhaps during the freeze/thaw process.  However, the bacteria were formalin 
fixed specifically to preserve their structural integrity and there is no evidence of this 
problem  with  either  Sialoadhesin  or  Siglec  F.    The  binding  buffer  (methanol)  and 
blocking  buffer  (3%  BSA)  were  also  tested  for  Siglec  E  binding  and,  while  the   139 
background was higher than for other siglecs, this did not account for the strong GB11 
knock out LOS binding.   
 
Siglec E is known to have a wider specificity than the other siglecs tested and the α2,3 
sialylactose epitope found on LOS is not its preferred epitope. However, this does not 
provide an explanation for the observed binding.  No satisfactory conclusion could be 
drawn as to the epitope in GB11 knock out LOS that Siglec E binds to.  The visualisation 
studies  suggest  the  reagent  is  sticky  and  non-specific.    This  further  confirms  the 
complexity and difficulty of studying carbohydrate epitopes. 
 
The  siglec  binding  results  confirm  one  of  the  central  hypotheses;  that  ganglioside 
mimicking LOS and whole ganglioside mimicking C. jejuni can bind to cellular receptors 
via their ganglioside mimics.  Only three receptors, out of many potential ganglioside 
receptors, were tested and their binding specificities were very idiosyncratic.  Although 
the function of siglecs is poorly understood, in principle this could result in additional 
LOS  signalling  events  (in  combination  with  TLR4)  or  altered  trafficking  of  bacteria.  
Experiments designed to test these hypotheses are reported later in the thesis. 
 
Complement is a conserved component of the innate immune system which consists of 
~40 serum  and cell associated proteins.  Complement functions to opsonise and lyse 
bacteria; link the innate and adaptive immune systems and remove immune complexes 
and apoptotic cells before they trigger unwanted inflammation.  There are three pathways 
of  complement  activation:  the  classical  pathway,  the  alternative  pathway  and  the 
mannose-binding lectin pathway.  The alternative pathway is continuously activated at a 
low level by the hydrolysis of C3.  Self-damage and amplification is kept in check by a 
number of complement regulatory proteins.  The classical pathway is activated by C1q 
binding  to  antibody  bound  to  the  surface  of  a  target.    The  classical  and  alternative 
complement  cascades  converge  at  the  level  of  C3  convertase.    The  final  common   140 
pathway involves the formation of a Membrane Attack Complex pore on the surface of 
the target by polymerisation of C9
262. 
 
Factor  H  is  150kDa  glycoprotein  consisting  of  20  short  consensus  repeats
263.    It  is 
synthesised  predominantly  in  the  liver  and  is  part  of  a  structurally  related  family  of 
proteins.  Factor H functions as a complement regulatory protein that inhibits the classical 
and alternate complement cascades by interfering with C3 convertase
199,200.  Factor H 
competes with Factor B and inhibits convertase formation
264, it facilitates the dissociation 
of the convertase
265 and fH is a cofactor for Factor I mediated cleavage of C3b
265.  Factor 
H binds to a number of ligands including C3b, C3d, heparin, self-glycosaminoglycans 
and bacterial virulence factors
266,267.  Sialic acid is an important target for fH binding on 
self-cells and this protects against complement activation
268,269.  However, sialylation is 
also used by pathogens where it is believed to increase their resistance to complement 
mediated lysis
242 
 
Using a variety of techniques, my assays showed no evidence of purified fH binding to 
either sialylated or non-sialylated strains of C. jejuni.  This was unexpected given the 
known binding site for sialic acid present on fH.  Previous publications have shown that 
fH  binds  to  GM1  ganglioside  and  inhibits  Complement  activation  on  liposomes
270.  
Factor H binding to sialylated N. gonorrhoeae
242 has also been demonstrated.  However, 
it has become clear that the gonococcal porin Por1B is responsible for fH binding to N. 
gonorrhoeae
245 while N. meningitidis produces a Factor H Binding Protein capable of 
mimicking charged carbohydrates and binding fH
271.  In support of my negative results, 
some  sialylated  strains  of  N.  gonorrhoeae  do  not  bind  fH
242.    The  contribution  of 
sialylation to complement resistance in these species is not clear and it appears that sialic 
acid is neither necessary nor sufficient for fH binding.  I could not show fH binding to 
sialylated C. jejuni and this may be due to complexities in the role of sialic acid in fH 
binding, due to a problem with the purified fH reagent or due to alterations of the sialic 
acid fH binding sites on the heat killed or fixed bacteria. 
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Following incubation with active human serum, fH was detected at higher levels on the 
non-sialylated  strains.    I  believe  this  is  due  to  deposition  of  C3b  on  the  C.  jejuni 
providing  a  binding  site  for  fH.    Alternatively,  this  may  be  due  to  the  anti-fH  mAb 
binding to the Factor H Related Proteins which are present in serum and share a similar 
structure  to  fH.    In  support  of  the  former  hypothesis,  I  showed  greater  C3  and  C9 
complement deposition on the non-sialylated strains.  C3c is a breakdown product of C3b 
under  the  influence  of  Factor  I  and  Factor  H.  Anti-C3c  antibodies  are  not  able  to 
distinguish between C3c and the C3c portion of native C3 or C3b. However measuring 
C3c has the advantage of not being sensitive to complement consumption as it gives a 
total measure of recent complement activation (i.e. native C3b and metabolised C3b). 
 
It  was  hypothesised  that  the  difference  in  complement  activation  is  due  to  enhanced 
classical pathway activation through the action of natural antibody and it was expected 
that there are less natural antibodies specific for the sialylated strains of LOS because of 
self-tolerance.    This  was  investigated  by  measuring  IgM  and  IgG  specific  for  the 
ganglioside mimicking or non-mimicking LOS.  In addition, I show that there are less 
natural antibodies to the ganglioside mimicking whole bacteria when compared to the 
non-mimicking control strains.  The complement and antibody experiments used sera of 
three naïve humans (that is, subjects who self-reported no known previous exposure to C. 
jejuni).  However, this is too small a number to draw definitive conclusions and further 
studies using pooled human serum from many donors are necessary.  
 
Further experiments are required to support these hypotheses.  For example, measuring 
complement deposition in the absence of immunoglobulin (purified human complement) 
would confirm or refute the role of natural antibody.  My findings that all of the serum 
components tested (fH, C3, C9 and Ab) bound more to non-sialylated bacteria could be 
due to an experimental flaw.  For example, my method of quantifying the bacteria might 
be inaccurate (if one strain is stickier than the other it might clump and affect the OD600 
reading).  The strong negative charge of sialic acid might reduce binding of these strains 
to the ELISA plate or it might repel complement and antibodies in a non-specific manner.    142 
My  studies  could  be  made  more  relevant  by  measuring  serum  resistance,  that  is, the 
ability  of  live  bacteria  to  survive  incubation  with  human  serum.    The  differences  I 
measured in complement and antibody binding are relatively small therefore such studies 
would give a better idea of the physiological importance of these findings.  This could not 
be done in my laboratory due to restrictions on the use of live pathogens. 
 
In conclusion, by demonstrating Sialoadhesin binding to GD1a mimicking C. jejuni and 
Siglec  F  binding  to  ganglioside  mimicking  LOS  and  C.  jejuni  I  have  confirmed  my 
hypothesis that the ganglioside mimics on GBS associated strains of C. jejuni can interact 
with endogenous immune system receptors.  Siglec E did not show specific binding.  In 
addition, and in contrast to my initial expectations, I found no evidence of fH binding to 
sialylated C. jejuni.  However, C. jejuni ganglioside mimicry results in less complement 
activation which may be related to my finding of lower natural antibody levels against 
these strains.  These findings require further clarification. 
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5  Immunostimulatory effects and potency of purified C. jejuni 
LOS 
 
5.1  Introduction 
 
The  aim  of  the  experiments  presented  in  this  chapter  is  to  investigate  the 
immunostimulatory properties of C. jejuni LOS and to establish if ganglioside mimicry 
has an effect on potency. 
 
Ganglioside mimicking C. jejuni LOS can be conceptually divided into two portions; the 
Lipid A tail and the ganglioside mimicking external core.  Lipid A is the “endotoxic 
principal”  of  lipopolysaccharides
111,210-212,272  and  mediates  a  plethora  of 
immunostimulatory  effects  via  signalling  through  the  LPS  receptor  complex,  TLR4-
MD2, in conjunction with co-receptor CD14
116,119.  The primary responder cells to LPS 
are  those  of  the  myeloid  lineage;  monocytes,  macrophages,  dendritic  cells  and 
neutrophils,  which  constitutively  express  CD14  and  TLR4
105-108.    B  cells  are  also 
sensitive to  LPS although the receptors  employed are less well characterised.  While 
TLR4 is not expressed on human B cells
108,197 a structurally related complex, RP105-
MD1, appears to confer sensitivity to LPS
273.  In mouse models, the absence of either 
RP105 or MD1 results in B cell hyporesponsiveness, although absence of TLR4 or MD2 
results in a complete loss of sensitivity
127,274-276.  This illustrates potential murine-human 
disparities and the complexity of the LPS sensing system. 
 
Myeloid  cells  respond  to  LPS  stimulation  at  picomolar  concentrations.    LPS  has  a 
panoply  of  effects,  principal  amongst  them  being  secretion  of  acute  phase  cytokines; 
TNF-α, IL-1 and IL-6, as well as immunomodulatory cytokines such as IL-12 and IL-
10
277-282.    LPS  has  important  adjuvant  effects  which  include  maturation  of  antigen 
presenting cells coinciding with increased co-receptor expression and enhanced antigen 
presentation
283-286.   144 
 
The B cell compartment is broadly divided into two subsets.  The B1 subset comprises 
B1a and B1b B cells and the B2 subset comprises MZ and FO B cells.  B1 B cells are 
located primarily in the peritoneal and pleural cavities
158 while MZ B cells are located in 
close  proximity  to  the  marginal  zone  and  Sialoadhesin  expressing  metallophilic 
macrophage populations near the marginal sinuses of the spleen
131.  Both B1 B cells and 
MZ B cells are important in T-independent antibody responses, have a tendency towards 
polyreactivity  and  autoreactivity,  and  produce  natural  antibodies  against  carbohydrate 
antigens
131,158.  In addition, and in contrast to FO B cells, they are highly responsive to 
LPS  stimulation  which  results  in  proliferation,  maturation  and  antibody  secretion
109.  
Marginal zone B cells are mobilised by LPS and play a role in transporting antigen into 
the  follicle
287-290  where  they  can  function  as  potent  antigen  presenting  cells
168.    In 
addition, following LPS stimulation, they are an important source of the cytokine IL-
10
291.  LPS is a Type I TI antigen which is capable of directly triggering polyclonal B cell 
activation and proliferation
292.   
 
Bacteria exhibit substantial inter-species differences in LPS structure
102.  LPS and LPS 
analogues,  derived  from  diverse  bacterial  species,  in  addition  to  causing  TLR4-MD2 
homodimerisation,  appear  capable  of  interacting  with  different  receptor  clusters, 
recruiting unique combinations of signalling proteins and stimulating different cellular 
responses
293-296.    While  differences  in  LPS  potency  clearly  exist,  such  studies  are 
inevitably  complicated  by  impurities  present  in  the  LPS  preparation  and  must  be 
interpreted with caution. 
 
C.  jejuni  LOS,  while  structurally  similar  to  related  species,  has  a  number  of  unique 
differences.  A glucosamine residue of the Lipid A backbone is replaced with a related 
sugar,  2,3-diamino-2,3-dideoxy-D-glucose,  and  the  inner  core  contains  a  unique 
tetrasaccharide (Glc–Hep–Hep–Kdo)
102,112.  In addition, the acyl chains are particularly 
long which, combined with the absence of an O-side chain, makes the molecule highly 
hydrophobic.     145 
 
GBS associated C. jejuni LOS are exclusively rough mutant.  Substantial differences are 
thought to  exist between sensing and signalling of smooth mutant  LPS (S-form) and 
rough mutant LPS (R-form).  While S-form LPS requires LBP and CD14 in order to 
signal, R-form LPS can bind to TLR4/MD-2 directly
99,123 and cells lacking CD14 (such 
as  mast  cells  and  B  cells)  can  recognise  R-form  LPS  without  the  CD14  and  LBP 
accessory molecules
99.  In addition, signalling by R-form LPS, in the absence of LBP and 
CD14, results in signal transduction via the MyD88 dependent pathway with only weak 
signalling via the TRIF dependent pathway
99,123,297. 
 
Gangliosides have long been recognised as immune system modulators
134.  Incubation of 
human  dendritic  cells  with  purified  GD1a  ganglioside  causes  inhibition  of  IL-12 
production and enhanced IL-10 production, although subsequent co-culture with naïve T 
cells  results  in  a  blunting  of  both  Th1  and  Th2  differentiation
298.    Pre-incubation  of 
dendritic  cells  with  GD1a  also  inhibits  subsequent  co-stimulator  upregulation  and 
cytokine production following LPS stimulation
299.  T cells incubated with GD1b, GT1c 
or  GQ1b  show  enhanced  Th1  cytokine  production  when  stimulated  with  PHA 
(phytohaemagglutanin)
300  while  human  B  cells  incubated  with  GM2  or  GM3  show 
inhibited immunoglobulin production and reduced thymidine uptake (GM1 and GD1a 
have no effect)
301.  Although gangliosides are generally considered immunosuppressive, 
there is no clear consensus on their specific effects or the mechanisms by which they 
produce these effects.  The complexity of the ganglioside repertoire complicates such 
studies.  Gangliosides, and ganglioside mimicking LOS, are capable of engaging immune 
system  receptors  such  as  siglecs  (demonstrated  previously  in  4.2.4  and  4.2.5).    In 
addition, gangliosides are important self ligands for presentation in the CD1 family of 
glycolipid antigen presentation molecules and this allows them to interact with specific 
subsets  of  T  cells
302-304.    Due  to  the  ubiquitous  nature  of  gangliosides,  and  their  co-
localisation on plasma membrane lipid rafts with a wide array of signalling molecules in 
lymphocytes
305,306, there is potential for exogenous gangliosides, or ganglioside mimics, 
to insert into membranes and disrupt signalling.   146 
 
One of my central hypotheses is that ganglioside mimicry alters the potency of LOS.  In 
the experiments in this chapter I compare ganglioside mimicking LOS to LOS derived 
from isogenic, non-mimicking, control strains in their ability to stimulate those cell types 
most likely responsible for the effector stage (B cells) and induction stage (myeloid cells) 
of GBS.  This hypothesis is not without precedent.  I have demonstrated ganglioside 
mimicking LOS engaging siglec receptors through the O-side chain and this may alter 
adjuvant activity in a similar manner to E. coli and Klebsiella LPS strains which contain 
mannose in the carbohydrate O-side chain and which show enhanced adjuvant activity 
through binding to the mannose receptor on myeloid cells
150-152,307-309.   147 
Figure 32: In vivo mobilisation of marginal zone B cells by LPS. 
A) PBS injected
MOMA1 FITC
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B) S. typhimurium LPS injected
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D) GB2 Knock out LOS injected
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B220 Alexa 647
C) GB2 Wild type LOS injected
MOMA1 FITC
B220 Alexa 647
 
Figure  32.  Immunohistology  of  murine  spleens  following  LOS  injection.    Metallophilic  macrophages 
(MOMA1 positive, green) mark the edge of the follicles.  B cells, including MZ B cells, are labelled with 
B220 (red).  (A) PBS injected. White arrows show B cells outwith the metallophilic macrophages. (B) 
Smooth mutant S. typhimurium LPS injected mouse spleen.  (C) GB2 wild type C. jejuni LOS injected 
spleen.  (D) GB2 knock out C. jejuni LOS injected spleen.  (B, C, D) White arrows show absence of B cells 
in the marginal zone following LPS or LOS injection.  Images representative of three experiments.   148 
5.2  Results 
 
5.2.1  In vivo mobilisation of Marginal Zone B cells  
 
Marginal zone B cells are potentially important in GBS because they are a source of 
antibodies directed against carbohydrate antigens
131,158, they are responsive to LPS
109 and 
they are believed to contain auto-reactive specificities within their repertoire.  Marginal 
zone B cells are also potent antigen presenting cells
168 and have been shown to migrate 
and carry antigen from the marginal zone of splenic follicles into the follicle
287,289,290.  
This mobilisation occurs rapidly in response to LPS stimulation and the aim of my initial 
experiments was to test whether or not C. jejuni LOS could do the same. 
 
Mice were injected intra-peritoneally with 50µg of GB2 wild type LOS, GB2 knock out 
LOS, S. typhimurium LPS (smooth mutant) and PBS (the latter two being positive and 
negative  controls  respectively).    After  18  hours,  spleens  were  harvested  and  frozen.  
Frozen  sections  were  stained  with  the  mAb  MOMA1,  which  is  specific  for  the 
metallophilic macrophage marker Sialoadhesin and distinguishes the edge of the follicle, 
and a mAb specific for the B cell marker B220.  Figure 32 shows immunohistology of 
splenic sections.  Figure 32 (A) shows a section from a mouse injected with PBS.  The 
white arrows indicate the position of B220 positive marginal zone B cells (red) outwith 
the MOMA1 positive metallophilic macrophage population (green).  Follicular B cells 
also stain positive for B220 and are present within the follicle which is surrounded by the 
MOMA1 positive macrophage population.  Figures 32 (B), (C) and (D) show sections 
following injection with S. typhimurium LPS, GB2 wild type LOS and GB2 knock out 
LOS respectively.  B cells are no longer present in the marginal zone (white arrows) 
indicating that LOS is capable of mobilising MZ B cells.  Ganglioside mimicry does not 
affect this property.   149 
Figure 33: Example FACS plots of labelled B cells. 
A (i) A(ii) A(iii)
B(i) B(ii) B(iii)
C(i) C(ii) C(iii)
 
Figure 33. Example FACS plots of (A) B cell selection, (B) tracking B cell division using CFSE and (C) B 
cell subpopulations.  B cells were purified from mixed splenocytes using the EasySep B cell negative 
selection kit. (A) FACS analysis showing B cell purity before and after magnetic bead negative selection. 
(A) (i) Parent lymphocyte gate on forward and side scatter, (A) (ii) Pre-selection purity  (51.24% B220+).  
(A) (iii)  Post selection purity (>91% B220+).  (B) FACS analysis of cell division. (B) (i) Forward v side 
scatter of mixed splenocytes including the parent lymphocyte gate and the Caltag counting beads (R1).  (B) 
(ii) Dot plot showing CFSE v B220.  Each gate is a B cell population in a particular round of division 72 
hours after E. coli LPS stimulation.  B(iii) as before except C. jejuni LOS stimulation.  (C) Examples of 
gates used to determine the size of each population (C) (i) B220+ B cell population (parent population to C 
(ii) and (iii)). C (ii) CD138 positive B cell population.  C (iii) IgG positive B cell population.   150 
5.2.2  B cell activation by ganglioside mimicking and non-mimicking C. 
jejuni LOS in a purified B cell culture  
 
To test the B cell stimulatory potency of C. jejuni LOS in a pure B cell culture, B cells 
were purified using negative selection from a mixed splenocyte population.  The EasySep 
B cell negative selection kit uses a panel of antibodies, directed against non-B cells, 
magnetic  nanoparticles  and  a  magnetic  sleeve  to  remove  unwanted  cells  without 
antibodies binding to the B cells.  Figure 33 (A) shows B cell purity before and after 
negative selection by labelling with the B cell marker B220 (all experiments resulted in 
purity of >90%).  To assess mitogenic potency, cells were labelled with the cell tracking 
fluorophore CFSE
310,311.  CFSE forms covalent bonds with intracellular molecules and 
the fluorescence of the cell halves with each round of mitosis.  Cell division can be 
tracked using flow cytometry and Figure 33 (B) shows example FACS plots of E. coli 
LPS and C. jejuni LOS stimulated B cells co-labelled with the B cell marker B220.  Each 
gate is a B cell population in the same round of division.  The concentration of cells was 
derived  from  the  FACS  data  using  Caltag  counting  beads,  a  known  concentration  of 
which was added to the samples prior to analysis and from which the cell concentration 
can be mathematically derived (according to the manufacturers lot specific instructions).  
B cells were stimulated with 20µg/ml ganglioside mimicking (GB2 wild type) or non-
mimicking (GB2 CSTII knock out) C. jejuni LOS or E. coli LPS as a control.  Plasma 
cell  differentiation  was  measured  by  co-labelling  with  the  plasma  cell  differentiation 
marker CD138
312 (Syndecan1) and IgG isotype switching measured by co-labelling with 
anti-IgG (example FACS plots shown in figure 33 (C)).   151 
Figure 34: B cell responses to C. jejuni LOS in a purified B cell population. 
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Figure 34.  Purified B cells responses to LOS/LPS stimulation measured by FACS analysis.  The cells were 
harvested  and  labelled  for  the  B  cell  marker  B220,  the  plasma  cell  marker  CD138  and  surface  IgG 
expression.  Cells were enumerated using Caltag counting beads.  (A) concentration of B cells (B220 
positive).  (B) concentration of B cells in each round of division.  (C) concentration of CD138 positive 
cells. (D) Concentration of CD138 positive cells in each round of division.  (E) Concentration of IgG 
positive B cells.  (F)  Concentration of IgG positive B cells in each round of division.  Mean and SEM 
calculated from triplicate tubes.  Representative of two experiments. Bar graphs analysed using  1way 
ANOVA  with Bonferroni’s  multiple comparison test, Line graphs analysed using 2way  ANOVA  with 
Bonferroni’s posttests (*=p<0.05, **=p<0.005, ***=p<0.001).     152 
Figure 34 (A) shows the total B cell concentration at 72 hours after stimulation with 
20µg/ml wild type LOS, knock out LOS or E. coli LPS.  There is no statistical difference 
between either of the C. jejuni LOS strains.  However, twice as many B cells are present 
following E. coli LPS stimulation (p<0.001).  Figure 34 (B) shows the concentration of B 
cells in each round of division.  C. jejuni LOS and E. coli LPS both induced B cell 
division.  However, there are significantly more B cells in rounds 0, 1, 2, 3 and 4 of 
division  following  E.  coli  LPS  stimulation  (p<0.001)  compared  to  C.  jejuni  LOS 
stimulation.  There is no statistical difference between the C. jejuni LOS strains.  These 
results suggest E. coli LPS is more potent at stimulating B cell mitosis in a pure B cell 
culture than C. jejuni LOS and that ganglioside mimicry has no effect on LOS potency. 
 
The ability of C. jejuni LOS to stimulate plasma cell differentiation in a purified B cell 
culture was assessed by co-staining the B cells with the plasma cell differentiation marker 
CD138.  Figure 34 (C) shows the concentration of CD138 positive cells present after 72 
hours.  There is no statistical difference between the C. jejuni LOS strains.  However, the 
E. coli LPS has stimulated greater CD138 positive cell differentiation (p<0.01).  Figure 
34 (D) shows the concentration of CD138 positive cells in each round of division.  A 
greater number of CD138 positive cells did not divide (remaining in round 0) following 
C.  jejuni  LOS  stimulation  compared  to E.  coli  LPS  stimulation  (p<0.05).    A  greater 
number of CD138 positive cells were in each subsequent round of division (except round 
5) following E. coli LPS stimulation (Round 1 p<0.01, rounds 2 to 4 p<0.001). There was 
no difference in potency at generating CD138 positive cells between the C. jejuni LOS 
strains.   
 
To assess the capacity of C. jejuni LOS to stimulate isotype switching to IgG, B cells 
were co-stained with an IgG specific antibody. Figure 34 (E) shows the concentration of 
IgG  positive  B  cells  after  72  hours  of  stimulation.    There  is  no  statistical  difference 
between the ganglioside mimicking and non-mimicking C. jejuni LOS strains.  However, 
E.  coli  LPS  stimulation  resulted  in  more  than  twice  as  many  IgG  positive  B  cells 
(p<0.001).  Figure 34 (F) shows the concentration of IgG positive B cells in each round   153 
of division.  There are no differences between either LOS strains.  E. coli LPS stimulation 
resulted in more IgG positive B cells in all rounds of division except round 6 (p<0.001).    154 
Figure 35: B cell responses to C. jejuni LOS in a mixed splenocyte population. 
No Stimulation
GB2 Wild Type LOS
GB2 Knock Out LOS
PBS
0
250
500
750
1000
No Stimulation
GB2 Wild Type LOS
GB2 Knock Out LOS
PBS
***
Stimulation
B
 
c
e
l
l
s
/
µ
µ
µ
µ
l
0 1 2 3 4 5 6
0
50
100
150
200
250
E coli LPS
GB2 Wild Type LOS
GB2 Knock Out LOS
PBS
*
***
***
***
Round of Division
B
 
c
e
l
l
s
/
µ
µ
µ
µ
l
PBS
GB2 Wild Type LOS
GB2 Knock Out LOS
E coli LPS
0
50
100
150
200
250
PBS
GB2 Wild Type LOS
GB2 Knock Out LOS
E coli LPS
Stimulation
P
l
a
s
m
a
 
c
e
l
l
s
/
µ
µ
µ
µ
l
0 1 2 3 4 5 6
0
10
20
30
40
50
60
70
80
E coli LPS
GB2 Wild Type LOS
GB2 Knock Out LOS
PBS
*
***
Round of Division
P
l
a
s
m
a
 
c
e
l
l
s
/
µ
µ
µ
µ
l
PBS
GB2 Wild Type LOS
GB2 Knock Out LOS
E coli LPS
0
25
50
75
100
PBS
GB2 Wild Type LOS
GB2 Knock Out LOS
E coli LPS
**
Stimulation
I
g
G
+
c
e
l
l
s
/
µ
µ
µ
µ
l
0 1 2 3 4 5 6
0
10
20
30
E coli LPS
GB2 Wild Type LOS
GB2 Knock Out LOS
PBS
***
***
***
***
Round of Division
I
g
G
 
p
o
s
i
t
i
v
e
c
e
l
l
s
/
µ
µ
µ
µ
l
A B
C D
E F
 
Figure 35.  Mixed splenocyte response to LOS/LPS stimulation measured by FACS analysis.  The cells 
were harvested and labelled for the B cell marker B220, the plasma cell marker CD138 and IgG expression.  
The number of cells was enumerated using Caltag counting beads.  (A) Concentration of B cells (B220 
positive)  (B) Concentration of B cells in each round of division.  (C) Concentration of CD138 positive 
cells. (D) Concentration of CD138 positive cells in each round of division.  (E) Concentration of IgG 
positive B cells.  (F)  Concentration of IgG positive B cells in each round of division.  Mean and SEM 
calculated from triplicate tubes.  Representative of two experiments.  Bar graphs analysed using  1way 
ANOVA with Bonferroni’s multiple comparison Test, Line graphs analysed using 2way ANOVA with 
Bonferroni’s posttests (*=p<0.05, **=p<0.01, ***=p<0.001).   155 
5.2.3  B cell activation by ganglioside mimicking and non-mimicking LOS 
in a mixed splenocyte culture 
 
Myeloid lineage cells can act as accessory cells for B cell activation and survivial
313 and 
are  sensitive  to  LPS.    It  was  decided  to  compare  the  B  cell  activating  potency  of 
ganglioside  mimicking  and  non-mimicking  LOS  in  a  mixed  splenocyte  culture  (i.e. 
including accessory cells).  The methods used were the same as before. 
 
Figure 35 (A) shows the total B cell concentration in a mixed splenocyte culture.  There 
are more remaining B cells after 72 hours following E. coli LPS stimulation than C. 
jejuni wild type or knock out LOS (p<0.001).  There is no statistical difference between 
either of the C. jejuni LOS strains.  Figure 35 (B) shows the concentration of B cells in 
each round of division.  LOS and LPS have both stimulated B cell mitosis although there 
are significantly more B cells in rounds 1 (p<0.05), 2 (p<0.001), 3 (p<0.001), and 4 
(p<0.001) of division following E. coli LPS stimulation.  There is no statistical difference 
between the C. jejuni LOS strains.  These results confirm E. coli LPS is more potent at 
stimulating B cell mitosis than C. jejuni LOS.  Ganglioside mimicry has no effect on 
LOS induced B cell mitogenicity. 
 
Figure 35 (C) shows the concentration of CD138 positive cells present after 72 hours.  
There is no statistical difference between either of the C. jejuni LOS strains or the E. coli 
LPS.  Figure 35 (D) shows the concentration of CD138 positive cells in each round of 
division.  There are more CD138 positive cells in round 3 of division following E. coli 
LPS stimulation (p<0.001).  There are no statistical differences between the wild type of 
knock out LOS strains. 
 
Figure 35 (E) shows the concentration of IgG positive B cells.  E. coli LPS stimulation 
results in more IgG positive B cells after 72 hours (p<0.01), while there is no difference 
between the C. jejuni LOS strains.  Figure 35 (F) shows the concentration of IgG positive   156 
B cells in each round of division.  There are more IgG positive B cells in rounds 1, 2, 3 
and  4  (p<0.001)  following  E.  coli  LPS  stimulation  compared  to  C.  jejuni  LOS 
stimulation.  There is no difference between either of the C. jejuni strains.   
 
Combined,  these  results  show  E.  coli  LPS  to  be  more  potent  than  C.  jejuni  LOS.  
Ganglioside mimicry does not appear to enhance C. jejuni LOS potency.   157 
Figure 36: Immunoglobulin production by LOS stimulated B cells and splenocytes. 
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Figure 36.  Purified B cells or mixed splenocytes were stimulated with 10 µg/ml of GB2 or GB19 strains of 
C. jejuni LOS or E. coli LPS for 72 hours and immunoglobulin secretion was measured in the supernatant 
using  ELISA.    (A)  Shows  IgM  production  by  purified  B  cells.  (B)  Shows  IgM  production  by  mixed 
splenocytes.    (C)  Shows  IgG  production  by  purified  B  cells.    (D)  Shows  IgG  production  by  mixed 
splenocytes.    Mean  and  SEM  calculated  from  triplicate  wells.  Analysed  using  1way  ANOVA  with 
Bonferroni’s multiple comparisons test (**=p<0.01, ***=p<0.001).    Representative of three experiments.   158 
5.2.4  Comparison of LOS potency at stimulating antibody secretion 
 
Having  compared  the  potency  of  ganglioside  mimicking  and  non-mimicking  LOS  at 
stimulating  B  cell  mitosis  and  CD138  positive  cell  differentiation  it  was  decided  to 
compare immunoglobulin secretion as another measure of potency. 
 
Purified B cells or mixed splenocytes were cultured for 72 hours with 10µg/ml LOS and 
antibody secretion into the supernatant was measured using an ELISA.  An additional 
ganglioside mimicking LOS, GB19 wild type mimicking GD1c, and the CSTII knock out 
control was included in the assay.  Figure 36 (A) shows IgM production by a purified B 
cell population.  There is no difference in IgM production between wild type and knock 
out  LOS  in  both  the  GB2  and  GB19  strains.    There  is  also  no  statistical  difference 
between both GB2 and both GB19 strains.  E. coli LPS is more potent than both GB2 
(p<0.001) and both GB19 (p<0.01) strains. 
 
Figure 36 (B) shows IgM production by a mixed splenocyte population.  There is no 
difference in IgM production between wild type and knock out LOS in both the GB2 and 
GB19 strains.  However, both GB19 LOS strains are more potent than both GB2 LOS 
strains (p<0.01) and E. coli LPS is more potent than both GB2 strains (p<0.001) and both 
GB19 strains (p<0.01). 
 
Figure 36 (C) shows IgG production by a purified B cell population.  Very low quantities 
of  IgG  were  produced  in  the  absence  of  accessory  cells  (compare  to  figure  36  (D)).  
There was no statistical difference in IgG production between any of the strains of LOS 
or LPS.  Figure 36 (D) shows IgG production by a mixed splenocyte population.  There is 
no difference in IgG production between wild type and knock out LOS in both the GB2 
and GB19 strains.  Both GB19 strains are more potent than both GB2 strains (p<0.01)   159 
and E. coli LPS is more potent than both GB2 strains (WT p<0.001, KO p<0.01) but is 
not statistically different from either GB19 strain. 
 
These results show that ganglioside mimicry does not affect the potency of C. jejuni LOS 
at stimulating IgM or IgG secretion from purified B cells or mixed splenocytes.  They 
highlight intra-species differences, as both GB19 LOS strains appear more potent than 
both GB2  LOS strains.    Inter-species differences are  also apparent as E. coli  LPS is 
generally more potent than either C. jejuni strain.   160 
Figure 37: Cytokine production by LOS stimulated B cells and splenocytes. 
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Figure 37.  Purified B cells or mixed splenocytes were stimulated with 10µg/ml C jejuni LOS or E. coli 
LPS and cytokine secretion was measured using ELISA after 72 hours.  (A) IL-10 production by purified B 
cells following GB2 wild type and knock out LOS or E. coli LPS stimulation.  (B) IL-10 production by 
mixed splenocytes following GB2 wild type and knock out LOS or E. coli LPS stimulation.  (C) IL-10 
production by purified B cells following GB19 wild type and knock out LOS or E. coli LPS stimulation. 
(D) IL-10 production by mixed splenocytes following GB19 wild type and knock out LOS or E. coli LPS 
stimulation.  (E)  IFN-γ  production  by  mixed  splenocytes  following  10µg/ml  LOS  or  E.  coli  LPS 
stimulation.    (F)  IL-12  production  by  mixed  splenocytes  following  10µg/ml  LOS  or  E.  coli  LPS 
stimulation.    Mean  and  SEM  calculated  from  triplicate  wells.    Analysed  using  1way  ANOVA  with 
Bonferroni’s multiple comparison test (*=p<0.05, ***=p<0.001). Representative of four experiments.   161 
5.2.5  Comparison of LOS potency at stimulating cytokine secretion 
 
A further functional measure of LOS potency is cytokine secretion.  Purified B cells or 
mixed splenocytes were stimulated with ganglioside mimicking or non-mimicking LOS, 
and E. coli LPS.  Cytokine secretion was measured after 72 hours.  Figure 37 (A) shows 
IL-10 production in a purified B cell culture and figure 37 (B) shows IL-10 production in 
a mixed splenocyte culture, following GB2 wild type and knock out LOS stimulation.  In 
both cases, there is no difference between ganglioside mimicking and non-mimicking 
strains.  However, E. coli LPS is more potent than either of the C. jejuni LOS strains in 
both cases (p<0.001).  Figures 37 (C) and (D) show similar experiments as before only 
using  GB19  strains  of  LOS.    Again,  there  is  no  difference  between  the  ganglioside 
mimicking and non-mimicking variants of LOS.  E. coli is more potent (p<0.05) than 
GB19 wild type C. jejuni LOS (with no statistical advantage over knock out LOS) in the 
mixed splenocyte culture, but not the pure B cell culture. 
 
IFN-γ production was measured in a mixed splenocyte culture (figure 37(E)).  None of 
the C. jejuni LOS strains induced detectable IFN-γ secretion although the E. coli LPS 
stimulated large quantities of IFN-γ.  In addition, no IL-12 could be detected from mixed 
splenocytes following LPS or LOS stimulation (figure 37 (F)). 
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Figure 38: Cytokine production by rough v smooth LPS stimulated mixed splenocytes. 
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Figure 38.  Mixed splenocytes were stimulated with a titrating dose of smooth (Ra) and rough (Re) mutant 
S.  typhimurium  LPS  and  GB2  C.  jejuni  LOS  following  which  IFN-γ  and  IL-10  secretion  into  the 
supernatant was measured by ELISA.  (A) IFN-γ production following stimulation.  (B) IL-10 production 
following stimulation. Mean and SEM calculated from triplicate wells.  Analysed using 2way ANOVA 
with Bonferroni’s post tests (**=p<0.01, ***=p<0.001).     163 
To test if an inability to stimulate IFN-γ production is a property unique to C. jejuni LOS 
or a general property of rough mutant LPS, a number of additional strains of LPS were 
tested.  Re (deep rough mutant) and Ra (smooth mutant) S. typhimurium LPS strains were 
used  in  an  IFN-γ,  mixed  splenocyte  assay  (figure  38  (A)).    The  smooth  mutant  S. 
typhimurium LPS induces more IFN-γ over a range of concentrations (10µg/ml, 1µg/ml 
and 0.1µg/ml (p<0.001)) than any of the rough mutant strains, including the rough S. 
typhimurium LPS.  C. jejuni LOS does not induce IFN-γ.  Figure 38 (B) shows IL-10 
production in the same experiment.  Smooth S. typhimurium LPS is statistically more 
potent than the rough mutant strains (greater than C. jejuni LOS at 10µg/ml, 1µg/ml and 
0.1µg/ml (p<.001) and greater than rough S. typhimurium LPS at 10µg/ml and 1µg/ml 
(p<0.001)).  Rough S. typhimurium LPS is more potent than C. jejuni LOS at 1µg/ml and 
0.1µg/ml (p<0.001).  There is no difference between the ganglioside mimicking and non-
mimicking C. jejuni GB2 LOS strains 
 
These cytokine experiments showed a small degree inter-experiment variability.  In two 
IL-10 repeats the GB2 knock out C. jejuni LOS induced slightly more IL-10 from mixed 
splenocytes (p<0.05) than the wild type strains while in two experiments there was no 
difference.  Where a difference was present it could be attributed to a single outlier.  
Although the rough S. typhimurium resulted in detectable IFN-γ (including statistically 
more than C. jejuni LOS at 0.01µg/ml (p<0.01)), a number of subsequent repeats (data 
not shown) using single concentration points (2µg/ml, 5µg/ml and 20µg/ml) resulted in 
no detectable IFN-γ following rough S. typhimurium stimulation.  The balance of results 
suggests that rough mutant  LPS/LOS from either S. typhimurium or C. jejuni do not 
induce  significant  amounts  of  IFN-γ  from  mixed  splenocytes.    These  results  also 
demonstrate  no  difference  in  potency  between  ganglioside  mimicking  and  non-
mimicking  LOS  in  stimulating  IL-10  secretion  from  purified  B  cells  or  mixed 
splenocytes. 
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Figure 39: Bone marrow derived dendritic cell and macrophage purity assessed by FACS. 
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Figure 39.  Bone marrow derived dendritic cell and bone marrow derived macrophage purity assessed using 
FACS analysis (monoclonal antibody to CD11c (dendritic cells) or F4/80 (macrophages)). (A)(i) Forward v 
side scatter of BMDC parent cells.  (A)(ii) histogram showing CD11c positive cells (blue, 70%) against 
isotype control (black).  (B)(i) forward v side scatter of BM macrophage parent cells.  (B)(ii) histogram 
showing F4/80 positive cells (blue, 96%) against isotype control (black). 
   165 
5.2.6  Potency of ganglioside mimicking and non-ganglioside mimicking 
LOS at stimulating myeloid antigen presenting cells 
 
Bone marrow derived dendritic cells (BMDC) and bone marrow derived macrophages are 
innate  immune  cells  of  myeloid  lineage.    Myeloid  cells  express  numerous  pathogen 
recognition receptors such as TLRs (including TLR4) and also express members of the 
siglec  family  of  ganglioside  receptors.    Bone  marrow  derived  dendritic  cells  and 
macrophages were stimulated with LOS in order to test if ganglioside mimicry alters the 
potency of LOS. 
 
Bone marrow derived dendritic cells were differentiated from bone marrow cells using 
GM-CSF  containing  supernatant  from  the  X-63  cell  line.    Before  use,  cells  were 
harvested and labelled with the dendritic cell marker CD11c in order to establish purity.  
Figure 39 (A) shows harvested cells labelled with anti-CD11c and the isotype control.  
Dendritic cell purity was greater than 70%.  Bone marrow derived macrophages were 
differentiated from bone marrow using M-CSF containing supernatant from the L-929 
cell  line  and  purity  was  confirmed  by  labelling  with  the  macrophage  marker  F4/80.  
Figure 39(B) shows F4/80 positive cells against isotype control.  Macrophage purity was 
greater than 90%.   166 
Figure 40: Cytokine production by LOS stimulated dendritic cells and macrophages. 
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Figure 40.  Dendritic cell or macrophage responses to wild type or knock out C. jejuni GB11 LOS.  The 
supernatants were harvested and analysed for cytokine production using OptEIA ELISA kits. (A) BMDC 
IL-10 production  following  overnight  stimulation  with GB11 wild type or knock out LOS.  (B)  BM 
macrophage IL-10 production following overnight stimulation with GB11 wild type or knock out LOS.  (C) 
BMDC TNF-α production following overnight stimulation with GB11 wild type or knock out LOS.  (D) 
BM macrophage TNF-α production following overnight stimulation with GB11 wild type or knock out 
LOS.  (E) BMDC IL-12 production following overnight stimulation with GB11 wild type or knock out 
LOS. Mean and SEM calculated from triplicate wells. Analysed using 2way ANOVA with Bonferroni’s 
posttests (**=p<0.01, ***=p<0.001).  Representative of three titration experiments.   167 
Bone marrow derived dendritic cells or macrophages were stimulated with a titrating 
dose of wild type or knock out GB11 C. jejuni LOS and the supernatants were harvested 
after overnight incubation.  Cytokine production was assayed using cytokine ELISAs.  
Figures  40(A)  and  (B)  shows  IL-10  production  by  dendritic  cells  and  macrophages 
respectively.  Dendritic cells produce double the amount of IL-10 (1433 pg/ml v 665 
pg/ml) following stimulation with 10µg/ml knock out LOS than compared to wild type 
LOS (p<0.001) and almost 50% more (509 pg/ml v 354 pg/ml) when stimulated with 
1µg/ml (p<0.001).  1µg/ml of knock out LOS has potency comparable to 10µg/ml of wild 
type LOS.  Macrophages produce one third more IL-10 when stimulated with 10µg/ml 
knock  out  LOS  as  compared  to  wild  type  LOS  (p<0.01)  although  no  difference  in 
potency is apparent at lower concentrations. 
 
Figures 40(C) and (D) show dendritic cell and macrophage TNF-α production under the 
same  conditions.    There  is  no  statistical  difference  in  dendritic  cell  TNF-α  secretion 
following GB11 knock out LOS or GB11 wild type LOS stimulation.  There is greater 
TNF-α production by macrophages at 10µg/ml and 1µg/ml (p<0.01) with knock out LOS 
having approximately double the potency of wild type LOS at each concentration. 
 
Figure 40 (E) shows bone marrow derived dendritic cell IL-12 production.  GB11 knock 
out  LOS  is  more  potent  at  0.1µg/ml  and  10µg/ml  (p<0.001)  than  wild  type  LOS 
producing just under twice as much IL-12 at each concentration. 
 
The differences in dendritic cell IL-10 production were reliably reproduced each time it 
was tested (over eight separate repeats) with similar levels of cytokines, high levels of 
statistical  significance  and  consistent  dose  response  curves.    However,  the  other 
cytokines showed marked inter-experiment variability with inconsistent dose response 
curves.    Small  differences  in  macrophage  IL-10  production  at  high  concentrations 
(10µg/ml)  of  LOS  were  generally  consistent  while  macrophage  TNF-α  production 
showed fluctuations in the dose response curves with knock out LOS being more potent   168 
at higher concentrations.  Dendritic cell IL-12 responses were extremely variable over a 
number of repeats making it difficult to draw definite conclusions.  
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Figure 41: Dendritic cell IL10 production in response to alternative C. jejuni LOS strains. 
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Figure 41.  IL-10 production by bone marrow derived dendritic cells following overnight stimulation with 
10µg/ml of wild type or knock out GB2 or GB19 C. jejuni LOS assayed using an OptEIA ELISA kit. Mean 
and  SEM  calculated  from  triplicate  wells.  Analysed  using  1way  ANOVA  with  Bonferroni’s  multiple 
comparison test. (**=p<0.01, ***=p<0.001).  Single experiment.   170 
In order to confirm that the difference in dendritic cell IL-10 production could be reliably 
related to the presence of ganglioside mimicry, dendritic cells were stimulated with an 
additional two strains of ganglioside mimicking LOS and their non-mimicking control 
strains (GB2 and GB19 wild type and knock out).  Figure 41 shows IL-10 production and 
confirms a similar trend to the previous results with knock out strains being more potent 
(GB19 p<0.01, GB2 p<0.001) than the wild type strains although the magnitude of the 
difference is less marked than with GB11 strains. 
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Figure 42: Whole C. jejuni stimulation of dendritic cells and macrophages. 
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Figure 42.  Bone marrow derived dendritic cells or macrophages were stimulated overnight with a titrating 
dose of whole heat inactivated GB11 wild type or knock out C. jejuni. Cytokine production was measured 
using  ELISA.    (A)    BMDC  IL-10  production  following  stimulation  with  whole  C.  jejuni.  (B)  BM 
macrophage IL-10 production following stimulation with whole C. jejuni. (C) BMDC TNF-α production 
following stimulation with whole C. jejuni  (D) BM macrophage TNF-α production following stimulation 
with whole C. jejuni. (E) BMDC IL-12 production following stimulation with whole C. jejuni. Mean and 
SEM  calculated  from  triplicate  wells.  Analysed  using  2way  ANOVA  with  Bonferroni’s  posttests 
(*=p<0.05).  Representative of three experiments.   172 
5.2.7  Potency of whole C. jejuni at stimulating myeloid antigen presenting 
cells 
 
To investigate the role of ganglioside mimicry in differences in potency, dendritic cells 
and macrophages were stimulated with whole ganglioside mimicking or non-mimicking 
bacteria.  The cells were stimulated overnight with whole heat killed C. jejuni.  Figures 
42(A)  and  (B)  show  dendritic  cell  and  macrophage  IL-10  production  following 
stimulation.  There is no difference in potency between the wild type and knock out 
strains in stimulating either cell type.  Figures 42(C) and (D) show TNF-α production.  
Although there is a small statistical difference in dendritic cell responses at a bacteria to 
cell ratio of 1.5:1 (p<0.05) there is no substantial difference in potency between the GB11 
wild type and knock out strains.  Figure 42 (E) shows dendritic cell IL-12 production 
following  whole  bacteria  stimulation  and  there  is  no  difference  in  potency  between 
ganglioside mimicking and non-mimicking strains.   173 
Figure 43: LOS and ganglioside stimulation of dendritic cells and macrophages. 
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Figure 43. Bone marrow derived dendritic cells or macrophages were incubated with 10 µg/ml gangliosides 
GD1a  and  GM1  alone,  GB11  wild  type  LOS,  knock  out  LOS,  and  knock  out  LOS  which  had  been 
sonicated with 10 µg/ml GD1a and GM1. The cells were incubated overnight and cytokine production was 
measured  in  the  supernatant  using  ELISA.    (A)  BMDC  IL-10  production  (B)  BM  macrophage  IL-10 
production.  (C)  BMDC  TNF-α  production  (D)  BM  macrophage  TNF-α  production.  (E)  BMDC  IL-12 
production.    Mean  and  SEM  calculated  from  triplicate  wells.    Analysed  using  1way  ANOVA  with 
Bonferroni’s  multiple  comparison  test  (*=p<0.05,  **=p<0.01,  ***=p<0.001).    Representative  of  three 
experiments.   174 
5.2.8  Effect of exogenous gangliosides on knock out LOS potency 
 
Exogenous  gangliosides  have  been  shown  to  alter  activation  of  immune  cells.    To 
establish if the measured differences in potency between ganglioside mimicking and non-
mimicking  LOS  are  due  to  the  ganglioside  mimic,  and  to  gain  an  insight  into  the 
mechanism,  myeloid  cells  were  stimulated  with  knock  out  LOS  in  the  presence  of 
exogenous  gangliosides.    The  cells  were  stimulated  with  10µg/ml  non-ganglioside 
mimicking LOS which was first sonicated in solution with 5µg/ml each of gangliosides 
GM1 and GD1a.  The cells were also stimulated with PBS, ganglioside alone or wild type 
LOS.  Contrary to expectations, rather than reduce the potency of knock out LOS to that 
of wild type LOS, the general trend was for GM1 and GD1a to slightly increase the 
potency of knock out LOS (although this was subject to inter-experiment variability and 
was usually not statistically significant).  Figures 43(A) and (B) show dendritic cell and 
macrophage IL-10 secretion.  Addition of exogenous gangliosides slightly increased the 
potency of knock out LOS (p<0.05) at stimulating IL-10 from dendritic cells although it 
had  no  effect  on  macrophages.    Figures  43  (C)  and  (D)  show  dendritic  cell  and 
macrophage TNF-α secretion.  There was no statistical difference in TNF-α production 
for either population when gangliosides were added to knock out LOS.  Figure 43 (E) 
shows dendritic cell IL-12 secretion.  Addition of gangliosides to knock out LOS had no 
effect on the LOS potency.  Gangliosides alone had no effect on the dendritic cells or 
macrophages.   175 
Figure 44: IL10 production by dendritic cells following blocking of siglec receptors. 
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Figure 44.  Bone marrow derived dendritic cell IL10 production following Sialoadhesin, Siglec E or Siglec 
F blockade and LOS stimulation.  The supernatants were harvested and assayed for IL10 production using 
an  ELISA.    Mean  calculated  from  triplicate  wells.    Analysed  using  2way  ANOVA  with  Bonferroni’s 
posttests  (***=p<0.001).  Representative of three experiments.   176 
5.2.9  Effect of siglec blockade on LOS potency 
 
The  greatest  and  most  reproducible  difference  in  LOS  potency  was  observed  with 
dendritic  cell  IL-10  secretion  following  10µg/ml  of  GB11  LOS  stimulation.    It  was 
hypothesised that wild type LOS is less potent than knock out LOS because of inhibitory 
signalling  through  a  siglec  receptor.    A  restricted  set  of  blocking  antibodies  against 
candidate  myeloid  expressed  siglec  receptors  was  used  to  block  potential  signals 
mediated  by  the  ganglioside  mimicking  LOS.    Figure  44  shows  IL-10  secretion  by 
dendritic cells following LOS stimulation in combination with blocking anti-Sialoadhesin 
(3D6 and SER-4
209), anti-Siglec F
258 or anti-Siglec E
258 antibodies (1µg/million cells).  
The cells were incubated with blocking antibody at 4
oC for 15 minutes before 10µg/ml 
LOS was added, and then cultured overnight.  The addition of siglec blocking antibodies 
has no effect on wild type LOS potency which remained less potent than knock out LOS 
under all the conditions (p<0.001).  Surprisingly, addition of siglec blocking antibody to 
knock  out  LOS  had  a  trend  of  increasing  potency  although  not  with  statistical 
significance.   177 
Figure 45: Upregulation of co-stimulator CD40 by LOS and whole C. jejuni stimulated 
dendritic cells and macrophages. 
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Figure 45. (A) (i)  Bone marrow derived dendritic cells were stimulated with 10µg/ml GB11 wild type or 
knock out LOS and incubated overnight.  CD40 upregulation was measured by FACS analysis (increase in 
CD40-PE  MFI  shown  in  histogram).  (A)(ii)  Graphical  representation.    (B)(i)  Bone  marrow  derived 
macrophages were pulsed with heat inactivated whole GB11 C. jejuni for 15 minutes, washed, and then 
incubated  overnight.    Upregulation  of  CD40  was  measured  by  increased  MFI.    (B)(ii)  Graphical 
representation.  Mean  and  SEM  calculated  from  triplicate  tubes.    Analysed  using  1way  ANOVA  with 
bonferroni’s multiple comparisons test.  Representative of three experiments.    178 
5.2.10 Upregulation  of  co-stimulatory  molecule  CD40  following  LOS 
stimulation 
 
CD40 is a co-stimulatory molecule expressed on a number of cells of the immune system 
including  dendritic  cells  and  macrophages.    CD40  is  up-regulated  on  dendritic  cells 
following stimulation via TLRs and is a useful marker of dendritic cell maturation as 
ligation of CD40 leads to increased expression of other co-stimulators such as CD80 and 
CD86 as well as pro-inflammatory cytokine production
314.  CD40 plays a similar role in 
macrophages
315. 
 
Having  established  differences  in  the  potency  of  ganglioside  mimicking  and  non-
mimicking LOS at inducing cytokines, it was decided to test if there were differences in 
the up-regulation of the co-stimulatory molecule CD40.  Dendritic cells were stimulated 
with  ganglioside  mimicking  or  non-mimicking  LOS  while  macrophages  were  pulse 
stimulated with ganglioside mimicking or non-mimicking whole C. jejuni.  The cells 
were stained with anti-CD11c mAb and F4/80 respectively and co-stained for CD40.  
Example FACS histograms are shown in Figure 45(A)(i) and (B)(i) (an isotype control 
antibody for CD40 showed no increase beyond PBS stimulated cells).  Upregulation was 
measured using the change in the MFI.  Figures 45 (A)(ii) shows the change in dendritic 
cell CD40 expression and indicates no difference between wild type and knock out LOS.  
(B)(ii) shows macrophage CD40 upregulation and no difference is noted between wild 
type and knock out whole C. jejuni.    179 
Figure 46: Dendritic cell and macrophage death following LOS stimulation. 
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Figure 46.  Percentage of dead cells determined by trypan blue exclusion assay.  (A) Bone marrow derived 
dendritic cells, (B) bone marrow derived macrophages.  Each population was stimulated with 10µg/ml wild 
type or knock out GB11 C. jejuni LOS and incubated overnight.  Mean and SEM calculated from triplicate 
wells.    Analysed  using  1way  ANOVA  with  bonferroni’s  multiple  comparisons  test    (*=p<0.05).  
Representative of three experiments.   180 
5.2.11 Effect of LOS on cell death 
 
The  inter-experimental  variation  in  cytokine  production  could  be  due  to  cell  death 
because of the high concentrations of LOS being used.  Dendritic cells and macrophages 
were stimulated overnight with 10µg/ml wild type or knock out LOS and cell death was 
assayed using a trypan blue exclusion assay.  Figure 46 (A) shows the percentage of dead 
dendritic cells.  There is no statistical difference in dead cells when stimulated with wild 
type  LOS,  knock  out  LOS  or  PBS.    Figure  46(B)  shows  the  percentage  of  dead 
macrophages.  There is no statistical difference between wild type and knock out LOS 
although knock out LOS caused more cell death than PBS alone (p<0.05).  The trend for 
increased cell death associated with knock out strains of LOS (GB11, GB2 and GB19) 
was seen in a number of dendritic cell and macrophage experiments, although the trend 
was not statistically significant.  To confirm these findings a single experiment was done 
using the 7AAD viability probe in conjunction with FACS analysis.  This confirmed the 
trend but was not statistically significant.   181 
Figure 47: C3H/HeJ and TLR2
-/- dendritic cell IL10 production following LOS 
stimulation. 
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Figure 47.  Bone marrow derived dendritic cells from (A) C3H/HeJ and C3H/HeN and (B) TLR2 Knock 
Out  and  C57BL/6  mice  were  stimulated  with  10µg/ml  wild  type  or  knock  out  LOS  and  IL-10  was 
measured by ELISA in the supernatant after overnight culture.  There is no statistical difference between 
PBS and LOS stimulation of C3H/HeJ cells.  There is no statistical difference between wild type and knock 
out LOS in TLR2
-/- cells.  Mean and SEM calculated from triplicate wells.  Analysed using 2way ANOVA 
with Bonferroni’s posttest (nd=no statistical difference, ***=p<0.001).  Single experiment.   182 
5.2.12 LOS  stimulation  of  dendritic  cells  from  C3H/HeJ  LPS 
hyporesponsive mice and TLR2
-/- mice 
 
Capsular polysaccharide is a frequent and tenacious contaminant of LPS preparations.  It 
is  sensed  by  immune  cells  using  TLR2
216.    In  order  to  test  for  contamination,  bone 
marrow derived dendritic cells from the LPS hyporesponsive mouse strain, C3H/HeJ, and 
the  normo-responsive  control  strain,  C3H/HeN,  as  well  as  a  TLR2
-/-  strain  and  the 
C57BL/6  background  strain,  were  stimulated  overnight  with  C.  jejuni  LOS  and  the 
supernatant assayed for IL-10 production.  Figure 47(A) shows that C3H/HeN dendritic 
cells, consistent with previous results for C57BL/6 derived cells, produce IL-10 and that 
knock out is more potent than wild type LOS (p<0.001 for knock out v wild type LOS 
and for both types of LOS v PBS alone).  The C3H/HeJ dendritic cells do not respond to 
LOS,  consistent  with  their  LPS  hyporesponsive  phenotype  (no  statistical  difference 
between either LOS and PBS). 
 
Figure 47(B) shows that C57BL/6 dendritic cells respond as before with knock out LOS 
generating more IL-10 than wild type LOS (and both being greater than PBS) (p<0.001).  
The  dendritic  cells  from  TLR2
-/-  mice  produce  IL-10  at  low  levels  but  both  were 
significantly  greater  than  PBS  (wild  type  p<0.01,  knock  out  p<0.001).    However,  in 
contrast to the C57BL/6 derived control cells, there is no statistical difference between 
the wild type and knock out LOS at inducing IL-10. 
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5.3  Discussion 
 
The aim of these experiments was to investigate the immunostimulatory properties of C. 
jejuni LOS and any potential effect of ganglioside mimicry.  There are a number of ways 
ganglioside  mimicry  can  potentially  modulate  the  subsequent  immune  activation 
following TLR4/Lipid A interactions.  Firstly, as shown in chapter 4, the ganglioside 
mimic can act as ligand for siglec receptors.  Secondly, sialic acid plays a direct role in 
TLR4 signalling which has been demonstrated in Neu1 (neuraminidase 1) deficient mice 
and with the use of pharmacological neuraminidase inhibitors such as Tamiflu.  Neu1 is 
expressed by macrophages and it associates with TLR4 where it specifically cleaves α2-3 
linked sialic acid residues, such as those found on gangliosides GM1 and GD1a, linked to 
β−galactoside of TLR4.  When Neu1 activity is blocked or absent there is a reduction in 
the  ability  of  TLR4  to  signal  with  significant  reductions  in  inflammatory  cytokine 
production such as IL-6 and TNF-α
153,154.  If the α2-3 linked sialic acids on ganglioside 
mimicking LOS can substitute for the α2-3 linked sialic acid residues on β−galactoside of 
TLR4 then this may alter signalling. 
 
LPS mobilises MZ B cells causing them to migrate into the follicle where they deliver 
antigen to FO B cells
287-290.  Marginal Zone B cells are important effector cells in the 
response to carbohydrate antigens and are believed to harbour auto-reactive specificities 
131,158,  making  them  potentially  important  in  GBS.    Results  presented  in  this  chapter 
provide evidence for the first time that C. jejuni LOS is capable of mobilising MZ B cells 
in  vivo  and  the  results  also  show  that  ganglioside  mimicry  has  no  effect  on  this.  
However, an alternative explanation for my observations is that LOS kills all of the MZ B 
cells.  My methodology, which does not differentiate between B cell subsets, does not 
exclude this.  My original intention was to label FO and MZ B cells separately using anti-
IgD and anti-IgM, but for technical reasons related to reagents, this did not work. 
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A number of immune cell populations were stimulated with wild type and knock out LOS 
in order to test for the effects of ganglioside mimicry.  B cells were chosen as they are the 
effector cells responsible for producing auto-reactive antibodies in GBS.  Both purified B 
cells and B cells as part of a mixed splenocyte population were used in order to examine 
direct  ganglioside  effects  on  B  cells  as  well  as  more  complex  multiple  cell  lineage 
interactions.  My results show that C. jejuni LOS triggers B cell division and CD138 
positive cell differentiation and that a number of the cells which divided were, or became, 
IgG positive.  However, this probably does not represent de-novo class switching as 72 
hours is too early for this to occur.  There is no difference in potency between ganglioside 
mimicking  and  non-mimicking  LOS  strains  in  this  assay.    Interestingly,  E.  coli  LPS 
stimulation results in statistically greater division, CD138 positive cell differentiation and 
class switching than either C. jejuni LOS strain.   
 
In  addition  to  cell  division  and  maturation,  IgM  and  IgG  antibody  production  was 
measured.    Consistent  with  the  previous  results,  no  difference  is  observed  between 
ganglioside mimicking and non-mimicking C. jejuni LOS, although E. coli LPS is more 
potent at stimulating purified B cell and mixed splenocyte IgM production.  In addition, 
there is an inter-strain difference in mixed splenocyte IgM production with the GB19 
strains (both wild type and knock out) inducing more IgM than the GB2 strains (wild 
type and knock out).  There is a similar trend in IgM production from purified B cells.  
This suggests that the specific strain of C. jejuni from which the LOS is derived is more 
important at determining potency than ganglioside mimicry.  This in turn suggests that 
the Lipid A portion is the only important part of the molecule in determining B cell 
stimulating potency.  A similar trend is seen for  IgG production by purified B cells, 
although it is not statistically significant.  The GB19 strains of C. jejuni LOS and E. coli 
LPS are equally potent and both are more potent than GB2 strains of C. jejuni LOS at 
stimulating IgG production by mixed splenocytes.  
 
An additional measure of potency is cytokine secretion and IL-10 was chosen as it is an 
important immune modulating cytokine secreted by both B cells and myeloid cells
291.    185 
My results show no difference in IL-10 production by B cells or mixed splenocytes when 
stimulated with LOS from ganglioside mimicking or non-mimicking strains of C. jejuni, 
and this was seen with both GB2 and GB19 strains.  Consistent with previous findings, E. 
coli LPS is more potent than GB2 strains of C. jejuni LOS and have a trend for greater 
potency than GB19 C. jejuni LOS.   
 
Previous  studies  of  C.  jejuni  LOS  show  that  it  is  50%  less  toxic  to  galactosamine 
sensitised mice, 30 to 50 fold less pyrogenic in rabbits and induces 100 fold less TNF-α 
from peritoneal macrophages than LPS from salmonella species
316.  The studies presented 
here demonstrate for the first time the potency of C. jejuni LOS in stimulating purified 
murine B cells and B cells as part of a mixed splenocyte population.  They show that C. 
jejuni  LOS  shares  similar  immunostimulatory  properties  as  other  types  of  LPS.  
However, consistent with previous publications, they show C. jejuni LOS to be generally 
less potent than other species of LPS (in this case E. coli LPS).  Some authors have 
suggested that the low potency is linked to a higher phase transition (lower fluidity) of C. 
jejuni LOS and the unique diaminoglucose structure in the Lipid A
316.  This evidence of 
low potency is reinforced when the molarity of my LOS is considered.  S-form LPS can 
have up to 100 times the mass of R-form LPS (LOS) which means that the C. jejuni LOS 
was used at significantly higher molar concentrations than the E. coli LPS.  S-form LPS 
is heterogeneous in size, so there is no definitive mass with which to calculate molarity 
and make a direct comparison to the C. jejuni LOS.   
 
No  difference  in  B  cell  stimulation  is  obvious between  the  wild  type  and  knock  out 
strains.    Given  that  LPS  is  one  of  the  most  potent  immune  stimulators  known,  it  is 
possible that any additional signal from a ganglioside receptor is overwhelmed by the 
TLR4 signal or that ganglioside specific receptors are unable to engage soluble LOS.  To 
address this possibility some assays were done with LOS pre-adsorbed onto the tissue 
culture  plate,  but  this  had  no  effect.    Siglec  receptors  are  known  to  be  held  in  cis 
interactions and require “liberating” from these bonds before they can engage in trans 
binding with external gangliosides.  Further experiments could address this issue by pre-  186 
treating the cells with a neuraminidase to release any siglec receptors from cis bonds 
prior to exposing them to LOS. 
 
IFN-γ  secretion  by  mixed  splenocytes  was  tested  to  establish  if  ganglioside  mimicry 
affects  production  of  polarising  cytokines.    Intriguingly,  no  IFN-γ  is  secreted  when 
splenocytes are stimulated with C. jejuni LOS, while E. coli LPS stimulates ample IFN-γ 
production.  No IL-12 production is detected from splenocytes following stimulation with 
any of the LPS/LOS types and this might be due to consumption of the cytokine by the 
cells themselves. 
 
To test if a lack of IFN-γ was unique to C. jejuni LOS, or a general property of R-form 
LPS,  splenocytes  were  stimulated  with  a  titration  of  C.  jejuni  LOS,  R-form  S. 
typhimurium  LPS  and  S-form  S.  typhimurium  LPS.    The  data  presented  shows  large 
quantities of IFN-γ production by splenocytes stimulated with S-form S. typhimurium 
LPS with significantly lower quantities from R-form S. typhimurium LPS and none from 
C. jejuni LOS.  In a number of subsequent repeats at varying concentrations, no IFN-γ 
could  be  detected  following  R-form  S.  typhimurium  LPS  stimulation.    These  results 
indicate  that  R-form  LPS,  and  especially  C.  jejuni  LOS,  does  not  stimulate  IFN-γ 
secretion by mixed splenocytes.  This has not been reported before.  Analysis of the same 
supernatant  shows  that  IL-10  secretion  remains  intact  and  confirms  that  S-form  S. 
typhimurium LPS is more potent than R-forms of LPS.  10µg/ml is considered a very 
high concentration for LPS stimulation so it is unlikely the lack of IFN-γ is due to the 
LPS concentration being too low. 
 
The mechanisms underlying these differences have not been investigated.  It is possible 
that IL-10 is inhibiting the IL-12/IL-18 – IFN-γ axis.  However, S-form LPS induces 
more IL-10 than R-form LPS and yet continues to induce IFN-γ.  R-form LPS signals 
principally  through  the  MyD88  dependent  pathway  in the  absence  of  CD14  and  this 
might  skew  the  resultant  cytokine  response  towards  Th2  and  away  from  Th1    For   187 
example,  Mast  cells  are  TLR4  positive/CD14  negative  and  are  a  potent  source  of 
cytokines such as  IL-5,  IL-13 and  IL-10.  The antibody isotypes commonly (but not 
exclusively) associated with GBS are IgG1 and IgG3 and this is classically thought to be 
a manifestation of a Th1 dominated response.  Therefore, confirming that C. jejuni LOS 
polarises towards Th2 under normal circumstances would be an important discovery. 
 
These results must be interpreted with caution.  Although all of the  LPS types were 
treated with enzymes to improve purity, the two S. typhimurium strains were purified 
using  different  methods  (the  S-form  by  hot  phenol  extraction  and  the R-form  by  the 
phenol-chloroform-petroleum ether method) and both S. typhimurium strains were bought 
commercially.    It  is  possible  that  they  contain  different  quantities  of  contaminating 
bacterial immune stimulators, such as capsular polysaccharide, from each other, or the C. 
jejuni LOS.  The observed phenomena can only be adequately investigated using sources 
of ultra-pure LPS and TLR
-/- mouse strains to exclude confounding effects. 
 
Myeloid cells, such as dendritic cells and macrophages, play an important early role in 
shaping  the  immune  response.    LPS  stimulates  maturation  of  dendritic  cells  and 
macrophages into potent antigen presenting cells whereupon they can secrete cytokines 
such as IL-10, IL-12 and TNF-α
277-286.  In order to compare the potency of ganglioside 
mimicking and non-mimicking C. jejuni LOS, and to establish if there is any difference 
in the production of polarising cytokines, bone marrow derived dendritic cells and bone 
marrow derived macrophages were stimulated with LOS and the resultant production of 
TNF-α (an acute phase inflammatory cytokine), IL-10 (a cytokine generally considered to 
be anti-inflammatory/Th2) and IL-12 (a Th1 cytokine) was measured.   
 
Dendritic cells stimulated with GB11 knock out LOS produce approximately twice as 
much IL-10 as wild type LOS at 10µg/ml stimulation.  This difference is consistent, 
entirely  reproducible  (being  present  in  at  least  eight  separate  repeats),  always  highly 
statistically significant and is considered a good candidate for biological significance due   188 
to the magnitude of the difference.  Importantly, this effect follows a dose response curve 
although the difference in potency only becomes significant above 1µg/ml.  In addition, 
the increased IL-10 production seen with knock out LOS (or reduced IL-10 production 
seen  with  wild  type  LOS)  is  also  present  when  GB2  and  GB19  strains  (mimicking 
GM1/GD1a  and  GD1c  respectively)  of  LOS  are  used.    This  too  is  consistent  and 
reproducible.  However, the magnitudes of the differences for these strains of LOS are 
not as great as for GB11.  
 
The  experiments  measuring  IL-12  and  TNF-α  suffered  from  a  degree  of  inter-
experimental  variation  and  the  results  presented  offer  a  fair  reflection  of  the  general 
trends of the experiments.  While the GB11 knock out LOS appears to be generally more 
potent at inducing cytokines from both dendritic cells and macrophages, the differences 
between knock out and wild type strains for TNF-α and IL-12 production is variable, not 
always  statistically  significant  and  therefore  of  questionable  biological  significance. 
Further  experiments  studying  an  alternative  marker  of  dendritic  cell  activation, 
upregulation of the co-stimulator molecule CD40, show no difference between wild type 
and knock out strains of LOS confirming differences in potency is largely specific to the 
cytokine IL-10.  
 
In order to further investigate the role of ganglioside mimicry and its affect on potency, 
dendritic  cells  and  macrophages  were  stimulated  with  heat  killed  whole  bacteria.    In 
contrast to the purified  LOS, this does not reveal any difference in potency between 
ganglioside mimicking and non-mimicking strains in inducing IL-10, IL-12 or TNF-α.  
This casts some doubt on the effect or biological relevance of ganglioside mimicry.  In 
the  context  of  multiple  separate  immunostimulators  (LOS,  bacterial  DNA,  RNA, 
flagellum etc) it is possible that subtle effects are lost.  Macrophages pulse stimulated 
with whole C. jejuni show no difference in upregulation of the co-stimulator molecule 
CD40. 
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Exogenous gangliosides directly affect activation of both dendritic cells and macrophages 
through what are believed to be non-receptor specific interactions
139,299 (i.e. gangliosides 
may  insert  into  membranes  or  lipid  rafts).    Interestingly,  such  studies  tend  to  use 
gangliosides at concentrations in the region of tens of micrograms per ml, which is within 
the range at which differences become apparent between ganglioside mimicking and non-
mimicking  LOS.    It  is  possible  that  both  halves  of  the  ganglioside  mimicking  LOS 
molecule are biologically active at different concentration ranges, with the lipid A portion 
being  highly  potent  and  active  at  sub-microgram  concentrations,  and  the  ganglioside 
mimic being less potent and active at tens of micrograms.  Studies of ganglioside effects 
tend  to  show  an  inhibitory  function  which  is  consistent  with  the  reduced  cytokine 
production, and in particular reduced IL-10, seen with ganglioside mimicking LOS.  To 
explore  non-receptor  specific  effects  of  ganglioside  mimicry,  dendritic  cells  and 
macrophages  were  stimulated  with  ganglioside  alone,  ganglioside  mimicking  LOS  or 
non-ganglioside mimicking LOS with exogenous gangliosides added at 10µg/ml.  The 
knock out LOS was first sonicated with the exogenous ganglioside in order to incorporate 
the LOS and gangliosides together in micelles to recapitulate the epitope structure of 
ganglioside mimicking wild type LOS. 
 
In  contrast  to  the  reduced  potency  of  ganglioside  mimicking  LOS,  knock  out  LOS 
combined with exogenous gangliosides has no effect on cytokine production or weakly 
increases cytokine production.  This effectively rules out the hypothesis that differences 
in potency are due to non-receptor specific effects of ganglioside mimicry.   
 
An alternative mechanism for differences in potency is receptor specific signals delivered 
by the ganglioside mimic.  Siglec receptors are generally inhibitory which is consistent 
with  the  reduced  IL-10  production  seen  with  wild  type  LOS.    In  order  to  test  this 
hypothesis,  dendritic  cells  were  stimulated  with  wild  type  or  knock  out  LOS  in  the 
presence  of  blocking  antibodies  to  a  restricted  set  of  myeloid  expressed  siglecs; 
Sialoadhesin, Siglec F and Siglec E.  The presence of blocking antibodies has no effect 
on the amount of IL-10 produced following wild type LOS stimulation.  Although this   190 
casts  doubt  on  this  hypothesis,  it  is  possible  that  signalling  is  taking  place  via  an 
alternative receptor not included in my panel of antibodies.  In addition, these antibodies 
were  affinity  purified  from  sheep  serum  and  presumably  contain  mixed  specificities.  
Apart  from  the  anti-Sialoadhesin  antibodies,  which  showed  blocking  activity  in  later 
experiments (chapter 6.2.8), it cannot be certain that anti-Siglec E and anti-Siglec F have 
a blocking function as there was no suitable positive control.  It is also possible that the 
antibodies were used at an insufficient concentration. 
 
A possible explanation for the inter-experimental variability seen with TNF-α and IL-12 
production is the extremely high doses of LOS being used to stimulate the cells.  For in 
vitro stimulation of myeloid cells, 10µg/ml of LPS is an exceptionally high concentration 
and  possibly  toxic,  although  it  is  difficult  to  draw  comparisons  between  the  more 
commonly used types of LPS (such as salmonella or E. coli) and C. jejuni.  Experiments 
were done to quantify cell death using both trypan blue exclusion and 7AAD uptake.  
There is no statistical difference in dendritic cell death between either LOS strains or PBS 
although  there  was  a  trend  seen  over  a  number  of  experiments  for  more  cell  death 
associated with knock out LOS. 
 
Having excluded non-receptor specific ganglioside effects and receptor specific effects 
(as far as is possible with limited reagents) a remaining possibility is that the difference in 
IL-10 production, and indeed the inter-experimental variability, is due to contamination 
present at higher levels in the knock out LOS strains.  An experiment was carried out to 
determine if bacterial capsular polysaccharide was present in the LOS and if this could 
account  for  differences  in  potency  between  wild  type  and  knock  out  strains.    The 
C3H/HeJ mouse strain is hyporesponsive to LPS due to a mutation in the Tlr4 gene
116.  
Before proceeding with this experiment it was recognised that there are a number of 
potential flaws in using this strain. Firstly, C3H/HeJ mice are hyporesponsive but not 
necessarily  non-responsive  to  LPS
317  and  secondly  there  has  been  one  report  that 
C3H/HeJ derived cells remain sensitive to R-type LPS
318.  In addition, if the ganglioside 
mimic is delivering an additional signal it may be impossible to distinguish this signal   191 
from signals due to contamination.  A better model may have been the TLR4 
-/- mouse, 
but it was not available.   
 
My  results  show  that  neither  the  wild  type  nor  the  knock  out  LOS  stimulates  IL-10 
secretion  from  dendritic  cells  derived  from  the  C3H/HeJ  strain.  This  indicates  that 
contamination is not present in the LOS and does not account for the difference in IL-10 
secretion  that  is  demonstrated  in  the  C3H/HeN  control  strain.    To  confirm  this 
interpretation, dendritic cells derived from a TLR2
-/- mouse strain were stimulated with 
LOS.    The  TLR2  receptor  senses  capsular  polysaccharide  although  it  is  more 
promiscuous than TLR4 in its specificity
216.  If capsular polysaccharide contamination is 
responsible for the differences in IL-10 secretion then there should be no difference in 
IL10 production by TLR2
-/- dendritic cells stimulated with wild type or knock out LOS.  
This is what was found. 
 
It was noted that TLR2
-/- dendritic cells produce IL-10 at a lower level than the C57BL/6 
controls.    However,  this  phenomenon,  and  the  resultant  IL-10  levels,  are  entirely 
consistent with a previous publication using E. coli LPS and TLR2
-/- derived dendritic 
cells
319.  These results suggest that a TLR2 ligand, such as capsular polysaccharide, could 
be responsible for the difference in IL-10 production and therefore this finding is at odds 
with my interpretation of the C3H/HeJ results.   
 
A recent study shows that bone marrow derived dendritic cells produce large quantities of 
TNF-α and IL-12 in response to highly purified LPS signalling through TLR4, but that 
IL-10 is only produced in very low quantities unless there is additional signalling through 
TLR2.  The same study demonstrates that TLR2 signalling alone (achieved using the 
TLR2 agonist Pam3CSK4) does not lead to IL-10 secretion.  TLR2 was shown to act 
synergistically  with  TLR4  to  increase  IL-10  but  not  TNF-α  or  IL-12  secretion  from 
dendritic cells
319.  Applying this paradigm to the data presented here suggests that the 
C3H/HeJ experiment does not exclude the presence of a TLR2 agonist as the cytokine   192 
tested  was  IL-10,  which  a  TLR2  agonist  alone  does  not  induce  in  dendritic  cells.  
However,  this  contrasts  with  previous  published  work,  again  using  Pam3CSK4  to 
stimulate  dendritic  cells,  which  shows  ample  IL-10  production  in  response  to  TLR2 
signalling
320.  These conflicting studies used substantially different techniques to purify 
dendritic cells with the former paper bearing a closer protocol to my own, while the latter 
paper used spleen derived dendritic cells. 
 
In  order  to  definitively  exclude  TLR2  signalling  in  the  C3H/HeJ  experiment,  the 
supernatant should also have been tested for an additional cytokine such as TNF-α or IL-
12.  Although a TNF-α assay was done on the supernatant, none could be detected in 
either the C3H/HeJ or the control C3H/HeN cells.  Unfortunately, the supernatants had 
undergone multiple freeze/thaw cycles and the need for additional assays only became 
apparent at a late stage.  This would be a suitable experiment to exclude contamination, 
however due to pressing limitations in time and reagents, these experiments have not 
been carried out. 
 
The presence of a TLR2 agonist contaminating the knock out LOS is in keeping with a 
number of observations.  Firstly, the difference in potency was only consistent for IL-10.  
This can be explained in the context of TLR2 signalling acting synergistically to boost 
IL-10, but not TNF-α or IL-12
319.  Secondly, the difference in potency only emerges at 
high concentrations.  This can be explained if trace concentrations of contamination reach 
an active dose only when the LOS is used at high concentrations.  Thirdly, the difference 
in potency was only consistent in dendritic cells, in which this synergistic action of TLR2 
and  TLR4  signalling  for  IL-10  has  been  described.   Although  ligands  for  TLR2  and 
TLR4 have been extensively studied it is clear that this is a very complicated area full of 
potential pitfalls. 
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Although  it  has  been  assumed  that  ganglioside  mimics  will  signal  through  siglec 
receptors, an additional possibility is that the ganglioside mimics signals through TLR2.  
TLR2 is known to be a promiscuous receptor and although GD1a is not a known ligand 
for TLR2 it has been shown to be a co-receptor for TLR2 with certain ligands
321.  This 
scenario  might  explain  the  results  seen  in  the  TLR2
-/-  cells.    It  is  also  important  to 
establish if the ganglioside mimicking LOS actively inhibits IL-10 secretion or simply 
causes less stimulation. 
 
Reduced IL-10 secretion by dendritic cells when stimulated by ganglioside mimicking 
LOS  potentially  has  wide  ranging  consequences  in  autoimmune  disease.    IL-10  has 
multiple immunosuppressive effects
322.  In dendritic cells and macrophages it is a potent 
inhibitor  of  antigen  presentation,  reducing  MHCII  expression  and  expression  of  co-
stimulators CD80 and CD86.  Through its inhibitory effects on antigen presenting cells it 
inhibits both Th1 associated cytokines (such as IL-2 and IFN-γ) as well as Th2 associated 
cytokines  (such  as  IL-4  and  IL-5).    IL-10  also  suppresses  myeloid  derived  pro-
inflammatory cytokines such as IL-1, IL-6, IL-12 and TNF-α.  Modulation of these latter 
two cytokines by IL-10 dependent feedback loops might explain the variability seen in 
my assays looking at these cytokines.  It is conceivable that a localised deficiency of IL-
10 production by dendritic cells could perturb the cytokine milieu sufficiently to facilitate 
greater inflammation and lead to a break in tolerance, leading to autoimmunity.  This 
scenario would be more plausible if it can be shown that ganglioside mimicry actually 
suppresses IL-10 rather than being less potent at inducing it, although the data suggests 
that ganglioside mimicking LOS is less potent in general.  It should of course be noted 
that this a simplification of the properties of  IL-10  which is also immunostimulatory 
under certain circumstances with positive effects on B cell survival and class switching as 
well as natural killer cell proliferation and cytokine secretion. 
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In summary, in relation to B cells, I show C. jejuni LOS to be less potent than E. coli LPS 
by a number of measures.  I find no differences in C. jejuni LOS potency related to 
ganglioside mimicry.  In relation to myeloid cells, and in particular dendritic cells, I show 
an intriguing phenomenon of less IL10 production associated with ganglioside mimicking 
LOS.  I am unable to establish a mechanism for this effect but have taken several steps to 
rule  out  contamination,  although  so  far  my  experiments  fall  short  of  definitively 
excluding this. 
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6  In vitro and in vivo tracking of ganglioside mimicking and 
non-mimicking C. jejuni 
 
6.1  Introduction 
 
The aims of the experiments in this chapter are to establish if differences in receptor 
binding and/or opsonisation between ganglioside mimicking and non-mimicking strains 
of C. jejuni translate into altered cellular association and uptake, both in vitro and in vivo. 
 
My third core hypothesis, that ganglioside mimicry alters C. jejuni trafficking, is not 
without precedent.  The results presented in chapter four demonstrate that ganglioside 
mimicry by C. jejuni enables the bacteria to bind to specific myeloid expressed siglec 
receptors in vitro, namely Sialoadhesin and Siglec F.  It has been shown by other groups 
that  Sialoadhesin  enhances  phagocytosis  of  sialylated  meningococci
255  and  I  aim  to 
investigate if this also occurs with C. jejuni.  In addition to receptor mediated effects, the 
reduced  natural  antibody  levels  and  complement  activation  directed  against  the 
ganglioside mimicking C. jejuni could also affect cellular association and trafficking and 
I aim to investigate this further.     196 
Figure 48: Analysis of CFSE labelled C. jejuni. 
A(i) A(ii)
B
 
Figure 48. Wild type and knock out C. jejuni were incubated with 2.5 µM CFSE for 30 minutes before heat 
inactivation.  The fluorescence was assessed using FACS analysis.  (A) (i) is a representative forward side 
scatter  FACS  plot  of  C.  jejuni  (ii)  is  a  histogram  plot  showing  CFSE  MFI  of  both  strains  including 
unlabelled  control  bacteria.    (B)  labelled  bacteria  visualised  using  a  fluorescent  microscope.    Inset  - 
mixtures of corkscrew (white arrow), C-shaped bacilli and coccoid morphology were often present.   197 
6.2  Results 
 
6.2.1  Fluorophore labelling of C. jejuni 
 
In order to track C. jejuni both in vitro and in vivo, without altering the surface epitopes, 
it was decided to develop a protocol to label the bacteria with the stable intracellular 
fluorophore CFSE.  Ganglioside mimicking and non-mimicking strains were grown as 
before and incubated with CFSE, washed, then heat inactivated.  As the bacteria were 
intended for use in quantification experiments using MFI they were first analysed by 
Flow Cytometry to ensure the GBS associated strains and control strains had acquired an 
equal fluorescence.  Figure 48 (A) shows the dot plot (i) and MFI (ii) of the bacteria.  
This figure shows that both the wild type and knock out bacteria are labelled with an 
equal fluorescence.  All batches were tested for fluorescence to ensure they were suitable 
for comparison.   
 
In addition to ensuring the consistency of fluorescence it is important ensure the bacteria 
have not been damaged by the labelling process.  Figure 48 (B) shows immunocytometry 
of  CFSE  labelled  bacteria.    The  bacteria  in  this  particular  batch  have  retained  their 
corkscrew morphology (white arrow).  It was noted in subsequent batches that there is a 
phase variation in morphology with coccoid forms being more common in aged agar 
cultures (48 to 72 hours old) and it is known that prolonged culture or oxygen exposure 
can induce this morphological change.  For the purposes of consistency, wild type and 
knock out strains were always grown and labelled simultaneously and bacteria from the 
same batch were used in each experiment.    198 
Figure 49: Confirmation of durable CFSE binding. 
A(i) A(ii)
 
Figure  49.    Confirmation  that  CFSE  remains  permanently  bound  to  bacteria.    Labelled  or  unlabelled 
bacteria  were  incubated  in  RPMI  for  1  hour,  removed  by  centrifugation  and  then  splenocytes  were 
incubated  with  the  RPMI.    (A)(i)  FACS  forward,  side  scatter  dot  plot  of  splenocytes.  (ii)  Histogram 
showing CFSE MFI of splenocytes following culture in RPMI which had, or had not, been incubated with 
CFSE labelled bacteria.  Single experiment.   199 
6.2.2  Confirmation that CFSE is retained by the C. jejuni 
 
CFSE is used as a fluorophore label for mammalian cells and is exceptionally bright.  For 
this reason it is necessary to confirm that it remains durably bound to C. jejuni and will 
not leak into co-cultured cells.  Labelled or unlabelled C. jejuni were incubated in RPMI 
for  1  hour  at  37
oC  then  removed  by  centrifugation.    Mixed  splenocytes  were  then 
cultured in the RPMI for 30 minutes.  The MFI of splenocytes cultured with RPMI from 
non-labelled C. jejuni was compared to the MFI of splenocytes cultured in RPMI from 
labelled C. jejuni.  Figure 49 shows a FACS plot of the mixed splenocytes (i) and the 
MFI  of  the  cells  (ii).    The  histograms  show  no  increase  in  MFI  of  the  splenocytes 
cultured with RPMI which had previously been exposed to labelled C. jejuni indicating 
that leakage of fluorophore and subsequent uptake by cells is not a confounding factor.   200 
Figure 50: Quantification of C. jejuni by optical density. 
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Figure 50.  Quantification of C. jejuni.  Graph showing dry weight v OD600.  Mean calculated from two 
tubes.  Single experiment.   201 
6.2.3  Development of a convenient and reliable method for quantification 
of C. jejuni 
 
C. jejuni had to be grown off-site (in a fully regulated diagnostic microbiology facility) 
because  of  restrictions  on  the  use  of  genetically  modified  class  2  pathogens  in  my 
laboratory  complex.  In  addition,  GBS  associated  C.  jejuni  are  rough  mutant  which 
rapidly form an amorphous growth pattern making quantification by traditional colony 
forming units impractical.  Due to these difficulties a convenient method of quantifying 
killed  C.  jejuni  was  established.    A  mixed  population  of  C.  jejuni  were  heat  killed, 
lyophilised and the dry weight established.  After being resuspended in PBS, a doubling 
dilution was carried out and OD600 measured.  Figure 50 shows a linear relationship 
between dry weight and OD600.  For experiments where an estimate of bacteria to cell 
ratio was required, the mass of one organism was taken to be 1x10
-12g (the estimated 
mass of an E. coli cell
208).     202 
Figure 51: Association of opsonised C. jejuni with B cells. 
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Figure  51.  Heat inactivated, CFSE labelled, C. jejuni were opsonised for 1 minute in fresh autologous 
mouse  serum,  heat  inactivated  serum  or  heat  inactivated  serum  with  added  exogenous  purified  mouse 
serum complement.  They were then incubated with mixed splenocytes derived from collagenase treated 
spleens.  Association of C. jejuni with B cells was assayed using FACS.  (A) Representative FACS plots 
showing (i) Splenocyte gate, (ii) CD19 positive B cells, (iii) B cells incubated without bacteria, (iv) B cells 
incubated with opsonised wild type bacteria and (v) B cells incubated with opsonised knock out bacteria.  
(B) Graph showing the percentage of B cells associated with C. jejuni following different opsonisation 
conditions (corrected for background A(iii)).  Following opsonisation, more B cells were associated with 
knock out bacteria than wild type bacteria (p<0.001).  There is no difference following heat inactivation of 
serum.  The difference reappears following addition of exogenous complement (p<0.001).  Mean and SEM 
calculated  from  triplicate  wells.    Analysed  using  two  way  ANOVA  with  Bonferroni’s  posttests. 
(***=p<0.001).  Representative of three experiments.   203 
6.2.4  Effect of complement opsonisation of C. jejuni on B cell association 
in vitro 
 
My previous results demonstrate that non-ganglioside mimicking strains of C. jejuni are 
more readily opsonised by complement and that this corresponds with increased natural 
antibody present in naïve sera against these strains.  In order to establish if this is likely to 
affect C. jejuni cell association in vivo it was decided to opsonise CFSE labelled bacteria 
and  track  cell  association  in  vitro  in  a  mixed  splenocyte  population  derived  from 
collagenase treated spleens.  B cells were chosen as the target cell as they are considered 
the main effector cell in GBS and express complement receptors. 
 
Wild type and knock out C. jejuni were opsonised for 1 minute in fresh homologous 
mouse serum before being incubated with splenocytes at a 3:1 ratio.  The cells were kept 
at 4
oC in the presence of 5mM Na Azide and 5mM EDTA to prevent phagocytosis by 
other populations and to prevent further complement activation.  Figure 51(A) shows 
representative  FACS  plots.    (A)(i)  is  the  splenocyte  gate.    (A)(ii)  shows  the  CD19 
positive gate (B cells) and A(iii), (iv) and (v) show the percentage of C. jejuni positive B 
cells following incubation with no bacteria (used for background correction), wild type 
bacteria and knock out bacteria respectively.  Figure 51(B) is the graphed data and shows 
the  percentage  of  B  cells  with  associated  C.  jejuni  under  different  opsonisation 
conditions. 
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The results show that opsonisation of knock out C. jejuni leads to greater association with 
B cells than wild type C. jejuni (p<0.001).  To confirm the role of complement in this 
association,  heat  inactivated  homologous  serum  was  used  to  opsonise  the  bacteria.  
Inactivation results in no difference between wild type and knock out C. jejuni B cell 
association.  When exogenous purified-mouse-serum-complement was reintroduced into 
the heat inactivated serum prior to opsonisation, the increased B cell association of non-
ganglioside mimicking strains is restored (p<0.001).  This experiment also shows the 
same trend when the data is analysed using the MFI of B cells rather than percentage 
positive. 
 
These results support the earlier finding that ganglioside mimicking strains show less 
opsonisation and indicate that this will potentially affect cell association and trafficking 
in vivo.   205 
Figure 52: Immunocytometry of Sialoadhesin on bone marrow derived macrophages. 
A(i) F4/80 Alexa 647 A(ii) MOMA1 FITC A(iii) DAPI
B Isotype controls merged
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Figure 52. Detection of Sialoadhesin expression by bone marrow derived macrophages.  A cytospin of 
formalin fixed bone marrow derived macrophages was prepared then labelled overnight with F4/80 and 
MOMA1.  Sialoadhesin could be detected on some, but not all F4/80 positive macrophages (white arrow 
shows Sialoadhesin negative cell).  (A)(i) to (iii) Single labels. (iv) Merged images.  (B) Merged isotype 
controls.  Single experiment.   206 
6.2.5  Identification of the Sialoadhesin receptor on bone marrow derived 
macrophages 
 
High  levels  of  Sialoadhesin  expression  are  found  on  specific  subpopulations  of 
macrophage,  notably  the  lymph  node  subcapsular  sinus  macrophages  and  splenic 
metallophilic macrophages.  Sialoadhesin is also expressed at low levels by conventional 
populations  of  macrophages
209,248.    In  order  to  establish  if  bone  marrow  derived 
macrophages would be a suitable population to study Sialoadhesin-C. jejuni interactions, 
a population of these macrophages was labelled with the Sialoadhesin specific antibody 
MOMA1 and the macrophage marker F4/80, and analysed using immunofluorescence 
microscopy. 
 
Figure 52 shows immunocytology of these macrophages.  Image (A) (i) to (iii) are single 
stains.  (A)(iv) shows that, following overnight incubation with the MOMA1 antibody, 
Sialoadhesin expression by F4/80 positive macrophages could be detected.  Interestingly 
Sialoadhesin  could  not  be  detected  on  all  of  the  F4/80  positive  cells  (white  arrow).  
Although  labelling  with  MOMA1  appeared  weak  and  patchy,  the  MOMA1  isotype 
control was negative.  The fluorophore used in conjunction with F4/80 was AlexaFluor-
647 which is adversely affected by DAPI (present in the mounting medium) and this is 
probably the reason for the weak F4/80 signal.   207 
Figure 53: Macrophage phagocytosis of C. jejuni analysed by FACS. 
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Figure 53.  Bone marrow derived macrophages were incubated with wild type or knock out C. jejuni (20:1 
bacteria:cell ratio) and phagocytosis was measured using the increase in CFSE MFI of the macrophages.  
The fluorescence of cells kept at 4
oC in cRPMI with 5mM NaAzide was subtracted as the control. (A)(i) 
and (ii) Cell gate and F4/80 positive gate with isotype control.  (B) Histogram FACS plots showing the 
CFSE  MFI  of  macrophages  at  (i)  0  minutes,  (ii)  15  minutes,  (iii)  30  minutes  and  (iv)  60  minutes.  
4
oC/NaAzide controls are included and were subtracted from the final MFI.  (C)(i) Graph of the MFI 
against time. There is increased phagocytosis of the wild type strain after 15 and 30 minutes compared to 
knock out.  C(ii) Graph showing the rate of phagocytosis over each time period and demonstrates an initial 
rapid uptake of wild type C. jejuni greater than knock out.  Mean and SEM calculated from triplicate tubes.  
Analysed using 2way ANOVA with Bonferroni’s posttests (*=p<0.05, ***=p<0.001).  Representative of 
three experiments.   208 
6.2.6  Bone marrow derived macrophage phagocytosis of C. jejuni 
 
Sialoadhesin has been shown to facilitate phagocytosis
255.  Results presented earlier in 
this thesis (chapter 4.2.1) demonstrate Sialoadhesin binding to ganglioside mimicking C. 
jejuni.  In order to test the hypothesis that Sialoadhesin binding will increase the rate of 
phagocytosis  of  ganglioside  mimicking  C.  jejuni,  bone  marrow  derived  macrophages 
were cultured with CFSE labelled wild type or knock out C. jejuni at a 20:1 bacteria to 
cell ratio and phagocytosis was assessed by measuring the increase in CFSE MFI in the 
macrophages.  To exclude confounding effects of natural antibody opsonisation, ultra-
low immunoglobulin foetal bovine serum was used to supplement the media.  In addition, 
to eliminate the effect of surface binding without phagocytosis, a control population of 
macrophages was incubated with C. jejuni at 4
oC in the presence of 5mM Na Azide. 
 
Figure 53 (A) shows the F4/80 positive macrophage population.  Figure 53(B) (i) to (iv) 
shows representative histograms of the MFI of the macrophages following incubation 
with CFSE labelled bacteria at 0, 15, 30 and 60 minutes.  As the MFI increases, it can be 
seen that phagocytosis of the ganglioside mimicking strain is more rapid than the non-
ganglioside mimicking strain. Figure 53(C)(i) illustrates the increase in MFI graphically 
and is corrected for background fluorescence (the shaded histograms in figure 53(B)).  
The  difference  between  wild  type  and  knock  out  is  statistically  significant  after  15 
minutes (p<0.05) and 30 minutes (p<0.01).  Of three experiments, the wild type and 
knock out reached equivalent phagocytosis by sixty minutes in one, and were close to 
equivalent in two, with the wild type still being ahead.  Figure 53(C) (ii) shows the same 
data  illustrated  as  a  rate  of  phagocytosis  over  each  time  period  and  shows  that  the 
enhanced rate of uptake of the ganglioside mimicking strain is an early phenomenon 
(p<0.001) with the rate equalising, and then reversing.    209 
Figure 54: Immunocytometry of phagocytosed C. jejuni. 
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Figure 54.  Visualised of macrophage phagocytosis of C. jejuni using light and fluorescent microscopy with 
Z-stacking to demonstrate the intracellular location of the bacteria.  (i) to (iv) is a Z-stack in which multiple 
bacteria can be seen in levels (ii) and (iii) which are absent in (i) and (iv) indicating their presence inside 
the cytoplasm (see inset).  This was confirmed for wild type and knock out strains in single experiments.   210 
6.2.7  Microscopy of phagocytosed C. jejuni 
 
To  confirm  that  phagocytosis  of  C.  jejuni  was  occurring,  a  cytospin  was  made  of 
macrophages that had been incubated with C. jejuni for 1 hour.  The cytospins were 
examined using light microscopy with overlaid fluorescence microscopy to identify the 
bacteria.  A Z-stack was made to confirm the intracellular location of the bacteria. 
 
Figure 54 (i) to (iv) shows selected images from the Z-stack of a representative slide.  A 
number of bacteria can  be seen present in the  middle two layers (highlighted by the 
insert) which are absent in the external layers, confirming that at least a proportion of the 
bacteria  are  intracellular.    Phagocytosis  of  both  wild  type  and  knock  out  strains  was 
confirmed by this method.   211 
Figure 55: Inhibition of phagocytosis by Sialoadhesin blockade. 
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Figure 55. Bone marrow derived macrophages were incubated with labelled C. jejuni (10:1 bacteria to cell 
ratio) for 40 minutes in the presence of a single concentration or a titrated dose of Sialoadhesin blocking 
antibodies SER4 and 3D6 and phagocytosis was measured as before.  (A)(i) and (ii) shows the MFI of 
macrophages incubated with labelled wild type and knock out bacteria respectively.  The unbroken line is 
with no blocking antibody, the broken is with Sialoadhesin blocking antibody and the shaded histogram is 
the isotype control.  4
oC/NaAzide controls are not included in the histogram for clarity, but were subtracted 
for the final MFI calculation. (B) Graph showing inhibition of phagocytosis of wild type C. jejuni in the 
presence  of  a  single  concentration  of  Sialoadhesin  blocking  antibody  with  no  effect  on  knock  out 
phagocytosis.  (C) Titration of blocking antibody until equivalence is reached. Mean and SEM calculated 
from triplicate tubes.  Analysed using 2way ANOVA with Bonferroni’s posttests (***=p<0.001).  (B) 
representative of three experiments, (C) single experiment.   212 
6.2.8  Phagocytosis  following  incubation  with  Sialoadhesin  blocking 
antibodies 
 
To  confirm  that  Sialoadhesin  is  the  receptor  mediating  the  enhanced  phagocytosis  of 
ganglioside mimicking C. jejuni, a phagocytosis assay was carried out at a single time 
point, at a bacteria to cell ratio of 10:1, in the presence of the Sialoadhesin blocking 
antibodies 3D6 and SER-4. 
 
Figures  55(A)  (i)  and  (ii)  respectively  show  representative  histograms  of  the  MFI  of 
macrophages incubated for 40 minutes with labelled wild type (red lines) and knock out 
(blue  lines) C.  jejuni.    The  histograms  show  bacterial  uptake.    The  unbroken  line  is 
phagocytosis with no blocking antibody.  The broken line is phagocytosis following prior 
incubation with 3D6 and SER-4.  The shaded histogram is a 3D6 and SER-4 isotype 
control.  The 4
oC, Na Azide controls are not shown in the histogram to aid clarity, but 
were subtracted from the final fluorescence.  This figure shows a reduction in the right-
shift of the wild type histogram in the presence of blocking antibodies with no such 
reduction in the knock out histogram. 
 
Figure  55(B)  shows  a  phagocytosis  blocking  experiment  at  a  single  concentration  of 
blocking antibody (0.3µg/million cells) (4
oC controls subtracted) and shows a statistically 
significant reduction in phagocytosis of wild type C. jejuni (p<0.001) with no reduction 
in knock out phagocytosis when Sialoadhesin blocking antibodies are present. 
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After it was established that Sialoadhesin blocking antibody inhibited wild type but not 
knock out C. jejuni phagocytosis, it was decided to do a titration of blocking antibody to 
establish if the rate of wild type phagocytosis could be reduced to match that of knock 
out.  Figure 55(C) shows the effect of increasing the dose of blocking antibody on the 
amount  of  wild  type  and  knock  out  phagocytosis.    At  0.5µg/ml  each  of  blocking 
antibodies 3D6 and SER-4, there is no statistical difference between phagocytosis of wild 
type and knock out C. jejuni. 
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6.2.9  In  vivo  tracking  of  i.v.  injected  C.  jejuni  to  metallophilic 
macrophages 
 
Having established in vitro differences in complement opsonisation and cell association 
as well as differences in receptor mediated phagocytosis of ganglioside mimicking and 
non-mimicking strains of C. jejuni it was decided to inject the bacteria into mice i.v. and 
establish which cell populations the ganglioside mimicking or non-mimicking bacteria 
associate with.  As Sialoadhesin is expressed at high levels by metallophilic macrophages 
I hypothesised that the wild type strains would associate with this cell population.  As the 
knock out strain is targeted by complement, I  hypothesised that these bacteria would 
either be rapidly lysed in the serum or associate with complement receptor expressing 
cells such as marginal zone macrophages or MZ B cells.  
 
Age and sex matched C57BL/6 mice were injected i.v. with 200µl of heat inactivated 
bacteria at an OD600 of 0.6 in PBS.  Control mice were injected with PBS alone.  After 1 
hour or 3 hours the mice were sacrificed and the spleen, lymphoid tissue and serum 
harvested and stored at -80
oC.  Following sectioning, the spleen was stained with a B220 
specific  antibody  to  identify  the  follicles  and  a  MOMA1  antibody  to  identify  the 
metallophilic macrophages.   
 
Figure 56(A) (i) to (iii) shows single stains.  (A)(iv) shows a representative image of a 
splenic follicle from a wild type strain injected mouse.  The inset shows labelled C. jejuni 
lying in association with MOMA1 positive macrophages (white arrows (a)).  In addition, 
bacteria can also be seen lying external to the MOMA1 positive population (white arrow 
(b)).  Figure 56(B) shows a representative section from a PBS injected mouse and the 
inset illustrates the background auto-fluorescence that can be distinguished from bacteria. 
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Figure 57(A) (iv) shows a representative image of a splenic follicle from a knock out 
strain  injected  mouse.    The  inset  shows  that  knock  out  bacteria  are  also  found  in 
association with the MOMA1 positive metallophilic macrophages.   216 
Figure 56: In vivo association of wild type C. jejuni with metallophilic macrophages. 
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Figure 56.  Fluorescent microscopy images of spleens from wild type C. jejuni injected mice after 1 hour.  
Spleen was stained for metallophilic macrophages (MOMA1) and B cells (B220).  (A) (i) to (iii) are single 
stains. (iv) Shows the merged images of a splenic B cell follicle and the inset shows wild type C. jejuni in 
association with metallophilic macrophages (a) and external to the metallophilic macrophages (b).  (B) Is a 
splenic  section  following  i.v.  PBS  injection  and  the  inset  shows  FITC  auto-fluorescence  clearly 
distinguishable from the labelled bacteria in (A)(iv). (n=4 for 1 hour time point and n=2 for 3 hour time 
point).   217 
Figure 57: In vivo association of knock out C. jejuni with metallophilic macrophages. 
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Figure 57.  Fluorescent microscopy images of spleens from knock out C. jejuni injected mice after 1 hour.  
Spleen was stained for metallophilic macrophages (MOMA1) and B cells (B220).  (A) (i) to (iii) is single 
stains. (iv) Shows the merged images of a splenic B cell follicle and the inset shows knock out C. jejuni in 
association with metallophilic macrophages. (n=4 for 1 hour time point, n=2 for 3 hour time point).   218 
6.2.10 In  vivo  tracking  of  i.v.  injected  C.  jejuni  to  marginal  zone 
macrophages 
 
Both wild type and knock out bacteria were identified outside the rim of metallophilic 
macrophages, lying in a region which is populated by marginal zone macrophages.  To 
test if these bacteria were associating with marginal zone macrophages the sections were 
stained with the marginal zone macrophage marker ER-TR9.  Figure 58(A) (iv) shows a 
representative image of a follicle from a wild type injected mouse.  Bacteria can be seen 
lying in association with the ER-TR9 positive marginal zone macrophages (inset white 
arrow (a)) and also internal to this population (white arrow (b)) in association with ER-
TR9  negative  cells  (presumably  metallophilic  macrophages).    Figure  58(B)  shows  a 
follicle  from  a  PBS  injected  control  mouse  and  again  illustrates  background  auto-
fluorescence. 
 
Figure  59  (A)  (iv)  shows  a  representative  image  of  a  splenic  follicle  from  a  mouse 
injected with knock out bacteria.  The inset shows bacteria lying in association with ER-
TR9 positive marginal zone macrophages (white arrow (a)) and also lying internal to this 
(white  arrow  (b))  in  association  with  ER-TR9  negative  cells  (again,  presumably 
metallophilic macrophages).   219 
Figure 58: In vivo association of wild type C. jejuni with marginal zone macrophages. 
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Figure 58.  Fluorescent  microscopy images of splenic sections 1 hour  following i.v.  administration of 
labelled wild type C. jejuni.  Spleen was stained for marginal zone macrophages (ER-TR9) and B cells 
(B220).  (A) (i) to (iii) are single stains.  (iv) Shows the merged images of a splenic B cell follicle and the 
inset shows wild type C. jejuni in association with marginal zone macrophages (a) and internal to the 
marginal zone macrophages (b).  (B) Is a splenic section following i.v. PBS injection and the inset shows 
FITC auto-fluorescence clearly distinguishable from the labelled bacteria in (A)(iv). (n=4 for 1 hour time 
point, n=2 for 3 hour time point).   220 
Figure 59: In vivo association of knock out C. jejuni with marginal zone macrophages. 
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Figure 59.  Fluorescent  microscopy images of splenic sections 1 hour  following i.v.  administration of 
labelled knock out C. jejuni.  Spleen was stained for marginal zone macrophages (ER-TR9) and B cells 
(B220).  (A) (i) to (iii) show single stains.  (iv) Shows the merged images of a splenic B cell follicle and the 
inset shows knock out C. jejuni in association with marginal zone macrophages (a) and internal to the 
marginal zone macrophages (b).  (n=4 at 1 hour time point, n=2 at 3 hour time point).   221 
Figure 60: Analysis of C. jejuni and macrophage in vivo co-localisation. 
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Figure 60.  The co-localisation of wild type and knock out C. jejuni with metallophilic and marginal zone 
macrophage  populations  was  quantified.    A(i)  representative  follicle.  (A)(ii)  representative  scatter  plot 
analysis. Co-localisation software identified the number of pixels in which CFSE (bacteria) and TRITC 
(macrophage  population)  were  co-localised.  (B)  Metallophilic  macrophages  (i)  Shows  the  total  CFSE 
positive  area  after  1  hour  and  3  hours.    (B)(ii)  Shows  the  percentage  of  C.  jejuni  and  metallophilic 
macrophage co-localisation ((co-localised area/total CFSE area) *100)).  There is no statistical difference 
between wild type and knock out C. jejuni at either time point.  (C) Marginal zone macrophages. (i) Shows 
the total CFSE positive area after 1 hour and 3 hours in the ER-TR9 stained sections. (C) (ii) Shows the 
percentage of C. jejuni and marginal zone macrophage co-localisation ((co-localised area/total CFSE area) 
*100)).  There is no statistical difference between wild type and knock out C. jejuni at either time point.  
Analysed using two way ANOVA with Bonferroni’s posttest.  (n=4 at 1 hour, n=2 at 3 hours. 3 follicles in 
each of 2 sections analysed per mouse).   222 
6.2.11 Quantification of C. jejuni association with macrophage populations 
 
In  order  to  determine  if  there  are  quantitative  differences  in  the  association  of  the 
different  strains  of  C.  jejuni  with  metallophilic  and  marginal  zone  macrophages,  co-
localisation software was used to quantify amount of CFSE (C. jejuni) positive area and 
establish how much it co-localises with the different macrophage populations.   
 
Figure 60 (A) (i) shows a representative follicle and figure 60 (A) (ii) shows the scatter 
plot generated when a follicle is analysed.  The number of pixels positive for both CFSE 
and TRITC are identified in the top right quadrant.  Two sections were taken per spleen 
and three follicles were analysed per section.  Four wild type and four knock out C. jejuni 
injected mice spleens were analysed at 1 hour and two each at 3 hours. 
 
Figure 60 (B) (i) shows the average total CFSE positive area per follicle in the MOMA1 
stained sections at 1 hour and 3 hours post injection, and demonstrates the steep drop off 
in fluorescence over this time period.  This rapid loss of fluorescence demonstrates one of 
the technical challenges in tracking the labelled bacteria.  There is no statistical difference 
between the total CFSE positive area for wild type and knock out injected mice at either 
time point showing that the same quantity of bacteria reached, and were retained in, the 
spleen for both wild type and knock out strains. 
 
Figure  60  (B)  (ii)  shows  the  percentage  of  C.  jejuni  co-localising  with  metallophilic 
macrophages.  This demonstrates that both strains of bacteria localise to this macrophage 
population and that these macrophages are associated with approximately half of all the 
bacteria that are present in the spleen.  There is no statistical difference between the two 
strains of C. jejuni at either time point. 
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Figure 60 (C) (i) shows the average total CFSE positive area per follicle in the ER-TR9 
stained sections at 1 hour and 3 hours post injection.  As expected, the results are similar 
to the MOMA1 stained sections with no statistical difference between the total CFSE 
positive area for wild type and knock out injected mice at either time point. 
 
Figure 60 (C) (ii) shows the percentage of C. jejuni co-localising with marginal zone 
macrophages.  Both C. jejuni strains localise with this macrophage population.  There is 
no  statistical  difference  between  the  two  strains  at  either  time  point.    A  smaller 
percentage  of  the  bacteria  localise  with  marginal  zone  macrophages  than  with  the 
metallophilic  macrophages.    However,  between  the  metallophils  and  marginal  zone 
macrophages it appears that that virtually all of the C. jejuni depositing in the spleen will 
be associated with these populations.     224 
Figure 61: FACS analysis of C. jejuni co-localisation with splenocytes in vivo. 
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Figure  61.  Mice were injected i.v. with 200µl of labelled wild type or knock out bacteria at an OD600 of 
0.6. The mice were sacrificed after 1 hour and a single cell suspension was made of the spleens without 
collagenase.  The cells were briefly fixed with paraformaldahyde then labelled for various cell populations.  
(A) to (F) Representative FACS plots. (A) Lymphocyte gate, (B) F4/80 positive cells (macrophages), (C) 
CD11c positive cells (dendritic cells), (D) GR1 positive cells (granulocytes), (E) MOMA 1 positive cells 
(metallophilic macrophages), (F) CD19 positive cells (B cells). Column (i) isotype control (not available 
for CD19), (ii) antibody marker for lymphocyte population (x axis, all APC), (iii) CFSE (C. jejuni) high in 
PBS injected mouse (negative control) and (iv) CFSE high from C. jejuni injected mouse.   
 
(G) (i) to (v) graphical representation of FACS data comparing association of wild type C. jejuni and knock 
out C. jejuni with different spleen populations  (i) F4/80 positive, C. jejuni positive, (ii) CD11c positive, C. 
jejuni positive, (iii) GR1 positive, C. jejuni positive, (iv) MOMA1 positive, C. jejuni positive and (v) CD19 
positive, C. jejuni positive.  There are no statistically significant differences between wild type and knock 
out populations.  Analysed using 1 way ANOVA with Bonferroni’s multiple comparison test. (n=3 mice for 
each injection, FACS tubes in triplicate).     226 
6.2.12 Analysis  of  C.  jejuni  association  with  different  splenic  cell 
populations using FACS 
 
In order to confirm the immunohistology results and to test a broader range of cell types, 
spleens from injected mice were analysed using Flow Cytometry. 
 
Nine age and sex matched C57BL/6 mice were divided into three groups and injected 
with C. jejuni or PBS as before.  After one hour the spleens were harvested and a single 
cell suspension was made.  The immunohistology results and pilot FACS studies had 
shown that bacteria, or the CFSE fluorescence, disappear rapidly in vivo.  The spleens 
were therefore fixed for 15 minutes in 1% paraformaldahyde and the usual red cell lysis 
step was omitted so that surface associated bacteria would remain intact.  
 
The cell populations studied were F4/80 high macrophages, CD11c high dendritic cells, 
GR1  positive  granulocytes  (using  the  anti-Ly-6G  neutrophil  specific  clone  1A8), 
MOMA1 high metallophilic macrophages and CD19 positive B cells.  Figures 61 (A) to 
(F) show representative FACS plots (detailed in the figure legend) and includes isotype 
controls where available and PBS injected controls. 
 
Figure 61 (G) (i) to (v) shows the percentage of CFSE (C. jejuni) positive cells in each of 
the populations studied.  There is no statistical difference in the association of wild type 
or knock out C. jejuni with any of the cell types studied.     227 
 
6.3  Discussion 
 
These  results  and  the  technical  challenges  that  were  met  in  achieving  them  led  to  a 
number of novel observations.  An ideal method of tracking C. jejuni involves an intrinsic 
fluorophore label which is stable and resistant to bleaching.  Plasmid transformation with 
green fluorescent protein (GFP) is one possible solution with the added advantage that 
the label is stable through multiple rounds of division.  Although such transformations 
have been done, they are technically challenging as commercially available gfp plasmids 
are not suitable for use in C. jejuni because the antibiotic resistance genes and origins of 
replication are not active in this species
323.  In addition, making the C. jejuni chemically 
competent would require prolonged periods of handling which was impossible due to 
safety restrictions which prevented the use of live, genetically modified, pathogens in the 
lab.  The off-site clinical bacteriology lab where the bacteria were cultured does not have 
the facilities to carry out such work. 
 
To overcome these difficulties, the cell tracking fluorophore CFSE was used to label the 
live bacteria which were then heat inactivated to prevent dilution of the dye.  CFSE enters 
bacteria where it is metabolised by esterases resulting in covalent intracellular binding
324.  
This makes it a suitable alternative to GFP as it is stable and is unlikely to alter surface 
epitopes.  CFSE has been used to label and track C. trachomatis, borreliae Sp., H. pylori 
and S. pneumoniae 
325-328.  However, it shows species specific differences in uptake with 
poor labelling of S. aureus and no labelling of E. coli
328.  This is the first time that CFSE 
labelling of C. jejuni is demonstrated and I also show that identical levels of labelling can 
be achieved within related strains of C. jejuni which allows tracking the bacteria while 
comparing individual genetic traits, in this case the expression of ganglioside mimics on 
LOS.  Durable binding of CFSE is important (i.e. the CFSE won’t leak out).  This has 
already been demonstrated using S. pneumoniae
328 and I confirm this quality in C. jejuni 
as there is no evidence of CFSE leakage into culture media.   228 
 
Previous  studies  in  this  thesis  have  demonstrated  reduced  complement  deposition  on 
ganglioside mimicking strains of C. jejuni compared to control strains (chapter 4.2.10).  
These studies looked at formalin fixed bacteria which had been adsorbed onto an ELISA 
plate.    In  this  chapter  I  demonstrate  that  this  difference  in  complement  opsonisation 
affects association of heat inactivated C. jejuni with splenic B cells in vitro.  This study 
suggests that ganglioside mimicry might affect which immune cells the bacteria associate 
with  in  vivo  and  that  ganglioside  mimicry  begins  to  shape  the  interaction  with  the 
immune system at a very early stage, i.e. when bacteria are first exposed to serum.  
 
B cells express complement receptors
329-331 and complement plays a vital role in B cell 
responses  both  directly  through  signalling  and  indirectly  by  controlling  delivery  of 
antigens.  Deficiency of complement components results in defective antibody responses 
332-335.  There are a number of mechanisms by which complement facilitates humoral 
immunity.  The complement receptors CD21/CD35 link antigen to the B cell, they act 
synergistically  with  B  cell  receptor  signalling  and  they  co-aggregate  with  CD19  to 
modulate signalling
336-341.   In addition, MZ B  cells deliver  IgM opsonised antigen to 
follicular dendritic cells in a complement and complement receptor dependent manner
289.  
Although the complexities of an in vivo system make it impossible to predict how small 
differences in opsonisation will affect immunity, in theory, my observations regarding 
opsonisation and cell association suggest the ganglioside mimicking strains should be 
less immunogenic due to less opsonisation.   
   229 
The results presented here show relatively more B cell association of non-ganglioside 
mimicking bacteria and that this is complement dependent.  Results presented earlier 
suggest that natural antibody is the important factor determining levels of complement 
opsonisation (chapter 4.2.12).  How efficiently C. jejuni are opsonised and delivered to 
follicular dendritic cells could be down to variations in an individual’s anti-ganglioside 
natural antibody levels and repertoires.  This is an important area for further work as it 
was not proven definitively that natural antibody was the sole cause of differences in 
complement activation.   
 
Sialoadhesin  has  affinity  for  ganglioside  mimicking  C.  jejuni  (chapter  4.2.1).  
Sialoadhesin mediates phagocytosis of sialylated meningococci
255.  The studies presented 
in  this  chapter  show,  for  the  first  time,  that  ganglioside  mimicking  C.  jejuni  are 
phagocytosed more rapidly than control strains and that this difference can be completely 
inhibited by blocking Sialoadhesin.  The margin of difference was very small, but had 
consistent statistical significance across several repeats.  The small margin might be due 
to the population of macrophages being used in the assay.  The presence of Sialoadhesin 
on bone marrow derived macrophages was demonstrated by immunocytology.  However, 
the cells required an overnight incubation with the MOMA1 antibody and the receptor 
was  not  detectable  on  all  of  the  F4/80  positive  cells.    This  is  not  surprising  as 
Sialoadhesin  is  highly  expressed  by  only  particular  subpopulations  of  macrophages.  
These populations cannot be isolated and studied without altering their physiology as the 
only reliable marker is Sialoadhesin itself.  It is therefore possible that any biological 
significance is not with the conventional macrophage populations but may lie with the 
specialised subpopulations.  If an assay could be designed to study C. jejuni phagocytosis 
by these cells it might show marked differences when ganglioside mimicry is present. 
 
Up until this point a number of in vitro phenomena have been demonstrated which have 
potential  to  alter  trafficking  and  delivery  of  ganglioside  mimicking  C.  jejuni  to  the 
follicle.  Importantly, differences in behaviour between these strains and control strains 
have been by degree rather than absolute.  In order to establish the biological significance   230 
of these observations, ganglioside mimicking and control strains were injected i.v. into 
wild type mice.  It was hypothesised that ganglioside mimicking strains can evade the 
complement cascade and localise to Sialoadhesin positive metallophilic macrophages.  
 
No such study tracking antigen trapping of labelled C. jejuni has been done previously 
and  in  particular  no  studies  have  addressed  trapping  of  a  pathogen  which  expresses 
surface  ligands  for  the  metallophilic  macrophage  receptor,  Sialoadhesin.    The  studies 
presented here show a trend for increased association of ganglioside mimicking C. jejuni 
with  the  metallophil  population  but  this  is  not  statistically  significant.    There  is  no 
statistical difference between strains when association with marginal zone macrophages 
is measured either.  In addition, a number of C. jejuni can be seen in the splenic medulla 
not  associated  with  either  of  these  macrophage  populations.    Although  I  did  not 
investigate  this  further,  this  may  be  association  with  medullary  macrophages.    The 
methods used in this study cannot reliably distinguish between phagocytosis and surface 
association. 
 
Although not the expected outcome, association of both wild type and knock out strains 
with  both  the  metallophilic  and  marginal  zone  populations  of  macrophages  is  an 
important finding, demonstrated for the first time.  With hindsight, these findings are 
unsurprising as marginal zone and metallophilic macrophages both contribute to trapping 
of diverse types of particulate antigen
342-345.  Marginal zone macrophages are reported to 
express  high  levels  of  CR3
342  and  my  own  experiments  show  efficient  complement 
opsonisation of both strains of C. jejuni, albeit with inter-strain differences.  The design 
of these experiments was insufficient to demonstrate the contribution of Sialoadhesin 
binding  because  both  strains  could  be  associating  with  both  marginal  zone  and 
metallophilic macrophage populations via complement receptors.  Another confounding 
factor is that the MOMA1 positive macrophage population overlies and interdigitates 
with the outermost B220 positive MZ B cell population and this might affect the ability 
of co-localisation software to discriminate between metallophil association and B cell 
association.   231 
 
An interesting observation is that the B220 positive MZ B cells are not visible beyond the 
edge of the follicle indicating that the MZ B cells have been mobilised in a manner 
similar to that shown following purified LOS injection (chapter 5.2.1).  Presumably LOS 
is shed from the bacteria during heat inactivation and is present in the injected whole 
bacteria sample.  The rapid kinetics demonstrated here (1 hour versus 18 hours in 5.2.1) 
might be due to the intravenous versus intraperitoneal routes of administration.  
 
Metallophilic  macrophages  are  believed  to  be  less  phagocytic  than  conventional 
macrophages
346,347 while their lymph node counterparts, subcapsular sinus macrophages, 
have been shown to transfer intact antigen on their surface into follicles.  Future work 
might establish if ganglioside mimicking C. jejuni are endocytosed (through Sialoadhesin 
mediated phagocytic activity) while control strains might remain surface associated (and 
available to B cell receptors).  There were a number of occasions where both wild type 
and  knock  out  metallophilic  macrophage  associated  C.  jejuni  appeared  convincingly 
intracellular but confocal microscopy is required to formally establish this.  In addition, 
cell sorting was employed to separate out the CFSE positive cells from a splenocyte 
suspension 1 hour after injection.  Cytospins of the sorted cells, which will reveal the 
location of the bacteria, await analysis.   
 
Functional  outcomes  might  also  prove  important.    The  metallophilic  macrophage 
population has been shown to be an important source of IFN-α/β following i.v. herpes 
simplex virus injection
348.  In my experiments, serum was taken at early and late time 
points, and combined with immunofluoresence labelling of the splenic sections, might yet 
reveal differences between C. jejuni strains at stimulating cytokines in vivo. 
 
The association of C. jejuni with a number of different cell types in vivo was studied 
using FACS analysis.  C. jejuni association with F4/80 positive macrophages, CD11c 
positive dendritic cells, GR1 positive granulocytes, MOMA1 positive macrophages and   232 
CD19 positive B cells was measured and no difference between the C. jejuni strains is 
detected.  These studies were difficult for practical reasons.  The CFSE fluorophore is 
very bright and has a tendency to bleed in to other channels.  Each cell type had to 
therefore be analysed as a double stain with C. jejuni in FL1 and the cell identifying 
antibody in FL4 (i.e. as far apart as possible in the spectrum).  In addition, pilot studies 
showed that C. jejuni fluorescence rapidly disappears (presumably due to being destroyed 
by complement lysis or lysosomal enzymes in phagocytes) and we therefore had to omit 
potentially  important  but  time  consuming  steps  in  the  protocol,  such  as  collagenase 
treatment of the spleens.  As this is used to enhance the release of populations of antigen 
presenting cells it may have affected our results.  Brief paraformaldahyde fixation was 
also used to preserve the bacteria.  Despite these difficulties, the FACS analysis appears 
to confirm the immunohistology results, that is, there is no apparent difference in cell 
association between C. jejuni strains. 
 
In  conclusion,  I  show  in  vitro  differences  between  ganglioside  mimicking  and  non-
mimicking strains in B cell association and macrophage phagocytosis.  These differences 
are due to differential complement activation and receptor binding.  However, in vivo I 
am unable to demonstrate differences in cell association.  This might be due to practical 
considerations,  such  as  the  use  of  heat  inactivated  dead  bacteria,  which  can  only  be 
tracked for a short period of time.  In addition, alternative measures of outcome, such as 
IFN production, might yield positive results.   233 
7  Conclusion 
 
The  experiments  presented  in  this  thesis  were  intended  to  address  the  following 
hypotheses:  
 
1.  LOS derived from a GBS associated strain of C. jejuni is able to bind to cellular 
or humoral ganglioside specific receptors through the ganglioside mimicking core 
sugars. 
2.  Binding  of  LOS  to  these  ganglioside  specific  receptors  alters  the  potency  or 
polarising properties of ganglioside mimicking LOS compared to non-mimicking 
LOS. 
3.  Binding of ganglioside mimics to these ganglioside receptors alters trafficking of 
the C. jejuni within the immune system. 
 
The maintenance of self-tolerance is an active process which is tightly regulated by the 
immune system.  The over-arching hypothesis is that the breaking of tolerance which 
occurs in GBS following exposure to C. jejuni LOS is not an idiopathic event, but is 
driven by both Lipid A-TLR4 stimulation and ganglioside mimic-ganglioside receptor 
interactions.    It  is  these  additional  signals  that  subvert  the  normal  immune  system 
homeostasis, and allow, or promote, the survival and expansion of auto-reactive B cell 
clones. 
 
Studies of GBS are numerous, but until now have focussed largely on the clinical aspects 
of  the  disease  or  the  function  and  fine  specificity  of  the  anti-ganglioside/anti-LOS 
antibodies and their role in neuroinflammation
233,349,350.  In addition, the physiology of C. 
jejuni has been well studied with particular reference to the biochemical synthesis of 
ganglioside mimicking LOS
101,202,203.  The general immunology of C. jejuni infection has 
also  been  the  subject  of  much  interest  due  to  its  role  as  an  important  food  borne   234 
pathogen
76,351,352.  However, very few studies have looked closely at the induction phase 
of GBS, how ganglioside mimicking C. jejuni, specifically, interact with the immune 
system and if the ganglioside mimic is simply a passive target for autoreactive B cell 
receptors (antibodies) or if it influences the evolution of the response via ganglioside 
receptor interactions. 
 
Studying  potential  interactions  between  ganglioside  mimicking  LOS  and  the  immune 
system has become possible in recent years due to the identification and characterisation 
of ganglioside specific receptors such as members of the siglec family
144,240 or galectin 
1
353.    In  addition,  an  understanding  of  the  biochemical  pathways  involved  in  LOS 
synthesis  allowed  the  generation  of  C.  jejuni  control  strains,  isogenic  with  the  GBS 
associated ganglioside mimicking strains, which lack the CSTII enzyme required to add 
sialic acid to the LOS and generate a ganglioside mimic
101.  These provide an excellent 
source of non-ganglioside mimicking control LOS with which to compare the ganglioside 
mimicking LOS in function and potency. 
 
To  the  best  of  my  knowledge  there  is  currently  only  one  study  which  has  reported 
binding  of  a  ganglioside  mimicking  C.  jejuni  strain  and  its  LOS  to  a  lymphocyte 
expressed ganglioside receptor (a GM1/GT1a mimicking strain binding to the NK cell 
receptor, Siglec 7)
148 and no functional outcomes were measured.  I sought to investigate 
LOS and C. jejuni interactions with ganglioside specific receptors and identify functional 
outcomes  dependent  on  these  interactions  and  idiosyncratic  to  ganglioside  mimicking 
strains.  It was hoped that this study would improve our understanding of the immune 
response  to  ganglioside  mimicking  C.  jejuni  and  shed  light  on  the  evolution  of 
autoimmunity in GBS. 
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7.1.1  LOS purification 
 
In order to test my hypothesis I needed highly pure forms of wild type and CSTII knock 
out LOS which were standardised both by primary structure (the actual concentration of 
LOS molecules) and by secondary structure (the size and nature of the spontaneous LOS 
aggregates that form during hot phenol extraction).  The secondary aggregate structures 
are important because they affect the rate at which LPS is taken up by cells
106 and LPS 
stimulated cytokine secretion
232. 
 
Protocols  for  purifying  LOS  are  well  established
316,  however  this  turned  out  to  be  a 
frustratingly difficult task.  The nature of my experiments, comparing two strains of LOS, 
meant that quantification, purity and secondary structures were of paramount importance 
which contrasts with previous studies in which the chemical structure of the LOS was the 
prime concern.  The thiobarbituric acid assay, for example, is commonly used to quantify 
LOS.  However, I demonstrated that ganglioside derived sialic acid interferes with this 
assay making it inappropriate for comparing concentrations of ganglioside mimicking 
and non-mimicking strains.  It is debatable whether the ganglioside effect is sufficient to 
render this assay useless.  However, when dry weight and the thiobarbituric acid assay 
gave contrasting results (as they did) it was decided to work with dry weight as this is the 
standard method of quantifying LOS/LPS in immunological methods. 
 
It was recognised that silver stains and Western blots can only act as surrogate markers 
when trying to determine the nature of the aggregate structures adopted by the LOS in 
aqueous solution.  This level of organic chemistry is beyond the scope of the study and 
beyond the levels of expertise available in the department.  However, the interpretation 
that “dimers” present in the silver stain represented two LOS molecules in a hydrophobic 
embrace,  via  their  extensive  acyl  chains,  is  in  fact  consistent  with  previous,  more 
specialised, work showing that dispersed LPS forms dimers, dependent on hydrophobic 
interactions,  when  in  solution
226,354.    The  nature  of  such  secondary  structures  is  an   236 
important consideration in the light of recent work showing that juxtaposed gangliosides 
form complexes which can dramatically alter the binding properties of antibodies and 
receptors
233,355,356 and this might also be the case for ganglioside mimicking LOS.  More 
importantly, when LOS forming dense precipitates was used in pilot studies it proved 
virtually inactive, or highly toxic, as the cells barely responded.   
 
It is impossible to predict how the micelle structure of LOS will be affected by culture 
conditions.    Clearly  tissue  culture  media  will  contain  cations.    However,  the  LOS  is 
diluted  massively  when  added  to  culture  media  which  presumably  makes  secondary 
structures less likely to form de novo.  However, if they are already present they may not 
be affected.  In addition, the serum added to RPMI media to make complete RPMI will 
contain  numerous  proteins  and  lipoproteins  (such  as  high  density  lipoprotein, 
chylomicrons  and  LPS  binding  protein)  which  are  known  to  have  a  physiological 
capacity to bind LPS and affect its transport, activity and detoxification
357-361.  Provided 
the wild type and knock out strains have comparable micelle structures before addition to 
cultures then any of these immeasurable considerations should be controlled for. 
 
The initial attempts to regulate aggregate structure by dispersal with Triton X detergent 
were stymied by an inability to remove the large detergent molecule using dialysis.  Pilot 
studies using the small planar detergent, sodium cholate (used frequently for this very 
purpose
232) looked more promising.  However, an alternative strategy, which avoided 
adding  divalent  cations,  which  facilitate  aggregate  formation
362,363,  was  used  by  a 
collaborating group who provided us with the aforementioned wild type and CSTII knock 
out C. jejuni and LOS.  The fact that the enzymes remained active can be explained by 
the high concentrations of Ca
2+ and Mg
2+ which associate with LPS during purification 
from bacteria
354.  I showed in my silver stain and Western blot analysis that using this 
technique resulted in only faint dimers and, combined with the visual appearance of the 
solution, interpreted this as meaning the LOS was no longer forming large secondary 
structures.  This purification could have been improved by combining the strategies of 
avoiding cations in the enzyme buffer with using cholate dispersal to produce mono-  237 
disperse LOS which could then be reconstituted into its spontaneous micelle forms under 
controlled buffer conditions to ensure parity between the wild type and knock out strains.   
 
Bacterial  LPS  is  frequently  contaminated  by  other  bacterial  immunostimulators
364-366.  
Glycolipids, such as capsular polysaccharide, represent the most tenacious contaminants 
because of their similar chemical properties to LPS, meaning that they do not necessarily 
partition  differently  during  chemical  extraction  techniques  such  as  hot  phenol.    In 
addition,  it  cannot  be  digested  out  using  enzymes,  and  although  some  protocols  use 
lysozyme for this purpose, I showed it to be inappropriate with my R-form LOS where it 
caused dramatic changes to the secondary LOS structures.  Prolonged ultra-centrifugation 
is included in many protocols possibly to take advantage of differing solubilities between 
LOS and capsular polysaccharide.  However, in my hands this resulted in a significant 
loss of reagent.  It was not included in my collaborators protocol as it was thought to be 
of dubious benefit. 
 
I  established  that  contamination  of  my  LOS  is  minimal  using  silver  stain  for 
protein/nucleic acids (sensitive to picogram quantities), alcian blue staining for capsular 
polysaccharide and spectrophotometry (again for protein and nucleic acids).  A biological 
assay was also employed by stimulating dendritic cells from the LPS hyporesponsive 
C3H/HeJ mouse strain and measuring IL-10 secretion which had been established as a 
cytokine reliably excreted by C. jejuni LOS stimulated C57BL/6 derived dendritic cells.  
 
Establishing purity could have been improved by using a more robust biological assay.  
However, the TLR4
-/- strain of mouse was not available and doing more extensive tests 
using the natural Tlr4 mutated C3H/HeJ strain might only have served to muddy the 
waters  as  this  strain  is  idiosyncratic  in  its  response  to  LPS.    For  example,  priming 
C3H/HeJ derived mononuclear cells with IFN-γ restores LPS responsiveness
317.  There 
has also been a report of these strains being responsive to rough, but not smooth, forms of 
LPS
318.  An alternative and highly sensitive biological method of detecting contamination   238 
is  using  TLR  transfected  reporter  cell  lines  which  are  commercially  available  (for 
example Invivogen’s HEK-Blue
tm C3H/WT murine embryonic fibroblasts).  These cells 
are transfected with a TLR of interest and  a reporter  gene is placed under an NFκB 
inducible  promoter  which  results  in  visible  colour  change  in  the  media  when  the 
transfected  TLR  receptor  is  activated.    This  represents  a  more  definitive  method  of 
excluding  contamination  or  demonstrating  that  the  contamination  is  present  in  equal 
amounts in wild type and knock out purified LOS. 
 
I believe that I achieved a high standard of purity and that the GBS associated and control 
strains of LOS were comparable in purity, concentration and secondary structures.  Any 
subtle differences in concentration, due to the differing molecular weights of the two 
strains, could be best addressed by using titrations of LOS.  I therefore felt it was possible 
to compare these strains of LOS to each other to establish if the ganglioside mimicking 
strain exhibited any unique receptor binding or immune stimulating properties.   
 
7.1.2  Binding of LOS to ganglioside specific receptors 
 
Using  ganglioside  specific  antibodies,  I  demonstrated  that  the  expected  ganglioside 
epitopes were present on LOS.  My first task in confirming my central hypothesis was to 
show  that  ganglioside  specific  receptors  can  also  bind  to  the  ganglioside  mimicking 
epitopes.    As  is  common  in  carbohydrate  immunology,  receptor  specificity  for 
gangliosides is not clear-cut and often defined by relative levels of affinity for closely 
related glycan structures, or indeed complexes of different glycan structures
144,146,356.  A 
number of receptors showing affinity for GD1a and GM1 exist and are expressed on 
several  lineages  of  immune  cells.    It  was  decided  to  focus  on  siglecs  expressed  by 
myeloid  cells  as  these  cells  play  an  important  role  in  B  cell  responses
367,368  and  the 
necessary reagents were kindly provided by a collaborating group. 
   239 
Surprisingly,  I  could  not  demonstrate  binding  of  the  macrophage  expressed  siglec, 
Sialoadhesin, to either native ganglioside or purified LOS under a number of conditions.  
In contrast to the native ganglioside and LOS findings, Sialoadhesin showed clear affinity 
for ganglioside mimicking whole bacteria, demonstrating dose dependent binding.  The 
ganglioside mimic was confirmed as the epitope.  Firstly, the Sialoadhesin did not bind to 
the control CSTII knock out strain which differs only in its lack of ganglioside mimicry 
and  secondly  because  Sialoadhesin  binding  was  lost  when  the  GD1a  epitope  was 
converted to GM1 by neuraminidase treatment.  This experiment demonstrated perfectly 
the difficulties in studying carbohydrate interactions where the context of the antigen (i.e. 
on a whole bacterium) appears to be crucial for binding to occur in this particular system.   
 
It is possible that the lack of binding to LOS is due to the Sialoadhesin-Fc fusion protein 
reagent, which is a truncated form of the mouse molecule comprising the distal three Ig 
domains rather than the entire seventeen Ig domain molecule.  This may reduce spacing 
of the Sialoadhesin molecule leading to a requirement for the target GD1a to be closely 
packed, which might be the case on the bacteria surface but not with native GD1a in an 
ELISA.  The binding of Sialoadhesin to C. jejuni could have been further characterised 
and the specificity proven definitively by the use of the SnR97A mutant Sialoadhesin 
reagent which has an amino acid substitution in the sialic acid binding pocket which 
obliterates sialic acid binding
369.  This reagent was not available for my experiments. 
 
Binding of Sialoadhesin to ganglioside mimicking C. jejuni is an interesting finding for a 
number of reasons.  GBS is an antibody mediated autoimmune disease
370 in which the 
target  is  a  carbohydrate
371-373  TI  antigen.    The  antibody  isotypes  commonly,  but  not 
exclusively, associated with GBS are the Th1 associated isotypes, IgG1 and IgG3
53,54,374, 
which is atypical for a carbohydrate antigen as these tend to induce antibodies of the 
IgG2 subclass in humans
58,59.  The macrophage populations which constitutively express 
high levels of Sialoadhesin are intimately involved in a number of facets of antibody 
responses  and  antigen  retention  by  these  macrophages  greatly  enhances  B  cell 
activation
368.   240 
 
Lymph node, Sialoadhesin positive, subcapsular sinus macrophages acquire particulate 
antigen in the sinus and transport it to B cells in the medullary region
375 where it is taken 
up by B cells and transported throughout the follicle
376,377.  In addition, the macrophages 
appear  to  discriminate  between  antigens.    Although  subcapsular  sinus  macrophages 
display a lower phagocytic capacity compared to medullary macrophages
378 and appear 
to transport antigen, intact, on their surface to the B cells, degraded viral particles have 
been demonstrated within the macrophages
375.  It is not known what discriminates the 
different  antigens  to  their  differing  fates  but  it  has  been  suggested  that  it  may  be  a 
function  of  different  receptor  interactions
368.    For  example,  lectin,  complement  or 
antibody  Fc receptor binding might determine  whether it is endocytosed or delivered 
intact on the surface.  As Sialoadhesin is a receptor expressed at high levels by these 
cells, and I have demonstrated Sialoadhesin binding to ganglioside mimicking C. jejuni, 
the  fact  that  Sialoadhesin  has  been  shown  to  enhance  phagocytosis  on  conventional 
macrophages
255  might  have  important  implications  for  how  GD1a  mimicking,  GBS 
associated strains, are presented to B cells. 
 
Sialoadhesin is also constitutively expressed by splenic metallophilic macrophages which 
in mice delineate the marginal zone of the follicles
347 and in humans are present in the 
perifollicular zone
379.  This places them in an ideal location to interact with MZ B cells 
which are a candidate population for the source of anti-ganglioside antibodies due to their 
participation in responses to T independent antigens and their tendency to harbour auto-
reactive specificities.  Depletion of the metallophilic macrophage population results in a 
marked decrease in antibody responses to T dependent antigens, although responses to T 
independent  antigens  remain  intact  but  with  a  notable  increased  bias  towards  Th2 
isotypes
380.  This can be explained by the findings that metallophils are an important 
source of Type 1 interferons
348 and IFN-γ
380 which are believed to drive antibody class 
switching  towards  Th1  isotypes
381-384,  such  as  IgG2a  in  mice  (the  equivalent  of  the 
pathogenic human isotypes in GBS). 
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My  finding  of  Sialoadhesin  binding  to  ganglioside  mimicking C.  jejuni  confirms  my 
initial hypothesis that the ganglioside mimic can engage endogenous receptors.  It also 
fits well with the over-arching hypothesis that such binding could significantly alter the 
antibody response and subvert tolerance.  My findings specifically link a GBS associated 
strain of C. jejuni with a receptor expressed by a specialised population of macrophages 
which provides antigen to B cells, enhances antibody responses and provides cytokines 
which promote Th1 antibody isotypes.  The specific function of Sialoadhesin in these 
cells is not known.  As GBS is a rare event, it may be that Sialoadhesin functions to 
enhance tolerance by facilitating phagocytosis and promoting degradation to prevent this 
antigen  reaching  B  cells.    Alternatively,  it  may  enhance  or  polarise  immunity  by 
delivering C. jejuni to endosomes where endosomal pathogen recognition receptors, such 
as TLR7 or TLR9, night signal to enhance interferon secretion, triggering B cell isotype 
switching.  Interestingly, even in the absence of GBS, infection with C. jejuni expressing 
sialylated LOS is associated with more severe enteric disease
385. 
 
An  additional  ganglioside  specific  receptor,  Siglec  F,  was  shown  to  bind  native 
gangliosides, ganglioside mimicking LOS and ganglioside mimicking C. jejuni, the latter 
two in a dose dependent manner.  This again confirms my initial hypothesis.  The closest 
human equivalent to Siglec F is Siglec 8 which is expressed on eosinophils and mast 
cells
146.    Cross  linking  of  Siglec  8  causes  apoptosis  of  eosinophils  and  counteracts 
stimulatory signals in mast cells
146. 
 
Mast cells and eosinophils lie at the front line of the immune system and are ideally 
placed to  respond  early and drive adaptive responses to mucosal pathogens.  Human 
eosinophils  are  considered  initiators  of  Th2  responses.    However,  eosinophils 
constitutively  store  an  array  of  pre-formed  cytokines  associated  with  Th1,  Th2  and 
immunoregulatory functions, including IL-4, IL-13, IL-6, IL-10, IL-12, IFN-γ and TNF-
α
386.  In addition, there is a differential release of these cytokines in response to different 
stimuli
386.    The  presence  of  large  quantities  of  pre-synthesised  cytokines  allows 
eosinophils to play a crucial role at the initiation of immune responses and an important   242 
area of future research is to determine what effect Siglec F (or Siglec 8) signalling has 
both  on  the  differential  cytokine  release  and  on  subsequent  antigen  presentation  by 
eosinophils
387. 
 
In addition to exploring cellular ganglioside receptors I also studied interactions with the 
humoral immune system, specifically looking at fH binding, complement activation and 
natural antibody binding.  Factor H has been reported to bind to sialic acid on cells and 
pathogenic bacteria where it was thought to inhibit complement deposition
241,242.  I could 
not demonstrate this with ganglioside mimicking C. jejuni.  However, subsequent studies 
have  shown  sialic  acid  to  be  neither  necessary  nor  sufficient  for  fH  binding  to 
bacteria
242,245,271 so it is likely that my negative results are accurate. 
 
All of my strains of C. jejuni were opsonised by complement.  However, I showed that 
complement activates less efficiently on ganglioside mimicking C. jejuni than control 
strains.  I believe that this is due to lower levels of natural antibodies in naïve human 
serum specific for the ganglioside mimicking LOS of the GBS associated strains.  My 
experiments stopped short of showing a causative link between natural antibody levels 
and  complement  deposition,  and  these  studies  could  have  been  improved  by  using 
purified  human  complement  to  establish  if  the  differences  were  only  present  when 
antibody was present.  It has been shown previously that C. jejuni are very sensitive to 
the  bactericidal  activity  of  human  serum,  in  a  complement  and  antibody  dependent 
manner, when compared to Campylobacter fetus.  It is therefore no surprise that C. fetus 
is frequently isolated from the bloodstream, whereas C. jejuni is very rarely isolated from 
the bloodstream
388.  Additional studies have also shown that sialylated strains of C. jejuni 
are more resistant to complement mediated killing than non-sialylated strains
389, which is 
in keeping with my findings of less complement activation on ganglioside mimicking 
strains.  Sialylation might be a strategy adopted by certain strains of C. jejuni to enhance 
their survival by compensating for their inherent complement sensitivity. 
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Complement and natural IgM function to clear self antigen and senescent cells from the 
circulation  and  complement  deficiency  is  related  to  autoimmunity  through  defective 
clearance  of  self-antigens
390,391,392.    Complement  resistance  in  ganglioside  mimicking 
strains could be considered analogous to an acquired complement deficiency, resulting in 
persistence of a self-antigen expressed in the context of an immunostimulatory molecule 
i.e. Lipid A.  Natural IgM can enhance or inhibit subsequent IgG responses and does so 
in a complement dependent manner which involves antigen trapping and delivery to B 
cells
393-395,396-398.  The role of natural IgM and complement in enhancing class switching 
to IgG is poorly understood, but is likely to be important in autoimmunity as switching 
from IgM to IgG correlates with the onset of autoimmune disease
65.  IgM enhances IgG 
responses.  Conversely, low levels or absence of IgM results in enhanced levels of auto-
reactive IgG and increased severity of autoimmune disease in a number of mouse models 
395,399,400.  How natural IgM protects against IgG mediated autoimmunity while enhancing 
IgG responses is unclear and suggested mechanisms include facilitating rapid clearance 
of self  antigen in collaboration with complement, protecting against chronic bacterial 
infections,  delivering  antigen  to  immature  B  cells  to  enhance  central  tolerance  and 
antigen  masking  of  self  epitopes.    Natural  antibody  and  its  collaboration  with 
complement may be important in C. jejuni associated GBS where individual variations in 
natural antibodies could alter the outcome of infection. 
 
7.1.3  Effect of ganglioside mimicry on LOS potency 
 
By demonstrating in vitro binding of cellular receptors to LOS and whole C. jejuni I 
confirmed my first hypothesis.  Next I decided to test my second hypothesis and establish 
if this ability to bind ganglioside specific receptors affects LOS potency.  Many studies of 
siglec function have relied on antibody cross-linking of receptors or the use of knock out 
animals
146.    To  the  best  of  my  knowledge  this  is  the  first  time  a  study  has  tried  to 
demonstrate functional activity of siglecs ligands using a ganglioside mimicking LOS.  
The relative strength of each signal (TLR4 v siglec) and how they might interact was 
unknown and therefore I looked at a broad range of markers in a variety of cell types,   244 
including B cell proliferation, CD138 positive cell differentiation, antibody secretion and 
cytokine secretion.  The cytokines chosen were broad markers of immune activity: TNF-
α as an acute phase inflammatory cytokine
278,  IL-10 as an inhibitory cytokine
322 and IL-
12 as a pro-inflammatory, Th1 polarising, cytokine
280. 
 
Within  the  parameters  measured,  my  studies  failed  to  demonstrate  any  difference  in 
potency  between  ganglioside  mimicking  and  non-mimicking  strains  of  LOS  at 
stimulating  B  cells.    Although  I  was  measuring  very  general  aspects  of  potency,  the 
greater capacity of E. coli LPS at stimulating B cell proliferation and CD138 positive cell 
differentiation  was  very  clear,  which  suggests  my  techniques  would  have  detected 
differences associated with ganglioside mimicry, had they existed.  In fact, the assays 
were  sensitive  enough  to  show  inter-strain  differences  in  immunoglobulin  production 
between GB2 and GB19 derived C. jejuni strains, while the wild type and knock out 
variants within these strains gave remarkably similar results. 
 
Very  few studies have looked at direct stimulation of B cells with C. jejuni LOS so 
virtually all of my findings, from its ability to cause proliferation to its ability to mobilise 
MZ  B  cells  in  vivo,  are  new  to  the  field.    The  discovery  that  its  properties  are 
qualitatively  the  same  as  E.  coli  LPS  is  not  an  unexpected  finding,  although  it  is 
surprising how low the potency of C. jejuni LOS is.  Low potency had been reported 
before when macrophage stimulation was measured
316.  However, when the size of LOS 
is considered (~4 kDa) relative to E. coli LPS (anywhere up to 100 kDa), the C. jejuni 
LOS molarity may have been as much as twenty times greater, and yet was substantially 
less potent.  It may be that mice are very insensitive to C. jejuni LOS, as exposure tends 
to lead to asymptomatic colonisation and clearance rather than the inflammatory response 
seen in humans
401. 
 
Myeloid  cells  express  a  wide  array  of  ganglioside  receptors  and  it  was  decided  to 
stimulate dendritic cells and macrophages with C. jejuni LOS or whole, killed, bacteria.    245 
A number of related studies have been done looking at live C. jejuni and LOS stimulation 
of human dendritic cells and macrophages, although these did not involve comparisons of 
ganglioside mimicking and non-mimicking strains
92,352,402,403.  These studies concluded 
that  LOS  and  whole  C.  jejuni  stimulation  of  dendritic  cells  induce  considerable 
production of IL-10, IL-12 and TNF-α as well as upregulation of costimulatory molecules 
such  as  CD40.    They  also  concluded  that  LOS  was  a  key  contributor  to  cytokine 
production  and  that  high  levels  of  IL-12  production  with  lower  IL-10  production 
suggested a Th1 polarising role.  Monocyte stimulation gave similar results. 
 
My studies on mouse dendritic cells found that LOS stimulation resulted in generally 
comparable IL-10 and IL-12 levels, although IL-12 was greater if whole bacteria were 
used.  My dendritic cells produced large quantities of TNF-α in response to LOS, while 
the  macrophages  were  less  responsive.    LOS  and  whole  bacteria  caused  CD40 
upregulation by dendritic cells and macrophages, respectively.  Therefore, the general 
properties of whole C. jejuni and LOS were comparable to previous work.  However, the 
IL-12 and TNF-α responses I achieved were quite variable and frequently had poor dose 
response curves.  This makes it difficult to draw firm conclusions about the potency of 
wild type and knock out strains in inducing these cytokines.  In contrast to IL-12 and 
TNF-α, IL-10 was a very reliable marker of potency, with levels which were reproducible 
and gave consistently good dose response curves. 
 
A  significant  difference  was  noted  in  dendritic  cell  IL-10  production  in  response  to 
ganglioside  mimicking  and  non-mimicking  LOS.    The  ganglioside  mimicking  strain 
induced half as much IL-10 as the non-mimicking strain, but this was only apparent at 
high concentrations of LOS. This difference was most marked with GB11 LOS but was 
also  present  with  GB2  and  GB19  strains.    A  number  of  possible  mechanisms  were 
explored to try and explain this difference.  Firstly, exogenous gangliosides were added 
to the knock out strains to establish if this was a “ganglioside effect”.  This strategy did 
not reproduce the reduced IL-10.  Secondly, a panel of siglec blocking antibodies was 
used to block potential receptor signalling.  Again, this did not reproduce the reduced IL-  246 
10.  Possible differences in cell death were also tested but this showed no statistical 
difference between strains.  In addition, whole bacteria were used to stimulate dendritic 
cells, and the difference in IL-10 production between wild type and knock out strains was 
not seen. 
 
In my final experiment designed to try and understand these results, dendritic cells from 
the LPS hyporesponsive C3H/HeJ mouse strain and from a TLR2
-/- mouse strain were 
used to establish if the difference in IL-10 could be accounted for by contamination by a 
TLR2 ligand such as capsular polysaccharide.  The results of this assay were conflicting 
as, in the absence of TLR2 signalling, there was no difference in IL-10 production, while 
in the absence of TLR4 signalling (C3H/HeJ cells) no IL-10 was produced to either LOS 
strain.  The former results indicated that a TLR2 agonist mediated the difference in IL-10 
production  while  the  latter  result  indicated  that  no  TLR2  agonists  were  present.  
However,  a  review  of  the  literature  reveals  conflicting  reports  on  whether  TLR2 
signalling alone stimulates IL-10 from dendritic cells
319,320,404 which calls into question 
the usefulness of the C3H/HeJ results.  The one study which reports no IL-10 from TLR2 
stimulated dendritic cells has a protocol which is most relevant to my study, however 
studies reporting IL-10 following TLR2 stimulation are more numerous.  
 
In  conclusion,  this  is  an  interesting  and  promising  observation,  but  falls  short  of 
confirming the second part of my hypothesis, that is, that binding to ganglioside receptors 
will lead to altered signalling and responses by immune cells.  Further work needs to be 
done to confirm that no contamination is present and this is a relatively simple set of 
experiments,  for  example,  looking  at  TNF-α  secretion  from  C3H/HeJ  dendritic  cells 
stimulated with wild type and knock out LOS. 
 
If these results are taken at face value, they suggest that ganglioside mimicry mediates an 
inhibitory signal, by undetermined means, which is relatively specific for downregulating 
dendritic cell IL-10 (there was no difference in CD40 upregulation and TNF-α and IL-12   247 
levels  were  highly  variable).    Such  a  scenario  would  fit  well  with  my  over-arching 
hypothesis,  that  altered  signalling  mediated  by  the  ganglioside  mimic  can  subvert 
tolerance.  Dendritic cells are the most important antigen presenting cells in the immune 
system as they are capable of driving primary responses and of instructing the adaptive 
immune response
405-408.  Several bacterial products, including LPS, induce dendritic cell 
maturation
409.  Dendritic cells can skew T cell responses towards Th1 or Th2
410 and, 
through downstream effects, control the isotypes of antibodies in the ensuing humoral 
response  (for  example,  eliciting  IgG2a  or  IgG1)
411.    Dendritic  cells  can  also  directly 
activate naïve and memory B cells, are able to induce plasma cell differentiation and can 
trigger antibody isotype class switching in an IL-10 dependent manner
412.  Dendritic cells 
exhibit plasticity in function and Th1 polarising dendritic cells can be converted to Th2 
polarising cells when treated with IL-10
412.   
 
IL-10  is  model  example  of  an  anti-inflammatory  and  tolerogenic  cytokine.    Through 
inhibition  of  accessory  cells
413  (e.g.  macrophages),  IL-10  can  inhibit  inflammatory 
cytokine production by T cells and NK cells
414,415, and it inhibits both the Th1 and Th2 
arms of the immune response.  IL-10
-/- mice develop inflammatory bowel disease as well 
as other inflammatory conditions
416-418 and, interestingly, they are the only mouse model 
of inflammatory C. jejuni enteritis as normal strains are colonised asymptomatically
419.  
The main biological action of IL-10 appears to be towards macrophages and dendritic 
cells where it inhibits antigen presentation, secretion of immune polarising cytokines and 
secretion of general inflammatory cytokines, such as TNF-α
322  
 
A  situation  in  which  ganglioside  mimicry  inhibits  production  of  this  important  anti-
inflammatory cytokine from the primary cells driving an immune response could lead to 
a micro-environment where there is greater inflammation, greater antigen presentation 
and higher levels of co-stimulator molecule expression.  A relative lack of IL-10 could 
lead to imbalances in the response and under such circumstances it is easy to imagine that 
auto-reactive  B  cell  clones  might  be  more  likely  to  escape  deletion  and  progress  to 
antibody secreting plasma cells.   248 
 
7.1.4  Uptake of ganglioside mimicking C. jejuni 
 
My  final  hypothesis  was  that  ganglioside  mimicking  strains  of  C.  jejuni  will  show 
different  immune  trafficking  than  non-ganglioside  mimicking  strains.    Having 
demonstrated  differences  in  complement  opsonisation  and  cellular  receptor  binding  I 
conducted a number of in vitro studies to establish how this affected interactions with 
cells. 
 
These  studies  required  the  development  of  a  means  of  tracking  my  C.  jejuni.  
Transformation of C. jejuni with gfp plasmid is difficult and I did not have the facilities 
to handle the live pathogens for prolonged periods.  Instead I developed a protocol to 
durably label the bacteria with the cell tracking fluorophore CFSE.  This has been used 
before for a number of bacterial species, but not C. jejuni
325-328.  In contrast to these 
previous studies, I wanted to compare two isogenic strains of bacteria and a protocol was 
developed that gave consistent levels of fluorescence regardless of the sialylation status. 
 
Following  on  from  my  earlier  complement  opsonisation  studies,  I  was  able  to 
demonstrate differences between wild type and knock out strains in their association with 
B cells, in vitro, following opsonisation with normal mouse serum.  These experiments 
showed higher levels of B cell association of a non-ganglioside mimicking strain and 
were dependent on the presence of active complement.  This confirmed my earlier results 
and  supports  my  third  hypothesis,  that  differences  in  humoral  and  cellular  receptor 
interaction, which are dependent on ganglioside mimicry, will affect trafficking.  It was 
possible to follow B cells within a mixed splenocyte population because they form a 
clearly delineated population when labelled for CD19.  I expect that these differences are 
the same for other complement receptor bearing populations, such as macrophages and 
dendritic cells.  However these proved difficult populations to clearly delineate because 
their markers, F4/80, CD11b and CD11c, show a spectrum in levels of expression, the   249 
cells themselves become autofluorescent and the CFSE fluorescence bleeds into other 
channels in the FACS analysis. 
 
Opsonisation by complement is important in enhancing antibody responses partly through 
increased  delivery  of  antigen  to  antigen  presenting  cells  and  B  cells
262,420.    I  would 
therefore predict that ganglioside mimicking strains induce weaker humoral responses, 
and this might be the case in the majority of people exposed to them.  Alternatively, these 
results  suggest  that  non-ganglioside  mimicking  strains  will  be  cleared  more  readily 
through  complement-receptor-mediated  uptake  which  might  ultimately  lead  to  less 
overall inflammation due to less chronic antigen stimulation.  Complement deficiency is 
strongly  associated  with  autoimmunity
390,391,  and  low  levels  of  opsonisation,  due  to 
ganglioside mimicry and low levels of natural antibody, might result in chronic antigen 
exposure. 
 
In order to expand on my assays showing Sialoadhesin binding to C. jejuni I decided to 
test if this enhanced in vitro phagocytosis as has been shown with Sialoadhesin binding 
strains of meningicocci
255.  My experiments showed early enhanced phagocytosis of a 
ganglioside mimicking C. jejuni strain compared to a non-ganglioside mimicking strain 
by  bone  marrow  derived  macrophages.    Sialoadhesin  was  shown  to  be  the  receptor 
mediating this by the use of blocking antibodies to reduce phagocytosis of the wild type 
strain to the same rate as the knock out.  Although the difference in phagocytosis was 
small, it remained significant in seven separate repeats (three in progressive time point 
experiments, and four at a single time point).  In addition, the small difference between 
strains can be accounted for by the fact that bone marrow derived macrophages express 
low levels of Sialoadhesin
209,248 and this experiment could have been improved by first 
priming the cells with interferons to upregulate Sialoadhesin
250. 
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These in vitro observations again support my third hypothesis that ganglioside mimicry 
affects trafficking and there are a number of ways it can be related to my over-arching 
hypothesis about subverting tolerance.  The populations of macrophages with the highest 
expression of Sialoadhesin are the metallophilic marginal zone macrophages and the sub-
capsular  sinus  lymph  node  macrophages.    They  have  been  shown  to  be  intimately 
involved in B cell activation and antibody production.  Metallophilic macrophages are a 
major source of type I and type II interferons.  These promote antibody isotype class 
switching to the Th1 isotypes (IgG1 and IgG3), which is one of the idiosyncratic features 
of the anti-ganglioside/LOS carbohydrate response often associated with GBS
53,54.  TLR4 
activation from inside endosomes (as oppose to the plasma membrane) triggers selective 
signalling through the TRIF/TRAM pathway which drives type I interferon production
421.  
Therefore efficient phagocytosis of ganglioside mimicking strains into these macrophage 
populations  (which  normally  have  low  phagocytic  activity)  might  enhance  these 
cytokines  within  the  B  cell  micro-environment.    In  contrast  to  the  anti-ganglioside 
mimicking  LOS  response  seen  in  GBS  patients,  anti-LOS  antibodies  to  non-GBS 
associated  C.  jejuni  enteritis  strains  are  predominantly  IgG2
60,  as  would  be  expected 
towards a glycolipid antigen.   
 
The Th1 isotypes (IgG1 and IgG3) are the most efficient at fixing complement
64, which is 
thought  to  be  a  key  part  of  GBS  pathogenesis
350.    They  are  also  more  commonly 
associated with viral infections
422,423.  It is possible that ganglioside mimicking C. jejuni 
induces a more viral-like, interferon driven, response than non-mimicking strains because 
of the way they are sensed by the immune system.  The function of Sialoadhesin remains 
obscure, but one possible explanation for why the immune system expresses a receptor 
for a self molecule is because enveloped virus particles carry gangliosides with them 
when they bud from the host plasma membrane
424 and Sialoadhesin may have evolved to 
detect these.  Atypical isotype switching is not loss of tolerance per se (as it still requires 
an  antigen  specific  component),  and  clearly  cannot  be  the  whole  story,  but  class 
switching has been shown to be a crucial event in murine models of autoimmunty
65. 
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The final test of whether ganglioside mimicry affects trafficking was in vivo inoculation 
of mice.  It was hoped that the ganglioside mimicking strains would engage Sialoadhesin 
on the metallophilic macrophages where I would be able to co-localise them using the 
metallophilic macrophage specific antibody MOMA1.  The non-mimicking strains were 
expected to be rapidly removed by the reticuloendothelial system.  Because the bacteria 
were  rapidly  destroyed  or  lost  fluorescence,  I  was restricted  to  looking  at  early  time 
points of 1 and 3 hours post-injection.   
 
Analysis  of  splenic  sections  using  co-localisation  software  revealed  no  difference 
between my strains in localisation to either metallophilic or marginal zone macrophages 
and both strains were found in association with both cell types.  In addition, I used FACS 
analysis to study C. jejuni association with a number of cell types and was unable to 
demonstrate any difference between strains.  This result was disappointing in the light of 
the positive results in my in vitro experiments leading up to the in vivo test.  However, 
with hindsight, this result could have been predicted given that my complement binding 
tests  had  shown  both  strains  to  be  opsonised  efficiently,  albeit  it  with  inter-strain 
differences in levels.  It is likely that both the ganglioside mimicking and non-mimicking 
strains  were  associating  with  both  macrophage  populations  via  complement  mediated 
interactions making it impossible to determine a role for Sialoadhesin interactions.   
 
A  number  of  studies  have  looked  at  antigen  localisation  in  subcapsular  sinus 
macrophages, metallophilic macrophages and marginal zone macrophages.  There appear 
to be subtle but distinct differences between these populations which require complex 
investigations  to  tease  out.    For  example,  while  marginal  zone  macrophages  and 
subcapsular  sinus  macrophages  both  capture  vesicular  stomatitis  virus  (VSV),  the 
marginal zone macrophages require IgM and C3 to achieve this.  These are not required 
by subcapsular sinus macrophages
375 suggesting other receptors are involved.  To the best 
of my knowledge this is the first time a ganglioside mimicking bacterial pathogen has 
been used to study these cells.  More complex studies, eliminating complement using   252 
cobra venom factor for example, might have shown the ganglioside mimicking bacteria 
localising to the metallophilic but not marginal zone population. 
 
These  results  do  not  conclusively  disprove  my  third  hypothesis  or  the  over-arching 
hypothesis.  For example, the bacteria used were heat inactivated using a harsh protocol 
(the  same  one  used  for  LOS  extraction)  which  will  have  left  them  vulnerable  to 
complement binding and lysis, which might have reduced differences between the strains 
and reduced the time window to analyse the spleens.  An improvement would be to use 
an  alternative  method  of  inactivation  such  as  U.V  cross  linking  or  sodium  azide 
poisoning.    As  the  initial  experiments  were  very  promising,  it  would  be  worthwhile 
transforming the bacteria to fluoresce, preferably using separate colours for each strain to 
allow simultaneous inoculation with live bacteria.  In addition, I was hoping different 
receptor  binding  would  have  functional  outcomes  in  terms  of  cytokine  production.  
Serum was retained from these experiments to test this hypothesis.  
 
In conclusion, the experiments presented in this thesis have successfully expanded our 
knowledge  of  how  C.  jejuni  in  general,  and  GBS  associated  ganglioside  mimicking 
strains specifically, interact with the mammalian immune system at a number of levels.  I 
have demonstrated basic properties of C. jejuni LOS which had not been formally shown 
before, for example B cell proliferation, antibody secretion and mobilisation of MZ B 
cells in vivo.   
 
The experiments successfully addressed my three core hypotheses. I conclusively showed 
that the ganglioside mimic in LOS is able to interact with cellular receptors in vitro, and 
also that the mimic affects the interaction of the bacteria with innate humoral components 
of the immune system.  While I did not conclusively show that the ganglioside mimic 
affected potency, I have gathered results which strongly support this hypothesis.  Finally, 
I presented conclusive in vitro evidence that ganglioside mimicry affects trafficking of 
the bacteria.  I was unable to show in vivo effects of ganglioside mimicry on bacterial   253 
trafficking  although  I  identified  several  technical  reasons  that  might  account  for  the 
discrepancy between the in vitro and in vivo results.  My over-arching hypothesis is that 
additional signalling /interactions of the ganglioside mimicking epitopes on LOS might 
contribute  to  the  breaking  of  tolerance  in  GBS.    The  results  presented  here  neither 
confirm nor refute this, although they provide a foundation for the hypothesis, in that 
such interactions have now been shown to exist.  Like much research, this ends with 
more questions than it started with, and the project can be carried forward addressing the 
precise effects of the ganglioside mimicking LOS receptor interactions. 
 
7.1.5  Future experiments 
 
Many of the findings in this project merit further investigation.  Firstly, the effects of 
ganglioside-mimicking C. jejuni binding to Siglec F were not explored.  This binding 
may  result  in  apoptosis  of  eosinophils  or  basophils,  and/or  alterations  of  cytokine 
secretion.  These could be important events in GBS.  Secondly, although Sialoadhesin 
mediated phagocytosis was demonstrated, I did not measure many functional outcomes in 
vivo or in vitro.  For example, it would be of interest to establish if IFN production was 
affected by the route of phagocytosis in metallophilic macrophages, or if the ganglioside 
mimicking  and  non-mimicking  C.  jejuni  strains  are  trafficked  into  the  same  antigen 
processing pathways.  Thirdly, the role of natural antibodies in determining the epitopes 
targeted by the adaptive immune response should also be explored further, for example 
by immunising mice with ganglioside antigens in the presence of blocking antibodies of 
known epitope specificity.  Such studies could not only shed light on the evolution of 
GBS but also open potential avenues for therapeutic interventions.   
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Appendix 1 – Buffers and media 
 
Complete RPMI (cRPMI) 
 
RPMI 1640 media (Gibco, UK) with 10% Foetal Bovine Serum (FBS) (Sigma, UK), 
100µg/ml Penicillin, 100µg/ml Streptomycin and 2mM L-glutamine (all Gibco, UK). 
 
Supplemented cRPMI 
 
RPMI  1640  media  with  10%  Foetal  Bovine  Serum,  100µg/ml  Penicillin,  100µg/ml 
Streptomycin and 2mM L-glutamine supplemented with 500µl 2-mercaptoethanol and 
5ml non-essential amino acids (both Gibco, UK) per 500ml of media. 
  
FACS Buffer 
 
3%  Bovine  Serum  Albumin  (BSA)  in  PBS  (phosphate  buffered  saline)  with  0.05% 
sodium azide (NaN3). 
 
Complete RPMI for phagocytosis experiments 
 
RPMI  1640  media  (Gibco,  UK)  with  10%  Ultra-low  IgG  Foetal  Bovine  Serum 
(Invitrogen, UK), 100µg/ml Penicillin, 100µg/ml Streptomycin and 2mM L-glutamine 
(all Gibco, UK). 
0.1 M Sodium Carbonate buffer for Ig ELISAs  
 
8.40 g NaHCO3, 3.56 g Na2CO3; dilute to 1.0 L in distilled water; pH to 9.5.    281 
Appendix 2 – Structure and expression of siglecs 
 
Human siglecs 
Sialoadhesin
(Siglec 1, CD169)
Siglec 2
(CD22)
Siglec 4
(MAG)
Siglec 15
Siglec 3
(CD33)
Siglec 6
(CD327)
Siglec 5
(CD170)
Siglec 7
(CD328)
Siglec 8 Siglec 10 Siglec 9
(CD329)
Siglec 11 Siglec 14
Conserved Siglecs
CD33 related Siglecs
V-set Ig domain
Sialic-acid binding
C2-set Ig
domain
ITIM
ITIM-like
GRB2 binding
motif
FYN kinase
Phosophorylation site
DAP12
Mac
B
Oligo D
Schw
Mac,
DC
MyP
Mo
N, 
Mo
(B)
Troph
(B)
NK
(Mo)
Eo
(Ba)
Mo, N,
cDC
(NK) B
(Mo, 
Eo)
Mac Gran,
Mo
DAP12
 
Human siglecs and their cellular expression 
144,425,426.  Siglecs are type 1 membrane proteins with an amino-
terminal V-set immunoglobulin domain that mediates sialic acid recognition and varying numbers of C2-set 
immunoglobulin domains.  Siglecs can be divided into two groups – those which show conservation 
between species (Sialoadhesin, CD22, MAG and Siglec 15) and those which differ between species (the 
CD33 related siglecs).  Cell expression has been determined by antibodies (brackets indicate low levels of 
expression).  B–B cells, Mac–macrophages, Mo-monocytes, Oligo-oligodendrocytes, Schw-schwann cells, 
DC-dendritic cells, MyP-myeloid progenitors, N-neutrophils, Troph-trophoblasts, NK-natural killer cells, 
Eo-eosinophils, Ba-basophils, cDC-conventional dendritic cells, Gran-granulocytes, ITIM-immunoreceptor 
tyrosine-based inhibitory motif, GRB2-growth-factor-receptor-bound protein 2.  DAP12 interacts with 
siglec 14 and 15 through charged residues.  Figure adapted with permission 
144.   282 
Murine siglecs 
Sialoadhesin
(Siglec 1, CD169)
Siglec 2
(CD22)
Siglec 4
(MAG)
Siglec 15
Siglec 3
(CD33)
Siglec E Siglec G Siglec H
Conserved Siglecs
CD33 related Siglecs
V-set Ig domain
Sialic-acid binding
C2-set Ig
domain
ITIM
ITIM-like
GRB2 binding
motif
FYN kinase
Phosophorylation site
DAP12
Mac
B
Oligo D
Schw
Mac,
DC
N
Siglec F
Eo N, 
Mo
cDC B
pDC
(Mac)
DAP12
 
Murine siglecs and their cellular expression
144,425,426 .  Cell expression has been determined by antibodies 
(brackets indicate low levels of expression).  B–B cells, Mac–macrophages, Mo-monocytes, Oligo-
oligodendrocytes, Schw-schwann cells, DC-dendritic cells, N-neutrophils, Eo-eosinophils, cDC-
conventional dendritic cells, ITIM-immunoreceptor tyrosine-based inhibitory motif, GRB2-growth-factor-
receptor-bound protein 2.  DAP12 interacts with siglec H and 15 through charged residues.  Figure adapted 
with permission 
144.   283 
 
Appendix 3 – Binding specificities of siglecs 
Sialic Acid Configurations 
Human                                                            Murine
0 + 0 0 +++ 0 + ND
+++ ++ 0 0 0 +++ ++ ND
0 ++ 0 0 0 + +++ 0
0 + +++ +++ + + + +++
+/- ++ + ++ + + + +++
++ ++ 0 + + + + 0
Siglec F Siglec E CD22 Siglec 10 Siglec 9 Siglec 8 Siglec 7 CD22
α3 β4
α6 β4
α6 β4
α3 β4 α8
α3 β4
6S
α3
α3 β4
6S
α3
Sequence
Neu5AC Galactose GlcNac Fucose S  Sulphate
Neu5Gc
 
Siglec  sialoside  binding  specificities  determined  by  glycan  array  analysis.    Sequences  are  present  in 
glycoproteins or glycolipids. +++ strong binding.  ++ moderate binding.  + low binding.  +/- detectable 
binding.  0 no binding.  ND not determined.  GlcNac N-acetylglucosamine.  Neu5Gc N-glycolylneuraminic 
acid.  Neu5AC  N-acetylneuraminic acid.  (Neuraminic acid = sialic acid) Figure adapted with permission 
144. 
 
Siglec binding to native gangliosides 
  GT1b  GQ1b  GD3  GM2  GM3  GD1a 
Siglec 5  +  ++         
Siglec 7  ++  ++  ++       
Siglec 8             
Siglec 9  ++  ++  ++    ++   
Siglec 10  ++           
Sialoadhesin            ++ 
Siglec F  ++          ++ 
Siglec E  +          ++ 
 
Siglec binding to gangliosides
369,427.  (blue is human siglecs, green is murine siglecs).  Sialoadhesin, Siglec 
F and Siglec E binding to gangliosides had not been demonstrated prior to this thesis.  (+  weaker binding, 
++  stronger binding). 
 
Siglecs do not have specificities for gangliosides per se.  Siglecs have specificity for sialic acid and the 
binding affinity is determined by the sialic acid linkages to the surrounding molecules.  A siglec can bind to 
sialic acid with the correct configuration whether on gangliosides, other glycolipids or glycoproteins.   284 
Appendix 4 – Structures of siglec-human-Fc fusion proteins 
Native murine siglecs
Siglec-human-Fc fusion proteins
Sialoadhesin Siglec F Siglec E
Sialoadhesin Siglec F Siglec E
-V-set Ig domain
Sialic-acid binding
-C2-set Ig
domain
-ITIM -ITIM-like -Human IgG
Fc Ig domain
 
Murine siglecs and the structures of siglec-human-Fc fusion protein reagents
255,258,428.  Ig, Immunoglobulin. 
Fc, fraction crystallisable.  ITIM, immunoreceptor tyrosine-based inhibitory motif.  
 
 